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Abstract 
Oesophageal cancer is the 13th most common cancer in the UK, but 6th most common cause of 
cancer death with only 15% of patients surviving 5 years (1).  The disparity between incidence and 
mortality is due to the fact that a large proportion of oesophageal cancers are diagnosed at a late 
stage (2).   
This thesis aims to investigate the patterns of management and outcomes associated with the 
treatment of early neoplastic changes in the oesophagus in England, in order to try and identify 
areas where care may be improved.  Four separate studies were performed on i) the management of 
high grade dysplasia (HGD) in England, ii) the proportion of oesophageal cancers missed at 
endoscopy, iii) the management and outcomes for early oesophageal cancer and iv) the safety and 
efficacy of radiofrequency ablation and complete endoscopic resection in the management of 
dysplastic Barrett’s oesophagus .  These studies (expect study iv, which is a systematic review) were 
performed by linking three national databases, the National Oesophago-Gastric Cancer database, 
Hospital Episode Statistics and Office for National Statistics mortality data.   
The results of our studies highlight, that 1. a third of patients with HGD are managed by surveillance 
alone, with patients treated in low volume centres more likely to be managed in this manner, 2. a 
substantial proportion of cancers were missed at endoscopy, 3. only 6.8% of oesophageal cancers 
were diagnosed at an early stage, but two thirds of these patients survived 5 years if managed 
curatively 4. radiofrequency ablation should be used in preference to complete endoscopic resection 
in the management of dysplastic Barrett’s.  Therefore there is still substantial room to improve the 
quality of care received by patients with early neoplastic changes in the oesophagus in England. 
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Oesophageal cancer is the 13th most common cancer in the UK, with 8,332 cases diagnosed in 2011 
(1).  Its incidence in the UK is the second highest in Europe for men and the highest for women (1).  
Furthermore the incidence of oesophageal cancer is rising steadily, such that between 1975-77 there 
were 8.8 cases per 100,000 population, but by 2006-8 this figure had increased to 14.5 per 100,000 
(1).  It is therefore concerning that in the UK only 15% of patients diagnosed with oesophageal 
cancer survive 5 years (1).  The disparity between the incidence and mortality of oesophageal cancer 
in the UK is due to the fact that a large proportion of oesophageal cancers are diagnosed at a late 
stage (2).  It is therefore very important that increased focus goes into the diagnosis and 
management of early stage oesophageal cancers.   
In recent years a number of studies have raised concerns about overall cancer outcomes in the UK 
compared to other countries with similar health care systems and wealth (3-6).  As a result the UK 
government has been taking steps to improve cancer outcomes (7, 9-11), including increasing GP 
access to diagnostic tests, improving timely access to specialist clinics and centralising cancer 
services, in order to try and reduce the inherent delays in diagnosis and treatment. 
Nonetheless key to substantially improving outcomes for oesophageal cancer in England is 
increasing the proportion of patients diagnosed with oesophageal cancer at an early stage, and 
optimising the management of these patients.  This thesis therefore aims to investigate in greater 
detail the patterns of management and outcomes associated with the treatment of early neoplastic 
changes in the oesophagus in England in order to try and identify areas where care may be improved 
in future.   
This chapter aims to provide an overview of the current management of oesophageal cancer and 
high grade dysplasia of the oesophagus, and the organisation of oesophageal cancer services in 
England.  The chapter concludes by identifying current gaps in the literature, and summarises the 
research that will be performed in this thesis to address these gaps.   
1.1 Oesophageal cancer  
 Types of cancer 1.1.1
There are two main histological subtypes of oesophageal cancer, adenocarcinomas (ACA) and 
squamous cell cancers (SCC).  Oesophageal ACAs currently account for over half of cases of 
oesophageal cancer in England, with SCCs accounting for a quarter, the remainder are made up of 
undifferentiated cancers, endocrine tumours, gastro-intestinal stromal tumours and a variety of 
other rarer tumours (1).  These proportions are changing though, with a marked increase in the 
24 
 
incidence of oesophageal ACAs over the last 20 years, while the incidence of oesophageal SCCs has 
remained relatively stable (1).  
The work in this thesis will focus on oesophageal adenocarcinomas specifically, because these have a 
defined pre-malignant stage and make up the majority of oesophageal cancers in England.  There is 
therefore the greater scope to improve patient outcomes for oesophageal adenocarcinoma in 
England.   
 Tumour classification 1.1.2
Oesophageal cancers can be sub-classified according to the site of the tumour using the 
International Classification of Diseases (ICD-10).  This classifies oesophageal cancers based on either 
their anatomical site, or the third of the oesophagus in which they arise (Table 1-1) (12).   
Table 1-1 ICD-10 classification for oesophageal and gastro-oesophageal junction cancers 
ICD-10 code Description 
C15.0 Cervical part of oesophagus 
C15.1 Thoracic part of oesophagus 
C15.2 Abdominal part of oesophagus 
C15.3 Upper third of oesophagus 
C15.4 Middle third of oesophagus 
C15.5 Lower third of oesophagus 
C15.8 Overlapping lesion of oesophagus 
C15.9 Oesophagus, unspecified 
 
Gastro-oesophageal junction tumours can be further sub classified according to the Siewert 
classification (13).  This assigns lesions into three groups, determined by the distance between the 
centre of the tumour and the anatomical cardia (Figure 1-1)(14).   
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Figure 1-1 Schematic illustration of the modified Siewert’s classification (14) 
 
 
The most recent National Oesophago-Gastric Cancer Audit (NOGCA) reported that in England and 
Wales, 64.9% of oesophageal cancers affect the lower oesophagus, with 27.2% affecting the middle 
third and only 7.9% affecting the top third (15). 
 Patient characteristics  1.1.3
Throughout most of the Western world the male to female sex ratio for oesophageal ACAs is in 
excess of 4:1 (16).  There is also a strong association with age at diagnosis, such that between 2009-
11 83% of patients were aged over 60 at diagnosis and 42% were over 75 (1) (Table 1-2).  Other 
patient characteristics associated with higher rates of oesophageal cancer include socio-economic 
deprivation (rates are over 40% higher in the most deprived areas compared the least deprived 
areas) (17) and white ethnicity (versus Asian and Black) (18).   
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Table 1-2 Summary of patient characteristics by tumour site  
 Oesophageal ACA 
Upper  
Oesophageal ACA 
Lower / Siewert I 
GOJ ACA Siewert 
II/ III  
Number of patients 
Total, n (%) 1,392 
(8.8%) 
7,171 
(45.1%) 
2,765 
(17.4%) 
Women, n 378 1,443 601 
Men, n 1,012 5,717 2,155 
Ratio 
women to men 
1:2.7 1:4.0 1:3.6 
Median age, years 
Women 78 74 74 
Men  72 69 70 
Performance 
Status1 ≥3, % 
16.3 11.8 10.4 
Patient with  
≥1 comorbidity, % 
29.3 35.7 33.9 
Data comes from the NOGCA 2014 Annual Report (2) 
1 European Cooperative Oncology Group (ECOG) score for performance status in cancer patients  
 Risk factors 1.1.4
Risk factors for oesophageal cancer can be divided into non-modifiable risk factors such as age and 
sex, and modifiable risk factors e.g. smoking.   
In the UK it has been estimated that 89% of all oesophageal cancers are associated with potentially 
avoidable lifestyle factors including smoking, obesity and alcohol.  These are reported to be linked to 
65.5%, 21.7% and 20.6% of all cases of oesophageal cancer respectively (19).   
Oesophageal cancer has also been linked to a number of specific diseases including Barrett’s 
oesophagus, gastro-oesophageal reflux disease, gastric atrophy, diabetes and asthma (1).  The next 
section goes on to explore Barrett’s oesophagus in greater depth. 
1.1.4.1 Barrett’s oesophagus 
Barrett’s oesophagus can be defined as (20):  
‘..an oesophagus in which any portion of the normal distal squamous epithelial lining has been 
replaced by metaplastic columnar epithelium, which is clearly visible endoscopically (≥1cm) above 
the gastro-oesophageal junction and confirmed histopathologically from oesophageal biopsies..’ 
It was first described in 1950 by Norman Barrett (21), and was soon shown to be an acquired 
condition which developed in the presence of chronic gastro-oesophageal reflux (22).  By 1975 a link 
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with oesophageal cancer was established (23), and in 1978 Haggitt et al proposed that Barrett’s 
oesophagus was a frequent precursor of oesophageal adenocarcinoma (24).  Subsequent studies 
have shown that the risk of oesophageal cancer is up to 11 times higher in patients with Barrett’s 
oesophagus compared to the general population (25).   
It is difficult to accurately determine the true incidence and prevalence of Barrett’s oesophagus, due 
to the need to perform an endoscopy to diagnose it.  Two studies have attempted to establish the 
prevalence of Barrett’s oesophagus in Europe.  The first was conducted in Italy and recruited 
participants from two villages, this study had a 66.5% response rate and estimated the prevalence of 
Barrett’s oesophagus was 1.3% (26).  The other study was conducted in two small communities in 
Sweden and randomly selected 1 in 7 inhabitants to participate, this study had a 73% response rate 
and estimated the prevalence of Barrett’s oesophagus to be 1.6% (27).  Both studies acknowledged 
the risk of selection bias in their results, as symptomatic patients were more likely to have 
participated and agreed to undergo an endoscopy.  Among populations with a history of reflux the 
prevalence of Barrett’s oesophagus is much higher with one study reporting that 12.4% of patients 
with a history of reflux had Barrett’s oesophagus (28), on the flip side it is important to realise that 
46.2% of patients with Barrett’s oesophagus have no history of reflux (26).  Recent studies have 
suggested that the incidence of Barrett’s oesophagus is rising, with one study performed in the UK 
reporting that the incidence had risen from 0.11 to 0.24/1000 population in men and from 0.06 to 
0.11/1000 in women between 1996 and 2005 (29).   
As discussed previously Barrett’s oesophagus is a recognised pre-malignant condition for 
oesophageal adenocarcinoma (23, 24, 30).  However, reported rates for the progression of non 
dysplastic Barrett’s oesophagus to invasive cancer vary widely.  While initial studies suggested rates 
of 4-5 per 1000 person years (31, 32), more recent studies have suggested much lower rates, 1.2-1.3 
per 1000 patient years (0.1% per year) (25, 33).   
Extensive research has therefore gone into investigating the factors associated with an increased risk 
of progression to cancer.  While there is little debate about the impact of some risk factors such as 
the presence of dysplasia, the relative importance of others remains controversial.  Some of the key 
factors associated with the risk of progression are reviewed below.   
Studies have consistently reported much higher risks of progression to cancer where there is 
evidence of more severe dysplasia within the Barrett’s segment.  Dysplasia is defined as the 
presence of unequivocal neoplastic epithelium strictly confined within the basement membrane of 
the gland from which it arises (34).  The significance of increasing severity of dysplasia was 
28 
 
demonstrated in a study by Montgomery et al who asked 12 pathologists to each grade the degree 
of dysplasia present in 138 Barrett’s oesophagus specimens on two occasions.  They reported that 
the risk of progression to cancer during follow up increased from 0% for non dysplastic Barrett’s 
oesophagus, to 15% for low grade dysplasia (LGD), to 61% for high grade dysplasia (HGD) (after a 
median of 38.5, 24 and 13 months follow up, respectively) (35).   
A substantially lower risk of progression was reported in a recent systematic review, this reported 
that the risk of progression to cancer was 5.6% per year if HGD was present (36).  This compares to a 
reported risk of progression of only 0.1% per year if there was no evidence of dysplasia (25).  These 
differences in the rates of progression are thought to be due to the fact that Barrett’s oesophagus 
progresses sequentially through a dysplasia-carcinoma sequence before developing into cancer 
(Figure 1-2) (35, 37).   
Figure 1-2 The morphological development of Barrett’s oesophagus 
 (http://pathology2.jhu.edu/beweb/Definition.cfm)  
 
However, it is important to realise that the grading of the degree of dysplasia present by 
pathologists can be subjective, and depends on both architectural changes (e.g.  glandular distortion 
and crowding), and cytological changes including nuclear alterations (38).  In order to try and 
standardise the classification of gastrointestinal neoplasia, the Vienna classification was developed 
with the aim of improving the uniformity of dysplasia reporting (Table 1-3) (39). Studies have since 
shown that where the diagnosis of dysplasia is confirmed by two pathologists the risk of progression 
to cancer is significantly higher than in cases where the second pathologist does not confirm the 
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diagnosis (40-42).  As a result the British Society of Gastroenterologists (BSG) recommends that all 
diagnoses of dysplasia are confirmed by two specialist gastro-intestinal (GI) pathologists (20).   
Table 1-3 Revised Vienna classification of gastrointestinal neoplasia  
Category Diagnosis 
1 Negative for neoplasia 
2 Indefinite for neoplasia 
3 Mucosal low grade neoplasia 
Low grade adenoma 
Low grade neoplasia 
4 Mucosal high grade neoplasia 
4.1 High grade adenoma/dysplasia 
4.2 Non-invasive carcinoma (carcinoma in situ) 
4.3 Suspicious for invasive carcinoma 
4.4 Intramucosal carcinoma 
5 Submucosal invasion by carcinoma 
 
Other factors thought to increase the risk of malignant progression in Barrett’s oesophagus include 
the presence of intestinal metaplasia (IM) in the Barrett’s segment and the length of the Barrett’s 
segment.  Studies have demonstrated that patients with an endoscopic diagnosis of Barrett’s 
oesophagus and evidence of IM on oesophageal biopsy are at three times greater risk of progression 
to cancer compared to patients with no evidence of IM (33).  As a result the US American 
Gastroenterological Association (AGA) guidelines for the diagnosis of Barrett’s oesophagus require 
the presence of IM on oesophageal biopsies to confirm the diagnosis (43). There is concern though 
that IM may have been missed at initial endoscopy, Gatenby et al reported that after 10-years follow 
up more than 90% of patients initially diagnosed with Barrett’s oesophagus without IM were later 
found to have IM (44).  As a result the current BSG guidelines do not require histological 
confirmation of the presence of IM to confirm the diagnosis Barrett’s oesophagus (20). 
One final factor thought to impact on the risk of progression of Barrett’s oesophagus is the length of 
the Barrett’s segment.  Length of Barrett’s oesophagus is traditionally classified as short segment if 
<3cm and long segment if ≥3cm.  Studies investigating the effect of the length of Barrett’s segment 
on the risk of progression to cancer have compared short versus long segment disease.  Three recent 
meta-analyses all demonstrated a trend towards increased cancer risk in long segments of Barrett’s 
oesophagus, however the difference was not statistically significant (45-47). 
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 Diagnosis 1.1.5
In order to confirm a diagnosis of oesophageal cancer a histological specimen must be obtained.  
Endoscopy (oesophago-gastro duodenoscopy, OGD) and biopsy is currently regarded as the 
investigation of choice for this purpose (48, 49).   
OGDs are readily available in the UK with 680,000 patients undergoing an endoscopy in England 
each year (50), this equates to around 1% of the population.  However, difficulty arises in deciding 
who to investigate for oesophageal cancer, because symptoms are frequently non-specific and occur 
in many people without malignant disease.  Current UK guidelines recommend that General 
Practitioners (GPs) send patients for an urgent OGD for suspected cancer if they present with any of 
the following: chronic gastrointestinal bleeding, dysphagia, progressive unintentional weight loss, 
persistent vomiting, iron deficiency anaemia, epigastric mass or a suspicious barium meal result (51).  
These are known as ‘alarm’ symptoms and signs.  The National Institute for Health and Care 
Excellence (NICE) guidelines also note that patients aged 55 or older should be referred for an urgent 
OGD if they present with unexplained and persistent recent-onset dyspepsia (51). 
When performing an endoscopy it is important that biopsies are taken of any suspicious lesions, in 
order to confirm or refute the diagnosis of cancer.  Studies have clearly demonstrated that 
increasing the number of biopsies taken at endoscopy increases the sensitivity of cancer diagnosis 
(52).  As a result the UK guidelines recommend that a minimum of 6 biopsies are taken to achieve a 
diagnosis of malignancy in areas of oesophageal or gastric mucosal abnormality (48).   
Despite being the gold standard investigation for the diagnosis of oesophageal cancer, previous 
studies have suggested that around one in ten oesophago-gastric (OG) cancers are potentially 
missed at initial endoscopy (53-59).  These studies have looked at the proportion of patients 
diagnosed with oesophago-gastric cancer within 2-3 years of an endoscopic examination, based on 
the fact that progression of early cancers is thought to be slow (60, 61).  These studies have reported 
miss rates of between 5.0% (57) and 14.3% (56) within 3 years of previous endoscopy.  To date only 
one study has focused on oesophageal cancer specifically.  This was a single centre study conducted 
in the US which found that 10/110 (9.1%) patients diagnosed with oesophageal cancer had had an 
endoscopy within 2 years of diagnosis (54).  The results of previous studies are summarised in Table 
1-4. 
31 
 
Table 1-4 Summary of results of previous studies looking at miss rates for oesophageal cancers 
1
st
 Author 
and Year 
Country Study Years Study Design Cancers 
identified 
1 year miss rate  2 year miss rate 3 year miss rate 
Raftopoulo
s 2010 (53) 
Australia  1990-2004 Retrospective review of endoscopy 
database for all OG cancers at Sir 
Charles Gairdner Hospital in Perth 
822  29/822 (3.5%)  NR Additional 26/822 (3.2%) 
within 1-3 years.   
55/822 (6.7%) within 3 
years.   
Bloomfield 
2005 (54) 
US  1997-2001 Retrospective review of tumour registry 
for oesophageal cancers only at Wake 
Forest University Baptist Medical Centre  
110  6/110 (5.5%)  10/110 (9.1%)  NR 
Yalamarthi 
2004 (55) 
Scotland 1994-2001 Retrospective review of endoscopy 
database for all OG cancers at Dumfries 
and Galloway Royal Infirmary 
305 20/305 
(6.6%)  
NR 30/305 
(9.8%)  
Abstracts 
Cheung 
2013 (56) 
UK 1999-2007 Retrospective review of endoscopy 
database for all OG cancers at Sandwell 
General and City Hospital  
524 42/524 (8.0%) NR Additional 33/524 (6.3%) 
within 1-3 years.   
75/524 (14.3%) within 3 
years. 
Cheung 
2013 (57) 
UK NR Retrospective review of all oesophageal 
cancers submitted to UK Primary Care 
Database (THIN)  
5354 NR NR 266/5354 (5.0%) 
Patel 2012 
(58) 
UK 2009-2010 Retrospective review of endoscopy 
database for OG cancers at Leeds 
Teaching Hospital 
148 NR NR 10/148 (6.8%) 
Excluded 6, diagnosed 
within 1 month of initial 
endoscopy.   
Parsons 
2010(59) 
UK 2005-2009 Retrospective review of electronic 
hospital record for all cases OG cancer at 
Nottingham City Hospital 
1075 NR 23/1075 (2.1%) 
Excluded 42, diagnosed 
within 3 months of 
initial endoscopy.   
NR 
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1.1.5.1 Diagnosis of Barrett’s oesophagus 
This can be identified at endoscopy as red velvety mucosa extending proximally from the gastro-
oesophageal junction, replacing the normal squamous oesophageal mucosa which appears pale and 
shiny (Figure 1-3). 
Figure 1-3 Barrett’s oesophagus 
 
Once identified, the extent of the Barrett’s segment should be documented using the Prague 
criteria.  This specifies both the circumferential (‘C’) length and the maximal (‘M’) length of 
endoscopically visible columnar lined oesophagus (62), and any more proximal islands of Barrett’s 
oesophagus should also be noted separately (Figure 1-4).   
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Figure 1-4 Prague criteria for Barrett’s oesophagus, developed by a Subgroup of the International Working Group 
for the Classification of Reflux Oesophagitis (IWGCO).   
(http://www.iwgco.net/) 
 
 
 
Having documented the extent of the Barrett’s oesophagus it is important to assess whether there is 
any evidence of dysplasia.  This is done in two stages, first the oesophagus needs to be carefully 
inspected for any visible nodules, then biopsies should be taken of any suspicious lesions with 
additional biopsies taken every 2cm from the segment of Barrett’s oesophagus, in line with the 
‘Seattle protocol’ recommended by the BSG (20).  It is important to ensure this rigorous biopsy 
regimen is followed in order to optimise detection of dysplasia (63, 64).   
Views of the mucosa need to be optimised to allow detection of subtle lesions, and numerous 
studies have looked at different approaches for improving this.  A recent RCT showed that high 
resolution endoscopy (HRE) alone had 79% sensitivity in detecting HGD, and that the addition of 
indigo carmine chromoendoscopy or narrow band imaging increased the sensitivity to 93% and 86%, 
respectively (65).  However, there are no RCTs comparing conventional endoscopy with high 
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resolution endoscopy in the detection of dysplastic Barrett’s oesophagus.  Current expert opinion 
suggests that HRE should be used as a minimum to inspect the mucosa in all patients with known 
Barrett’s oesophagus (66), chromoendoscopy and narrow band imaging may provide useful 
adjuncts.   
Most cases of HGD are diagnosed as a result of biopsies taken at routine endoscopy, performed 
either because the patient has developed new symptoms (52.9%) or as part of a Barrett’s 
oesophagus surveillance program (39.4%) (15).  Once a provisional diagnosis of HGD has been made, 
it is important to confirm the diagnosis with at least one other GI pathologist (20, 40) and consider 
performing a high-quality repeat endoscopy.  The aim of this repeat endoscopy is to identify any 
additional lesions and plan further management.  The importance of this repeat diagnostic 
endoscopy was highlighted by a study from Australia which demonstrated that a significant 
proportion of patients who were rescoped at a specialist centre were found to have additional 
lesions (p<0.001) and early cancers detected (p=0.036) at repeat endoscopy (67).   
 Staging 1.1.6
Once the initial diagnosis of oesophageal cancer has been made further staging investigations need 
to be performed to determine the extent of the disease, and assess whether it is potentially curable 
(48).   
1.1.6.1 Staging Classification 
Oesophageal cancers can be staged according the Union for International Cancer Control (UICC) 
TNM 6/7 Classification (68).  This classification takes into account depth of tumour invasion (T stage), 
extent of lymph node involvement (N stage) and evidence of metastatic spread (M stage).  This three 
pronged approach to staging is important because it reflects the fact that oesophageal cancer can 
spread via several different routes: direct invasion of adjacent structures, via the lymphatic channels, 
via the blood stream and by transcoelomic spread into the peritoneal cavity.   
Table 1-5 outlines the current UICC classification and the slight differences between the two most 
recent versions, TNM 6 and TNM 7.  One of the major changes seen with the introduction of TNM 7 
was the ability to differentiate T1 tumours according to the degree of mucosal/submucosal invasion.  
This is very important when it comes to determining the most appropriate treatment regimen for 
early oesophageal cancers, as will be discussed later.   
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Table 1-5 TNM Classification for oesophageal cancers 
 TNM 6 TNM 7  
T   TX Primary tumour cannot be assessed. 
T0 No evidence of primary tumour. 
Tis Carcinoma in situ 
T1 Tumour invades lamina propria or 
submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades adventitia 
T4 Tumour invades adjacent structures 
 
TX  Primary tumour cannot be assessed. 
T0  No evidence of primary tumour. 
Tis  Carcinoma in situ /High-grade dysplasia 
T1  Lamina propria or submucosa 
T1a Lamina propria or muscularis mucosae 
T1b Submucosa 
T2  Muscularis propria 
T3  Adventitia 
T4a Pleura, pericardium, diaphragm, or 
adjacent peritoneum 
T4b Other adjacent structures, e.g.  aorta, 
vertebral body, trachea 
N   NX Regional lymph nodes cannot be 
assessed. 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
 
NX Regional lymph nodes cannot be 
assessed. 
N0  No regional lymph node metastasis 
N1  1 to 2 regional lymph nodes 
N2  3 to 6 
N3  >6 
M  MX Distant metastasis cannot be assessed. 
M0 No distant metastasis. 
M1 Distant metastasis 
 
For tumours of lower thoracic oesophagus: 
M1a Metastasis in coeliac lymph nodes 
M1b Other distant metastasis 
 
For tumours of upper thoracic oesophagus: 
M1a Metastasis in cervical lymph nodes 
M1b Other distant metastasis 
 
For tumours of mid-thoracic oesophagus: 
M1a Not applicable 
M1b Non-regional lymph node or other 
distant metastasis 
MX Distant metastasis cannot be assessed. 
M0 No distant metastasis. 
M1 Distant metastasis 
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1.1.6.2 Staging Investigations 
In order to accurately assess the stage of the disease, it is important to make good use of a variety of 
different staging investigations to assess the degree of both local and distant spread.   
Investigations include:  
- Computed Tomography (CT)  
A CT scan of chest and abdomen should be performed in all cases of oesophageal cancer to 
look for evidence of loco-regional and distant metastatic spread (48).   
However a CT is not generally considered useful in determining T-stage at diagnosis, other 
than in identifying T4 disease.   
- Endoscopic Ultrasound (EUS)  
EUS combines the benefits of high frequency ultrasound with the ability to endoscopically 
visualise the tumour.  This allows one to define the separate layers of the oesophageal wall 
thereby providing a more accurate T-stage than CT alone, while also allowing visualisation of 
local nodes to look for evidence of their involvement.   
A recent study reported that the sensitivity and specificity of EUS in assessing T stage was 
82% and 91% for T1, 43% and 85% for T2; and 83% and 86% for T3, respectively.  While the 
sensitivity and specificity in detecting N1 disease was 71% and 74%, respectively.  (69).   
- Endoscopic mucosal resection (EMR) 
EMR uses an endoscopic snare to remove sections of the mucosa endoscopically, providing a 
relatively large histological specimen.  As a result EMR has now superseded EUS in the 
assessment of early oesophageal lesions, as it can clearly differentiate tumours involving just 
the mucosa from those involving the submucosal layer as well.  This is particularly important 
if one is considering localised endoscopic therapy for an early cancer, because the risk of 
lymphatic spread rises rapidly once the submucosal layer is involved (70).   
It is now recommended that an EMR is performed when staging all T1 oesophageal tumours 
(48).  Studies have shown that provision of a large EMR specimen can result in both up and 
down staging of the initial histological diagnosis, resulting in changes in the management 
plan in up to 30% patients (71-73). 
- Staging laparoscopy 
A staging laparoscopy should be considered for all GOJ tumours to look for evidence of 
peritoneal or hepatic metastases.  De Graaf et al found that performing a staging 
laparoscopy provided additional treatment information in 17% of lower oesophageal and 
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GOJ cancers (74).  It is important to collect peritoneal cytology at the time of the staging 
laparoscopy, because 15% of patients with no overt peritoneal metastases have positive 
peritoneal cytology and this is associated with a worse prognosis (75).   
- Positron emission tomography (PET)-CT 
A PET scan is a nuclear medicine imaging technique that allows you to look for changes in 
the activity of cells.  In order to achieve this, the patient is usually injected with 
fluorodeoxyglucose, an analogue of glucose, which is taken up by cells.  The patient is then 
scanned to detect the concentration of this tracer in different tissues.  Malignant cells 
usually metabolise glucose at a faster rate and therefore show up more brightly. 
Combining PET and CT scans provides both functional and anatomical data and may improve 
detection of spread to regional and distant lymph nodes, thereby providing more accurate 
staging information than CT-EUS alone (76).  However, PET-CT should not be relied upon for 
detecting spread to local nodes because high uptake of contrast by the adjacent tumour can 
obscure uptake by smaller volume local nodes (48).  It is therefore important to ensure that 
EUS continues to be used for this purpose.   
 Management  1.1.7
Once patients with oesophageal cancer have had their disease staged, decisions need to be made as 
to whether the disease can be managed with curative intent and if so what the most appropriate 
treatment modality is.  In England decisions about the management of both oesophageal HGD and 
oesophageal cancer are made at an upper gastro-intestinal (UGI) multidisciplinary team meeting 
(MDT) (20, 48).  The MDT will usually consist of an interventional endoscopist, an UGI surgeon, a 
specialist gastro-intestinal pathologist, and a radiologist.  Decision making is a two-step process, 
firstly in the case of oesophageal cancer the team need to establish whether the disease is localised 
with no evidence of distant spread in which case the patient can be considered for curative 
treatment.  The focus then shifts towards determining the most appropriate treatment modality for 
the patient, taking into account both disease site and stage, and also patient characteristics (e.g.  
age, comorbidities, and performance status) and wishes.   
Currently only around 35% of all oesophageal cancers diagnosed in England are managed with 
curative intent (77), but this proportion is significantly higher for patients who are diagnosed with 
early stage disease (75%) (2).  Where the disease is potentially curable several different treatment 
options are available, and this section goes on to explore these options for both oesophageal 
adenocarcinomas and high grade dysplasia of the oesophagus.   
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1.1.7.1 Surgery 
Until recently surgery has been considered the main stay of treatment for both oesophageal HGD 
and cancer (48, 78).   
The previous recommendation of surgery for the treatment of HGD was based on literature 
suggesting that a concomitant focus of invasive cancer was found in up to 40% of oesophagectomy 
specimens taken from patients with a history of HGD alone (79, 80).  However a more recent review 
found that while the overall incidence of invasive cancer in such specimens was still 13%, the 
incidence dropped to 3% once all patients with endoscopically visible lesions were excluded (81).  
With increased focus on performing high quality endoscopies for the assessment of HGD, along with 
the increased use of EMR to provide large histological specimens of any visible lesions it is likely this 
figure will fall further in future.   
Furthermore it is also important to realise that oesophagectomy is associated with significant 
morbidity and mortality (82-84), and therefore careful consideration needs to be given to 
performing an oesophagectomy for HGD alone or early cancer.  The 2010 NOGCA report found that 
the 90-day mortality post oesophagectomy for oesophageal cancer was 5.7% (85), this figure has 
fallen over recent years but was still reported to be 4.4% in the 2014 NOGCA report (2).  In addition, 
a third of patients suffer significant post-operative complications post-oesophagectomy (such as 
respiratory 17.1%, cardiac 7.3% and anastomotic leak 7.1%) (2).   
As a result over recent years localised endoscopic treatment options have superseded surgery as the 
treatment of choice for HGD (20), although surgery remains the mainstay of treatment for most 
oesophageal ACAs.  Nonetheless localised endoscopic therapy may be considered where 
oesophageal ACA is diagnosed at a very early stage before there is evidence of submucosal invasion.  
The next section goes on to explore these endoscopic treatment options in greater detail.   
1.1.7.2 Endoscopic treatment 
Given that dysplastic changes are, by definition, limited to the mucosa, there is no concern about the 
risk of spread with HGD (as there is with cancer), consequently localised endoscopic therapy is now 
considered the treatment of choice for HGD, thereby avoiding the need for an oesophagectomy and 
its associated risks (20).  When managing HGD endoscopically it is important to ensure the entire 
Barrett’s segment is treated, to reduce the risk of future recurrence or development of a 
metachronous lesion in the remaining Barrett’s segment (86, 87). 
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Localised endoscopic therapy can also be used to treat early oesophageal cancers limited to the 
mucosa, due to the very low risk of lymphatic spread in this situation (88, 89).  It may also be 
considered for cancers invading the most superficial layer of the submucosa (sm1), if the tumour is 
well differentiated with no evidence of lymphovascular invasion, or if the patient is unfit or unwilling 
to undergo an oesophagectomy (20).   
There are several different endoscopic treatment options available for the management of 
oesophageal HGD and cancer, and this section goes on to explore these options in greater detail.   
Endoscopic Resection  
Endoscopic resection is useful for treating both early oesophageal cancers and HGD if there is a 
visible nodule.  There are two broad approaches to endoscopic resection, endoscopic mucosal 
resection and endoscopic submucosal dissection.   
Endoscopic mucosal resection (EMR) uses an endoscopic snare to remove sections of mucosa 
endoscopically.  The technique was first developed to treat gastric cancers in 1980 (90), and by 1990 
was being used successfully to treat early oesophageal cancers (91).  More recently it has been used 
to treat HGD of the oesophagus (92).  EMR is now considered the treatment of choice for treating 
both visible dysplastic nodules and intramucosal cancers of the oesophagus (20).   
The aim of EMR can be two fold, firstly to remove any obvious nodules of concern within the 
oesophageal mucosa, alternatively it can be used to remove the entire segment of Barrett’s mucosa.  
The later approach is called complete endoscopic mucosal resection, and is performed to reduce the 
risk of cancer in future.  Evidence regarding the outcomes that can be achieved with EMR in treating 
dysplastic Barrett’s will be presented in Chapter 4.   
When resecting an early cancer endoscopically it is important to try to achieve an enbloc resection, 
to allow accurate histological assessment of the lesion and reduce the risk of local recurrence (93).  It 
is not always possible to achieve this using EMR, and as a result endoscopic submucosal dissection 
(ESD) was developed.  ESD allows the en bloc resection of larger lesions and of lesions extending into 
the submucosa, this is achieved by injecting solution under the lesion of concern to allow the 
submucosa under the lesion to be dissected using a specialised knife.  To date most studies using 
ESD for the treatment of oesophageal cancer have come from Japan and have focused on the 
treatment of oesophageal squamous cell cancers (94-96).  Very few studies have reported on the use 
of oesophageal ESD in the West and in particular to treat oesophageal adenocarcinomas, and where 
these have been done initial studies reported disappointing results.  A study from Germany reported 
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that a complete resection (R0) was only achieved in 38.5% (97), while another small study from the 
US reported that an R0 resection was only achieved in 2/4 (50%) oesophageal cancers treated with 
ESD (98).  A more recent German study has produced more encouraging results, reporting a 95.4% 
R0 resection rate for oesophageal adenocarcinomas, with a recurrence rate of 2.4% over 2 years 
follow up (99).  The variability in the results reflect the fact that ESD is a much more technically 
demanding technique than EMR, and studies have shown that outcomes after ESD are closely linked 
to the volume of cases managed at that institution, with increased rates of complications at lower 
volume centres (100).  As a result the role of ESD in the management of oesophageal 
adenocarcinomas in Europe has not yet been clearly defined, and use is currently limited to a few 
specialist centres.   
Endoscopic Ablation  
An alternative approach for managing dysplasia within a segment of Barrett’s oesophagus is to 
ablate the neoplastic mucosa, allowing regrowth of normal squamous mucosa in its place.  This 
technique is useful for treating flat areas of dysplasia, and to treat residual Barrett’s mucosa after 
endoscopic resection of any visible nodules. 
There are several different ablative therapies available including radiofrequency ablation, 
photodynamic therapy, argon plasma coagulation, multipolar electro-coagulation, laser therapy, and 
cryotherapy.  This section goes on to describe in more detail some of the more commonly used 
techniques. 
Photodynamic therapy (PDT) was one of the earlier ablative treatments developed to treat 
dysplastic Barrett’s oesophagus.  Administration of PDT is a laborious process.  First a 
photosensitizer (e.g. porfimer sodium or oral 5-aminolevulinic acid (5-ALA)) is administered 
systemically, and then at a later date an endoscopy needs to be performed to expose the 
oesophagus to a specific wave length of light which activates the photosensitiser which has been 
preferentially retained by the abnormal cells causing their delayed cell death.  Studies looking at the 
success of PDT in eradicating Barrett’s oesophagus have produced variable results and have been 
associated with a high risk of complications.  For instance a randomised controlled trial (RCT) by 
Overholt et al found that while administration of porfimer sodium as a photosensitiser achieved 
significantly better rates of regression of HGD compared to omeprazole alone (77% vs 39%, 
P<0.0001), 13% of patients treated with PDT went on to develop cancer during follow up, and 94% 
developed complications associated with treatment (101).  While another trial using 5-ALA as 
photosensitiser produced better results short term outcomes (97% of patients with HGD and 100% 
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of patients with early cancer achieved a complete response), but recurrence rates were still high 
affecting 2.8% of patients treated for HGD and 32% of patients treated for early cancers (102).   
Argon plasma coagulation (APC) is an alternative treatment using ionised argon gas to conduct 
monopolar current into the tissue, causing cell death through electrocoagulation.  Studies using APC 
to treat dysplastic Barrett’s have produced poor results (103, 104), with only 65% of patients 
achieving complete eradication of intestinal metaplasia above the GOJ after a median of 3.8 
treatment sessions (104).  Furthermore the rates of buried Barrett’s associated with APC are also 
high (103).   
More recently radiofrequency ablation (RFA) has been developed; this technique uses high-
frequency alternating current to destroy the mucosa.  Before applying RFA it is important to ensure 
that any visible nodules are resected first using EMR, this is important for two reasons firstly RFA 
does not provide a histological specimen needed to look for evidence of deeper tissue invasion and 
secondly the mucosa needs to be flat in order to apply RFA effectively and evenly.   
RFA can be applied using the HALO system (BARRX Medical, Sunnyvale, CA).  There are two main 
types of HALO device available; HALO360 which provides circumferential treatment to the mucosa, 
and HALO90 which provides focal treatment to localised areas of disease.  Patients usually require 
initial circumferential RFA, followed by focal RFA to treat any small areas of residual disease.  
However, short-segments of non-circumferential Barrett’s oesophagus can often be treated with 
focal RFA alone.   
Circumferential RFA is usually applied, using standard energy settings (12J/cm2, 40W/cm2).  After 
initial application the probe is cleared of debris and the process is repeated again ablating the same 
segment for a second time.  In contrast focal RFA is usually administered using a ‘double-double’ 
approach, here RFA is delivered twice in succession to each area (12-15J/cm2, 40W/cm2), before the 
probe is cleaned and the area is then ablated again twice.   
Studies have consistently demonstrated that better outcomes can be achieved with RFA compared 
to older ablative techniques, consequently use of both PDT and APC has declined in recent years 
(105).  Evidence regarding the use of RFA to treat dysplastic Barrett’s will be reviewed in detail in 
Chapter 4.   
1.1.7.3 Summary of treatment options 
For locally advanced oesophageal adenocarcinoma surgery is still regarded as the curative treatment 
of choice.  However, two recent reviews have shown that for patients with disease limited to the 
42 
 
most superficial layers of the oesophagus the morbidity and mortality is substantially lower for 
patients treated endoscopically than for those treated surgically (105, 106).  As a result the current 
BSG guidelines advocate the endoscopic treatment of early oesophageal cancers limited to the 
mucosa and carefully chosen cases invading the most superficial layer of the submucosa (20).  
Endoscopic treatment options include endoscopic mucosal resection and endoscopic submucosal 
dissection.  The choice of modality used depends on the tumour size and depth of invasion, as well 
as local expertise available.   
Similarly for oesophageal HGD the BSG guidelines now recommend that this is treated 
endoscopically, in preference to either surgical resection or surveillance alone (20).  There are two 
broad approaches to the endoscopic treatment of HGD, endoscopic resection and ablation, each 
approach has their own advantages and disadvantages.  In Western countries RFA is now considered 
the ablative treatment of choice, associated with better outcomes and fewer complications than 
previous ablative techniques such as PDT and APC (105).  Chapter 4 will go on to compare outcomes 
achieved with complete endoscopic resection with those achieved with RFA for treating dysplastic 
Barrett’s oesophagus.   
 Survival  1.1.8
Despite being only the 13th most common cause of cancer in the UK, oesophageal cancer is currently 
the 6th most common cause of cancer death (1).  The disparity between the incidence and mortality 
of oesophageal cancer is due to the fact that a large proportion of oesophageal cancers are 
diagnosed at a late stage (2).  As a result only a third of patients are managed with curative intent 
(77) and only 15% of patients survive 5 years (1).   
However the overall survival for oesophageal cancer does appear to be improving.  A study from the 
US found that overall 5 year survival for oesophageal cancer had increased from 5% in 1974-1976, to 
16% between 1995-2000 (107).  Nonetheless UK outcomes are still far behind the rest of Europe (1), 
with several papers raising concerns about overall cancer outcomes in the UK compared to other 
countries with similar health care systems and wealth (3-6).  One paper estimated that between 
1985-1999 there were 6600-7500 excess deaths in Britain each year among cancer patients, which 
could have been avoided if the overall 5 year cancer survival was the same as the mean survival in 
Europe (108).  As a result the UK government has been taking steps to improve cancer outcomes (7, 
9, 10, 109).   
Key to improving survival for oesophageal cancer is increasing the proportion of patients diagnosed 
at an early stage, but identifying these patients is difficult because symptoms of oesophageal cancer 
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frequently present at a late stage.  In January 2015 the government launched a ‘Be Clear on Cancer’ 
campaign for oesophago-gastric cancer.  The aim of this campaign was to improve early diagnosis of 
these cancers by raising public awareness of their symptoms and signs, and to encourage patients to 
see their GP without delay if they were concerned (9).  The campaign targeted men and women 
aged 50 years and over with persistent heartburn for 3 weeks or more, or problems swallowing (9).  
However these symptoms are non-specific and frequently seen in individuals without cancer, so it 
will be important to investigate the impact this campaign has on both the proportion of cancers 
diagnosed at an early stage and the number of urgent endoscopies being performed.   
1.1.8.1 Early oesophageal cancer outcomes 
The outcomes associated with the treatment of early stage oesophageal cancer are much better.  
Wani et al reported that up to 90% of patients diagnosed with early oesophageal cancer who were 
managed with a curative oesophagectomy survived 5 years (110).   
Until recently surgery had been considered the only curative treatment for oesophageal cancer, 
however with studies demonstrating the low risk of lymphatic spread with early stage disease and 
recent advances in endoscopic options have meant that endoscopic treatment options are being 
considered with increasing frequency for early cancer.  Given the changing patterns of management 
for early oesophageal cancers it is important to ensure that comparable long term outcomes can be 
achieved with localised endoscopic therapy.   
Several papers have attempted to compare outcomes for early oesophageal cancers managed 
surgically and endoscopically.  Previous single centre studies from the US and Germany (111, 112) 
have reported similar outcomes for both therapies, but these studies were small and consequently 
underpowered to detect significant differences.  These studies report that the risk of procedure-
related mortality was higher after surgery, but that the risk of recurrence was higher for patients 
treated endoscopically.  Population based studies performed in the US, using the Surveillance 
Epidemiology and End Results (SEER) database (113-115) reported no difference in cancer specific 
mortality at 5 years, but that patients treated surgically had better overall 5 year survival.  However 
it is important to realise that there were differences in the baseline characteristics of the two groups 
which could not be accounted for.   
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1.2 Care provision in England 
 Organisation of cancer services in England 1.2.1
In 2000 the National Health Service (NHS) Cancer Plan was developed to provide a comprehensive 
strategy to tackle the disease (109).  This aimed to target everything from disease prevention, to 
diagnosis, treatment and research. 
As a result in 2001, the ‘Improving Outcomes Guidance’ document was published (7), this provided 
guidance on how NHS services should be organised resulting in the major reorganisation of 
oesophago-gastric cancer services in England.  Its key recommendations included:  
- Development of Cancer Networks.  These were designed to provide specialist diagnostic 
services and curative therapies (including surgery and oncology) at a single specialist centre 
(Cancer Centre) to all patients living in a geographical area.  While more general diagnostic 
services and most palliative services would continue to be provided by local NHS trusts 
(known as Cancer Units).   
- Development of specialist treatment teams to treat OG cancer, with each serving 
populations of more than one million.  Within this strategy they recommended the 
introduction of specialist UGI cancer MDTs, which met regularly to collectively decide on 
individual patient’s management.  There is good evidence to suggest use of the MDT 
approach to plan treatment improves overall survival for patients with oesophageal cancer 
(116). 
When the NOGCA started in 2007 there were 30 Cancer Networks in England (117), since then there 
has been further centralisation of services.  An organisational survey of OG cancer services in 
England was conducted in 2012, at that time there were 28 Cancer Networks providing services to 
the 151 trusts treating OG cancer, with 39 of these trusts designated as specialist Cancer Centres 
(77).   
Further changes to the organisation of cancer services took place in 2013, resulting in the 
replacement of Cancer Networks by 12 Strategic Clinical Networks (SCNs) in England (118).  It is the 
responsibility of these SCNs to provide clinical and managerial support to Clinical Commissioning 
Groups, Health and Wellbeing Boards and NHS England in order to improve regional healthcare 
(119).   
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 Management of HGD in England 1.2.2
In the past several surveys have been conducted to investigate the services available for the 
management of HGD in England.  These have reported significant variability in the management of 
HGD and poor adherence to published guidelines (Table 1-6) (120-123).  This in part reflects the fact 
that new treatment options have become available over recent years resulting in substantial 
changes to national guidelines. 
As recently as 2002 74% of clinicians considered surgery as the treatment of choice for HGD where 
active treatment was being considered (115), but surveillance alone was still considered the 
treatment of choice by 83% of clinicians in preference to active treatment as recently as 2004 (120).  
Since then there has been a dramatic shift in the treatment options available for HGD, such that 
endoscopic therapy is now considered the treatment of choice in preference to surgery or 
surveillance alone (20).  As a result a recent study from the Netherlands reported that the 
proportion of patients treated endoscopically for HGD had risen rapidly over the last 15 years, from 
18% between 1998-2003 to 42% between 2004-2008 (124).  During this time frame there was a 
corresponding decline in the use of oesophagectomy from 82% to 56%.  It is expected that a similar 
trend will have been seen in UK practice, but no recent studies have been done to investigate the 
current management of HGD in the UK.   
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Table 1-6 Summary of key findings of previous studies looking at the management of Barrett’s oesophagus 
1st Author 
and Year 
Country Study Years Study Design Key Findings  
Ramus 
2008 (120) 
 
UK 2004-2005 Questionnaires on 
Barrett’s oesophagus 
sent to endoscopy 
leads at 41 centres 
across the UK 
33 (73%) of centres responded 
- 73% adhered to the Seattle protocol in biopsying Barrett’s oesophagus 
- Management of HGD: 83% of centres adopted frequent surveillance of HGD, 7% made direct 
referral for surgery and 1 stated they would repeat biopsy and ask for the opinion of a second 
pathologist.   
Das 2008 
(121) 
UK 2002 Questionnaires on 
Barrett’s oesophagus 
sent all 387 consultant 
members of BSG and 
further 14 trainees 
across the UK 
228 (57%) of clinicians responded  
- 55% adhered to the Seattle protocol in biopsying Barrett’s oesophagus 
- 55% reported having access to a specialist GI pathologist 
- 50% always had diagnosis of HGD confirmed by 2nd pathologist, a further 23% reported this was 
frequently the case.   
- Management of HGD: 74% consider surgical resection as their preferred treatment option for 
HGD.   
Mandal 
2003 (123) 
UK 2001 Questionnaires on 
Barrett’s oesophagus 
sent to 300 members of 
BSG across the UK 
203 (68%) of clinicians responded 
- 41% adhered to the Seattle protocol in biopsying Barrett’s oesophagus 
- 55% had all diagnoses of HGD confirmed by 2nd pathologist, 23% did only if surgery considered 
- Management of severe (HGD) dysplasia:  23% referred directly for surgery without repeat 
endoscopy.   
Smith et al 
1999 (122) 
UK 1997 Questionnaires on 
Barrett’s oesophagus 
sent to 297 members of 
BSG across the UK 
152 (51%) of clinicians responded 
- 8% adhered to the Seattle protocol in biopsying Barrett’s oesophagus 
- 3% had diagnosis of HGD confirmed by 2nd pathologist 
- Management of severe dysplasia:  70% (74/106) considered surgery as their preferred treatment 
(some after repeated OGD to confirm diagnosis), 21% (22/106) continued regular surveillance. 
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In 2012 the NOGCA conducted an organisational survey to investigate the services available for the 
management of HGD in England at a local cancer network level, and reported on adherence to 
national guidelines for the management of HGD (20, 125).  Valid responses were obtained from 137 
out of 151 NHS trusts (90.7%).  The results of the survey are summarised below:  
- 26 out of 30 Cancer Networks (86.7%) had a policy for the management of HGD. 
- 105 trusts (76.6%) reported that the diagnosis of HGD was confirmed by a second 
pathologist with an interest in GI pathology. 
- 130 trusts (94.8%) reported that patients with HGD were discussed at the upper GI MDT, this 
could be either at their local hospital or the patient could be referred on to their local 
specialist centre for discussion at their UGI MDT.  Mechanisms for referral to the MDT varied 
locally, with 11 (8.5%) trusts reporting that they had no specific mechanism for the referral 
of patients with HGD to their specialist MDT.   
- 132 (96.4%) trusts reported having access to both endoscopic and surgical treatments for 
HGD within their Cancer Network.  Further details on the proportion of trusts who reported 
access to different therapeutic modalities is shown in Table 1-7. 
 
Table 1-7 Therapeutic procedures available for patients with HGD 
 Available at local trust or another hospital 
with their Cancer Network, n (%) 
Oesophagectomy 134 (97.8%) 
Endoscopic mucosal resection 133 (97.1%) 
Argon plasma coagulation 116 (84.7%) 
Radiofrequency ablation 111 (81.0%) 
Photodynamic therapy 100 (73.0%) 
Laser therapy 75 (54.7%) 
 
The results of this survey raised several areas requiring further investigation, firstly reported 
adherence to some of the BSG guidelines remains poor, for instance only 76.6% of trusts reported 
that the diagnosis of HGD was confirmed by a second pathologist, and secondly there was significant 
variation in availability of the difference HGD treatment modalities across the country.   
One of the key new recommendations of the most recent BSG guidelines was that endoscopic 
treatment with EMRs should be centralised to high volume centres (20).  This mirrors changes which 
have already been seen in OG cancer surgery services where care is centralised to a limited number 
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of specialist centres across England, based on a large body of evidence demonstrating that better 
outcomes can be achieved after oesophagectomy in high volume centres (126-128).  The evidence 
base for centralising the endoscopic treatment of HGD treatment is currently limited, with only a 
few studies investigating the effect of treatment volumes on the outcomes of endoscopic 
interventions.  A study by Van Vilsteren et al showed that EMRs performed in the hands of 
experienced therapeutic endoscopists were associated with very low complication rates, but that 
the risk of complications was significantly higher when procedures were performed by less 
experienced endoscopists performing their first 20 procedures (129).  On the basis of this evidence, 
the most recent BSG guidelines for the management of Barrett’s oesophagus suggest that EMRs 
should be performed in high volume tertiary referral centres (managing at least 15 cases per year) 
(20).  A further recent study looked at the effect of the learning curve on RFA outcomes, this found 
that the number of RFA treatment sessions required to achieve complete eradication of intestinal 
metaplasia was significantly higher if the endoscopist/centre had performed less than about 30 RFA 
procedures (130).  This was in contrast to an earlier study which had reported that performing RFA 
appeared to be associated with minimal learning curve (129).  Finally a recent observational study 
from Australia investigated the effect of assessment in specialist centres on the detection and 
staging of oesophageal cancer within Barrett’s oesophagus, and found this improved detection of 
lesions (67).  This evidence suggests that further consideration should go into whether all 
management of patients with HGD should be centralised to a few specialist centres in England.   
1.3 Conclusions from the literature search 
The aim of this thesis is to investigate the patterns of management and outcomes associated with 
the treatment of early neoplastic changes in the oesophagus in England.  As a result of the literature 
search performed in this Chapter several clear gaps in the literature were identified.  These will be 
discussed in further detail in the next section, and will provide the focus for my research.   
 Management of HGD in England 1.3.1
As discussed earlier, previous studies have suggested that there is considerable variation in the 
management of patients with HGD in England (120-123).  However these studies were conducted 
between 1997 to 2005, a period when endoscopic therapies were still relatively novel and were not 
widely available.  Since these studies were performed there has been a dramatic shift in the 
treatment options available for the management of HGD, such that endoscopic therapy is now 
considered the treatment of choice for HGD in preference to either surgery or surveillance alone 
(20).  Furthermore these surveys all relied on clinician reported management of patients with HGD, 
and did not have access to patient level data. 
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In April 2012 the NOGCA started collecting data on all patients with a new diagnosis of oesophageal 
HGD and this provides us with a unique opportunity to investigate the management of HGD at a 
national level using patient level data.  The aim of Chapter 3 is to investigate current management of 
HGD in England and adherence to published guidelines.  In addition it aims to investigate whether 
specific features in the patient’s management pathway (e.g.  confirmation of the diagnosis on repeat 
biopsy, discussion as the MDT and management of the patient in a high volume centre) impact on 
choice of treatment modality.   
 Choice of endoscopic treatment  1.3.2
When treating dysplastic Barrett’s oesophagus it is important to ensure that both the dysplastic 
lesion of concern and the remaining Barrett’s segment is effectively treated in order to reduce the 
risk of cancer developing in future (86, 87).  There are two broad approaches that can be taken to 
achieve this, resection of the entire Barrett’s segment endoscopically or ablation (with prior 
resection of any visible nodules).   
Given that RFA is now the ablative treatment of choice in Europe for treating dysplastic Barrett’s 
oesophagus, it is important to investigate its safety and efficacy and compare this to that of 
complete endoscopic resection.  To date there has only been one RCT done directly comparing the 
two approaches (131), so Chapter 4 aims to address this gap in the literature by systematically 
reviewing the literature comparing the risks and benefits of each approach.   
 Are we missing the opportunity to diagnose some cases of oesophageal cancer at an 1.3.3
early stage? 
Although endoscopy is seen as the definitive investigation for the diagnosis of oesophageal cancer, 
several previous studies have suggested that a significant proportion of cancers are potentially 
missed at initial endoscopy (53-59).   
However, these studies have been subject to significant limitations.  Firstly, the majority of studies 
have been small single centre studies (53-56, 58), preventing meaningful investigation into patient 
factors that may be associated with a missed diagnosis.  Secondly many of the studies were 
conducted over many years (up to 14 years (53)), during a period when there were significant 
advances in endoscopic equipment and imaging techniques, this may make their results less 
applicable to current practice.  Finally very few studies had access to information on stage at 
diagnosis; this makes it difficult to be certain that lesions were missed at previous endoscopy.  Prior 
endoscopies may have been performed as part of a planned surveillance programme, representing 
good practice by promoting early diagnosis of cancer rather than representing missed lesions.  As a 
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result, previous studies may have overestimated the true value.  Nonetheless, if the natural history 
of oesophageal cancer is long as previous studies have suggested (60, 61), then one should consider 
any cancers detected within three years of endoscopy as potentially missed.  It is also important to 
realise that none of the previous studies have attempted to investigate the impact of a missed 
diagnosis on patient outcomes.   
By linking data provided by the NOGCA on all patients diagnosed with oesophageal cancer in England 
over a 1 year period with data provided by Hospital Episode Statistics (HES) and Office for National 
Statistics (ONS) mortality data, Chapter 5 aims to investigate the proportion of oesophageal cancers 
missed at endoscopy on a national level and address some of these limitations.   
 Management and outcomes for early oesophageal cancers 1.3.4
Over recent years endoscopic therapy has superseded surgery in the management of early 
oesophageal cancers (20, 132, 133).  In the past several studies have attempted to investigate 
outcomes associated with both techniques, but these have been associated with significant 
limitations.  Most importantly previous studies have collected data over many years (up to 14 years), 
over a period when significant advances were made in the endoscopic treatment of early stage 
disease.  Previous national studies have also had limited access to details on patient characteristics 
which may potentially confound their results.  Finally it is important to realise while most research 
comes from specialist research centres, no national population studies investigating outcomes for 
early oesophageal cancers have been performed outside of the US. 
As a result it is important to investigate the patterns of management of early oesophageal cancer in 
England, looking at the use of surgery and endoscopic therapy and the associated long-term 
outcomes.  This study was made possible by linking data from the NOGCA to HES and ONS, and the 
results are presented in Chapter 6.   
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2. Methods 
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The research presented in this thesis results from work done while I was Clinical Fellow for the 
National Oesophago-Gastric Cancer Audit (NOGCA).  Data derived from the audit dataset was linked 
with other data sources, to provide the comprehensive dataset required for further analysis.  The 
specific methodology for each study is detailed in the relevant chapter, while the more general 
methodology relevant to all chapters is outlined below. 
2.1 Data sources 
 National Oesophago-Gastric Cancer Audit 2.1.1
The NOGCA was set up in October of 2006 with the aim of measuring the quality of care received by 
patients with oesophago-gastric (OG) cancer in England and Wales, and was funded for three years 
in the first instance.  The long term goal was to identify areas where services could be improved in 
future and to provide a bench mark against which services could be compared.   
The first audit collected data between 1st October 2007 and 30th June 2009.  On the back of the 
success off the first audit, funding was secured for further five years.  The second audit started 
collecting data again in April 2011 (after a gap in data collection of 21 months).   
In April 2012 the audit was extended to include patients with high grade dysplasia (HGD) of the 
oesophagus.  The aim was to assess whether patients with HGD were managed consistently with 
uniform access to different treatment modalities across the UK, and to assess whether management 
of these patients was adhering to current UK guidelines.   
The audit is commissioned by Healthcare Quality Improvement Partnership (HQIP), and is a 
collaboration of:  
- Clinical leadership from:  
o The Association of Upper Gastro-Intestinal Surgeons (AUGIS) 
o The British Society of Gastroenterology (BSG) 
o The Royal College of Radiologists (RCR) 
- Project management and administrative support is provided by The National Clinical Audit 
Support Program (NCASP) of the Health and Social Care Information Centre (HSCIC).   
- Audit design, analysis and reporting is performed by The Clinical Effectiveness Unit (CEU) of 
The Royal College of Surgeons of England (RCS) and London School of Hygiene and Tropical 
Medicine (LSHTM) 
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A project team made up of representatives from these organisations work together to run the audit.  
Additional clinical input is provided by the Clinical Reference Group (CRG), who meet on a bi-annual 
basis to discuss the progress of the audit and future plans.   
2.1.1.1 Inclusion Criteria  
The NOGCA is a national clinical audit that prospectively collects data.  All patients aged 18 or over, 
diagnosed in England or Wales are eligible for inclusion in the audit if they meet the following 
criteria:  
Oesophago-Gastric Cancer 
- Invasive, epithelial cancer of the oesophagus, gastro-oesophageal junction (GOJ) or stomach 
(International Classification of Diseases (ICD-10) codes C15 and C16) 
- Date of diagnosis  
o First audit: 1st October 2007 and 30th June 2009  
o Second audit: 1st April 2011 to present 
The audit does not include patients with non-epithelial OG tumours (e.g.  endocrine tumours, 
gastrointestinal stromal tumours or lymphomas), due to the different behaviour and management of 
these tumours.   
High grade glandular dysplasia of the oesophagus 
- Diagnosed with high grade glandular dysplasia of the oesophagus 
- First biopsy (either initial referral or as part of routine surveillance) which diagnosed HGD 
performed after 1st April 2012 
The audit does not include patients with squamous dysplasia.   
2.1.1.2 Dataset 
The dataset was designed to collect information on all stages of the patient’s management pathway.  
It was developed by the project team with input from the CRG.   
The dataset collects information on a series of different forms:  
- Tumour Record: Provides details on patient characteristics, site of cancer, staging 
investigations, pre-treatment tumour stage (according to the Union for International Cancer 
Control Classification (UICC) TNM classification) (68), comorbidities, performance status 
(Eastern Cooperative Oncology Group (ECOG) score for performance status in cancer 
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patients) (Appendix A)), treatment intent and management plan.  It also collects data on 
date of diagnosis, hospital where diagnosis was made, and source of referral.   
- Surgery Record: For patients undergoing surgery it collects details on surgical intent, pre-
operative American Society of Anaesthesiologists (ASA) grade (Appendix B), surgical 
approach, postoperative complications, and length of stay.   
- Pathology Record: A separate post-operative pathology record is collected for all surgical 
patients.  This records information on final post-operative stage, status of the resection 
margins, and the number of lymph nodes examined and involved.   
- Oncology Record: Provides details on any oncological treatments administered and their 
timing and treatment intent.   
- Endoscopic/Radiological Palliative Record: Provides details on the first endoscopic 
procedure a patient undergoes post-diagnosis, including its timing, and any immediate 
complications.   
- Oesophageal High Grade Dysplasia Dataset (From April 2012 only): Provides details on the 
initial diagnosis of HGD, initial endoscopic report, planned treatment and outcomes after 
endoscopic mucosal resection.  Data items were pilot tested and selected to allow practice 
to be compared against current guidelines for the management of HGD (20, 78).   
 
Data for both the first and second audits were collected using the same skeleton dataset, but 
revisions were made to the dataset in April 2012.  Changes included removing some items that were 
poorly completed and not reported on in the 1st audit, and making some additional variables 
mandatory (in order to improve case-mix adjustment).  Finally some data items were added to aid 
analysis of patient flow.  The final dataset is detailed in Appendix C. 
Data items were defined to be consistent with: 
- The Scottish Upper GI cancer dataset (July 2005) 
- The All Wales Oesophago-Gastric Cancer Minimum Reporting requirements (v. 2.0) including 
Core Reporting Items v5.0 
- The Royal College of Pathologists Datasets for reporting oesophageal and gastric cancers 
- The Royal College of Radiologists radiotherapy dataset (version 3.7) 
 
All variable definitions are clearly outlined in the NOGCA Data Manual (134). 
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2.1.1.3 Data Collection 
In England all National Health Service (NHS) hospitals are part of an NHS trust.  NHS trusts consist of 
one or more hospitals that provide the required range of services to a particular patient population, 
but are managed by a single management structure.  Each NHS trust was asked to prospectively 
identify all patients with a new diagnosis of oesophago-gastric cancer or HGD through their upper 
gastro-intestinal multidisciplinary team meetings (UGI MDT), and submit data on all patients via an 
online reporting system.  Within each trust local audit coordinators were responsible for managing 
the input of their data into the audit, with clinical teams providing assistance where needed to 
clarify responses.   
Participation in the NOGCA is mandatory for NHS trusts in England.  It is a requirement of the Health 
Act 2009 that trusts demonstrate their participation in this and other National Clinical Audits via 
their Quality Accounts which are submitted to the Secretary of State.  Since 2012 it has been a 
requirement that these Quality Accounts are externally audited.   
Additional steps were taken by the HSCIC in order to optimise data submissions to the audit.  Firstly 
the HSCIC provided trusts with an email address and contact details, so that trusts could contact 
them directly with any queries regarding data submission.  In addition the HSCIC sent regular 
newsletters and updates to trusts regarding the audit’s progress, highlighting any problems in either 
the quality of data submitted or low volumes of data submitted.   
2.1.1.4 Data Submission 
Data could be submitted to the audit in a variety of different ways, depending on where the patient 
was diagnosed. 
English Patients 
Data could be submitted to the audit in two ways:  
- If data was already being collected locally, then the relevant fields could be extracted and 
uploaded to the audits secure database via a ‘csv’ file upload facility 
- Alternatively data could be collected manually via a secure web-based data entry form 
The majority of trusts submitted records to the audit via data extraction from local databases, these 
records were uploaded as a ‘csv’ file.   
Data submitted to the audit was frequently analysed at a trust level.   
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Welsh Patients  
Data was provided by the Cancer Network Information System Cymru (CaNISC).  However, this data 
was limited and did not provide information on complications after surgery, or on patients with a 
new diagnosis of HGD.  As a result this data is not reported on for Welsh patients.   
2.1.1.5 Ethical Approval 
As the audit involved analysis of data for service evaluation it was exempt from the UK National 
Research Ethics Committee approval.  Section 251 approval was obtained for the collection of the 
personal health data from the Ethics and Confidentiality Committee. 
2.1.1.6 My responsibilities within the audit 
I started work as Clinical Research Fellow for the NOGCA in October 2012, and was based at the 
Royal College of Surgeons of England for the duration of this role.  Within this role I was supported 
by my supervisors and members of the Project Team.   
The work I performed in this role included: 
- Analysing the prospective data collected for the audit and drafting the Annual Reports (2, 
15, 77) 
- Revision of the High Grade Dysplasia dataset in September 2015 
- Communicating with clinical leads and audit coordinators at local NHS trusts to support data 
collection, addressing queries raised and providing feedback on the case-ascertainment and 
completeness of data submitted 
- Drafting regular newsletters to NHS trusts to update them on the audit’s progress  
- Communicating with AUGIS, BSG and RCR providing regular updates for their websites 
- Presenting the audit’s findings at national conferences including Digestive Disease 
Federation, National Cancer Intelligence Network, National Awareness and Early Diagnosis 
Initiative.   
 Hospital Episode Statistics (HES) 2.1.2
NOGCA records were linked with patient’s HES records to allow more in depth research to be 
performed.  HES is a national administrative health database, which records information on all day 
cases and admissions to English NHS hospitals since 1987 (135). 
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Each record describes the period during which a patient is under a particular hospital consultant (an 
episode).  Within HES it is possible for more than one episode to occur during an admission to 
hospital.  For each episode routine administrative data is recorded (e.g.  patient details, date of 
admission and discharge), as well as clinical data including information on comorbidities and 
complications and operative procedures that occur during an episode.  The ICD-10 system is used to 
record a primary diagnosis and up to 19 secondary diagnoses for each episode (12).  While up to 24 
operative procedures are recorded using the UK Office of Population Censuses and Surveys 
Classification version 4, 4th revision (OPCS-4) (136).   
Data was extracted from the HES database for all episodes relating to patients resident in England 
with an ICD-10 diagnostic code of C15 (oesophagus) or C16 (stomach), over a specified time frame.   
It should be noted that HES data is not available for patients treated in Wales, and as such Welsh 
patients are excluded from all analysis involving HES. 
 Mortality database from the Office for National Statistics (ONS) 2.1.3
The ONS collects information on the date and cause of death for all deaths registered in the UK.  The 
extract of ONS used for our work presented in this thesis was restricted to the date of death only.   
2.2 Data Linkage  
In order to provide the in depth analysis required to address the specific research questions raised in 
this thesis, data from the NOGCA was linked to HES and the ONS death register records for each 
patient.  Data from the various data sources were linked using a hierarchical deterministic approach, 
using patient identifiers including NHS number, date of birth, sex and postcode.  Overall linkage 
rates were very good.   
By linking the NOGCA dataset to HES it was possible to estimate the overall case ascertainment for 
each audit.  For the first audit it was estimated that 71% of cases of OG cancer were recorded in the 
audit (85), this figure had risen to 83% by the second audit with over 95% case ascertainment for 
patients undergoing curative surgery (77). 
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2.3 Statistical Analysis 
Details on specific statistical methods used in each Chapter are included in the Methods section for 
that Chapter.  Certain aspects were common throughout; STATA 11.2 (Statacorp, College Station, TX, 
USA) was used for all statistical calculations.   
Patient characteristics were compared across the groups using the t-test and chi-square test as 
appropriate to test for statistically significant differences between the groups.  All p-values were two 
sided and those <0.05 were considered statistically significant.   
Multiple logistic regression models were used to examine the relationship between a previous 
endoscopy, planned treatment intent (curative vs palliative) and 1-year survival.  Relative risks were 
adjusted for patient age, sex, and performance status, as well as type of cancer, tumour site and 
TNM stage at diagnosis.  Missing values for these covariates were imputed using multiple imputation 
by chained equations (138).  The imputation model included age at diagnosis, sex, type of cancer, 
tumour site, performance status and referral source.  Ten imputation datasets were created. Logistic 
regression models were also used to investigate the effect of HGD treatment centre volume on 
treatment plan, this time adjusting for only the patient’s age and sex.  
Kaplan-Meier graphs were used to present estimated 5 year survival rates for patients with early 
oesophageal cancer according to their primary treatment modality.  The log rank test was used to 
test for significant difference between survival curves. 
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3. Management of Barrett’s Oesophagus High Grade 
Dysplasia  
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3.1 Introduction 
As discussed in Chapter 1, studies have shown that Barrett’s oesophagus is a premalignant condition 
that progresses through a dysplasia-carcinoma sequence to oesophageal adenocarcinoma (37), as it 
does the risk of progression to cancer increases from 0.1% per year for non-dysplastic Barrett’s 
oesophagus (25) to 5.6% per year if high grade dysplasia (HGD) is present (36).   
It is therefore very important to ensure that patient’s found to have HGD are managed optimally to 
minimise the risk of progression to cancer in future.  As a result the BSG has made recently updated 
their guidelines for the management of HGD, and their key recommendations are highlighted below 
(20).   
 
 
 
 
 
 
 
 
 
 
 
Previous studies have reported significant variation in the management of HGD on a national basis 
(120-123), although these studies have been subject to significant limitations (as discussed in 
Chapter 1).   
  
Summary of key BSG recommendations 
- Diagnosis of dysplasia should be confirmed by a second gastro-intestinal (GI) 
pathologist. 
- A high-resolution endoscopy should be performed by an expert in all patients with 
biopsy-detected HGD in order to detect visible abnormalities suitable for EMR.   
- All patients with dysplasia should be discussed at a specialist upper GI multi-
disciplinary team meeting (MDT). 
- Endoscopic treatment of HGD is preferred over oesophagectomy or endoscopic 
surveillance alone.   
- Endoscopic resection should be performed in high-volume tertiary referral centres, 
managing at least 15 cases per year.  While RFA should be performed in centres 
equipped to perform EMR.   
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3.2 Aims of this chapter 
Since April 2012 the National Oesophago-Gastric Cancer Audit (NOGCA) has been prospectively 
collecting data on all patients newly diagnosed with HGD of the oesophagus in England.  This 
provides us with the unique opportunity to examine the management of HGD in England using 
patient level data.   
This study aims to: 
- Provide an initial description of this cohort of patients 
- Provide a summary of treatment modalities used to treat HGD in England 
- Compare current practice with national guidelines (20) 
3.3 Methods 
This population based cohort study used data collected prospectively for the NOGCA.  All patients 
with a new diagnosis of oesophageal HGD between 1st April 2012 and 31st March 2013 reported to 
the NOGCA were considered for inclusion in this study.   
Trusts were asked to prospectively identify all patients with a new diagnosis of HGD through their 
upper gastro-intestinal (UGI) multi-disciplinary team meeting (MDTs), and submit data for these 
patients to the audit via the online reporting system (as discussed in Chapter 2).  This was felt to be a 
secure method for identifying these patients because results from the previous NOGCA 
organisational survey in 2012 revealed that 92% of trusts had specific mechanisms in place to ensure 
all new cases of HGD were discussed at their MDT and had their data recorded in their MDT 
information system (125).  As a result identification of new cases of HGD did not rely on the 
engagement of individual clinicians.   
In order to optimise submissions to the audit for patients with HGD, the Health and Social Care 
Information Centre (HSCIC) sent out repeated newsletters to the audit leads at each NHS trust to 
ensure they were aware of the inclusion of patients with HGD in the audit.  Furthermore, all 
pathologists with an interest in UGI pathology in England were contacted by the Royal College of 
Pathologists, to make them aware of the inclusion of patients with HGD in the NOGCA and to remind 
them of the requirement to refer such patients to the UGI MDT.   
The NOGCA HGD dataset collected data on patient characteristics, the process of diagnosis, findings 
at initial endoscopy, treatment planning, and treatment provided (Appendix C).  Within this dataset 
some variables were mandatory, and had to be entered by the trust in order for the record to 
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successfully upload onto the audit platform, but other variables were made optional in order to 
reduce the burden of data collection and maximise the case ascertainment of the audit.  The option 
of ‘not known’ was also available for several of the data items.  A summary of the variables used in 
this paper are shown in Table 3-1. 
Table 3-1 NOGCA dataset variables analysed for patients with HGD, including whether the submission of the 
variable was mandatory 
Mandatory Non-mandatory 
Date of endoscopic biopsy Length of circumferential columnar lining 
Hospital of first biopsy Maximum length of columnar lining 
Second biopsy Date that the treatment plan was agreed 
Second biopsy confirmed HGD Treatment plan agreed at a specialist MDT 
meeting 
Hospital at which treatment plan was made  
Planned treatment modality (Endoscopic mucosal 
resection, endoscopic submucosal dissection, 
photodynamic therapy, radiofrequency ablation, 
argon plasma coagulation, multipolar 
electrocautery, laser therapy, cryotherapy, no active 
treatment, surveillance) 
Option of ‘not known’ 
Route to referral 
Appearance of HGD (flat, nodular, depressed) 
Barrett’s segment 
HGD lesion (uni- focal or multifocal)$ 
Second pathologist confirmation of diagnosis 
 
$ Focality of lesion was based on the patient’s pathology report 
 
At the analysis stage the cohort of patients with HGD was stratified by patient characteristics (e.g.  
age at diagnosis, route to referral), whether the diagnosis was confirmed by a second pathologist 
and whether the case was discussed at a specialist MDT to assess whether these characteristics were 
associated with the choice of treatment.  In addition trusts where treatment was provided were 
classified as high or low volume (based on whether they managed 15 or more cases a year (20)), and 
analysis was performed to assess the effect of trust volume on treatment plan.   
The chi-squared test was used to compare differences across patient groups, with p-values <0.05 
considered statistically significant.  Logistic regression models were used to investigate the effect of 
centre volume on treatment plan.   
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3.4 Results 
 Patient Characteristics 3.4.1
465 patients were diagnosed with HGD in England between 1st April 2012 and 31st March 2013, and 
had records submitted to the NOGCA.  Table 3-2 summarises the characteristics of these patients.  
The mean age of patients at diagnosis was 71.3 years (SD ± 10.5 years), and 333 (71.6%) patients 
were male.  246 (52.9%) patients were diagnosed following investigation of symptoms, with the 
majority of the remainder being diagnosed as a result of Barrett’s surveillance (n=183, 39.4%). 
Table 3-2 Characteristics of patients diagnosed with HGD  
Patient Demographics  
Number of patients, n 465 
Age, years (mean ±SD) 71.3 ± 10.5 
Sex, n (%*)  
  Male 333 (71.6) 
  Female 132 (28.4) 
Source of Referral, n (%*) 
  Symptomatic 246 (52.9) 
  Surveillance 183 (39.4) 
  Not known 36 (7.7) 
 
* Column percentage 
 Diagnosis  3.4.2
Of the 154 NHS trusts participating in the NOGCA across England, 103 (67%) submitted data on 
patients newly diagnosed with HGD.  The number of cases diagnosed at each trust varied hugely, 
median 3 (IQR 2-5) (Figure 3-1).   
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Figure 3-1 Number of patients diagnosed with HGD at each trust  
 
Where a diagnosis of HGD was made 263 (56.6%) patients had the diagnosis confirmed on a repeat 
biopsy and 270 (79.4%) patients had the diagnosis of HGD confirmed by a second pathologist (for 
125 patients this information was not recorded).   
 Endoscopic findings 3.4.3
It was not mandatory to submit details on the endoscopic findings to the NOGCA; as a result this 
information was missing for some cases.  Where known the overall patterns of endoscopic findings 
are summarised in Table 3-3.  In 112 (24.1%) cases the maximum circumferential length of Barrett’s 
was recorded, the mean circumferential length (±SD) was 4.6cm (±3.7).  42 of these patients had a 
short segment of Barrett’s oesophagus, less than 3cm.   
Further details about the endoscopic appearance of the Barrett’s segment were available for 245 
patients, where this was known 139 (56.7%) cases had an endoscopically visible nodule, 98 (40.0%) 
had flat mucosa and in 8 (3.3%) cases there was a depressed lesion.  The proportion of endoscopies 
done for symptomatic referrals did not vary according to the whether the lesion was nodular or flat.   
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Table 3-3 Endoscopic findings of patients diagnosed with HGD  
Endoscopic findings  
Length of circumferential Barrett’s, n (%*) 
  <3cm   42 (37.5) 
  3-10cm    55 (49.1) 
  >10cm   15 (13.4) 
  Missing 353 
Endoscopic appearance, n (%*) 
  Flat mucosa   98 (21.1) 
  Nodular lesion 139 (29.9) 
  Depressed lesion     8 (  1.7) 
  Not known 220 (47.3) 
Type of lesion, n (%*) 
  Unifocal 136 (29.3) 
  Multifocal 100 (21.5) 
  Not known 229 (49.2) 
 
* Column percentage 
 Management of HGD 3.4.4
30.0% of patients were referred onto a specialist centre for treatment; as a result only 77 trusts 
treated patients with HGD.  Trusts treated between 1 and 34 cases over the year, with only 8 trusts 
treating 15 or more cases (Figure 3-2).   
Figure 3-2 Number of patients who had treatment for HGD planned at each trust  
 
Once a diagnosis of HGD was confirmed, 86.0% (374/435) of cases were discussed at an UGI MDT in 
order to plan their treatment.  However, there were frequently significant delays between the date 
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when HGD was first diagnosed on biopsy and the date the treatment plan was agreed (Table 3-4).  
The median delay was 36 days (IQR 18-78), but 22 patients (6.3%) waited more than 6 months.   
Table 3-4 Delay between date of diagnosis of HGD and date when treatment plan was made  
Delay from diagnosis to 
treatment plan (n=465) 
Frequency, n (%*) 
< 30 days 156 (44.4) 
30-90 days 123 (35.0) 
90-180 days   50 (14.3) 
>180 days   22 ( 6.3) 
Missing 114 
 
* Column percentage 
Choice of primary treatment modality was investigated and is summarised in Table 3-5.  Almost a 
third of patients were planned to receive no active treatment or undergo surveillance alone.  This 
proportion increased significantly as the patient’s age increased, such that while 19.5% of patients 
under 65 were managed by surveillance alone this figure increased to 63.8% for patients aged 85 or 
more at diagnosis.  Patients with flat HGD lesions were more likely to have no planned active 
treatment than those with nodular lesions (26.5% vs 14.4%, p=0.02), but whether the lesion was 
multifocal or unifocal did not impact on choice of treatment.   
Table 3-5 Management of patients with HGD  
 Number of patients, n (%*)  
Primary treatment modality (n=465)  
  Endoscopic treatment 290 (62.4) 
  Surgery   26 (  5.6) 
  Surveillance 138 (29.7) 
  No treatment$   11 (  2.4) 
Choice of endoscopic treatment (n=290)  
  Endoscopic mucosal resection 184 (63.4) 
  Radiofrequency ablation   67 (23.1) 
  Endoscopic submucosal dissection   15 ( 5.2) 
  Other ablative therapy   24 ( 8.3) 
 
* Column percentage 
$ Patient did not receive any treatment and had no further surveillance endoscopies planned 
 
Additional factors associated with choice of treatment included whether the diagnosis of HGD was 
confirmed (either on repeat biopsy or by a second pathologist), whether the patient was referred to 
a specialist centre for treatment, whether the case was discussed at the UGI MDT and the volume of 
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patients treated at the trust.  Patients who had had the diagnosis of HGD confirmed on second 
biopsy were significantly more likely to receive active treatment (76.8% vs 56.4%, p<0.001), as were 
patients who had the diagnosis confirmed by a second pathologist (78.2% vs 58.6%, p=0.001).  
Furthermore patients who had their case discussed at the UGI MDT (73.5% vs 44.3%, p<0.001), or 
who were referred to a specialist centre for treatment (83.0% vs 59.7%, p<0.001) were more likely to 
be actively treated.  Finally patients managed in high volume NHS trusts (planning treatment for 15 
or more cases a year) were more likely to receive active treatment (87.8% vs 55.4%, p<0.001).  After 
adjusting for age and sex, our results showed that patients managed in high volume trusts were five 
times more likely to receive active treatment than patients managed in lower volume trusts (Table 
3-6).   
Table 3-6 Association between volume of patients who had treatment planned at trust and choice of treatment  
Trust volume 
 
N N (%) who received 
active treatment  
Odds Ratio (95 % CI) Adjusted Odds Ratio 
(95 % CI)* 
< 5   77   44 (57.1%) 1 1 
5 – 9 124   70 (56.5%) 0.97 (0.56-1.73) 0.87 (0.48-1.58) 
10 – 14   84   44 (52.4%) 0.82 (0.44-1.54) 0.76 (0.40-1.46) 
>=15  180 158 (87.8%) 5.39 (2.86-10.16) 4.94 (2.57-9.51) 
Total 465    
 
* Rates adjusted for patient age (treated as continuous) and sex 
 
For 182 (91.5%) patients who had had an endoscopic resection the outcome of the resection was 
known.  120 (65.9%) patients had the lesion completely excised but for the remaining 62 (34.1%) 
patients the excision was incomplete.  Where the excision was incomplete 13 patients went on to 
require an oesophagectomy, while 17 had a further endoscopic resection, and the remaining 32 
were managed by surveillance alone.  The final pathological diagnosis following endoscopic resection 
was altered in 89 (48.9%) cases, with 24 (13.2%) patients found to have no evidence of HGD or IMC 
in the resected specimen and 65 (35.7%) patients found to have evidence of more advanced disease. 
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3.5 Discussion 
For the first time this study has explored the management of patients with oesophageal HGD using 
patient-level data in England.  This study corroborates the findings of previous studies, reporting on 
clinician’s perceptions of the management of HGD, by revealing considerable variation in its 
management.  This study highlighted two key findings.  Firstly, a third of patients received no active 
treatment for HGD.  Secondly, patients were more likely to receive active treatment for HGD if they 
had been referred to a specialist centre or they were managed at a high volume trust.  The later 
finding supports the new BSG recommendation that care of patients with HGD should be centralised 
(20).   
Previous studies have reported that within a segment of Barrett’s oesophagus dysplastic changes are 
frequently focal and microscopic (139, 140).  This suggestion is supported by the fact that 57.6% 
patients in this study had a unifocal lesion and in 40.0% of cases the mucosa was flat.  As a result 
diagnosis of HGD is difficult unless a rigorous biopsy regimen is followed.  The BSG currently 
recommend that when surveying a segment of Barrett’s oesophagus biopsies are taken of any visible 
nodules, with additional random quadrantic biopsies taken every 2 cm (20, 78).  If only a few 
selective biopsies are taken there is an increased chance of a dysplastic lesion being missed (141, 
142).  In the past studies from both the UK and US have reported that adherence to this 
recommendation is poor, with the guidelines followed in only half of cases (121, 123, 141).  The 
current NOGCA dataset did not allow further investigation into this, however changes were made to 
the dataset in September 2015 which will allow this to be studied in future.   
Histological criteria for the classification of dysplastic Barrett’s were developed in 1988 (143), 
despite this studies continue to demonstrate significant inter-observer variability in the diagnosis of 
dysplasia (144).  As a result, the BSG guidelines recommend that where a diagnosis of HGD is made 
the diagnosis is confirmed by a second pathologist (20, 78).  This is based on evidence showing that 
the risk of progression to cancer is higher where the diagnosis of HGD has been confirmed by two 
pathologists (40, 41).  Compliance with this recommendation appears to be improving, in this study 
79.4% of patients had the diagnosis of HGD confirmed by a second pathologist.  In comparison, only 
55% of clinicians reported having the diagnosis of HGD confirmed by a second pathologist in 2001 
(123).   
Once a diagnosis of HGD is confirmed it is recommended that all cases of HGD that are considered 
for active treatment are discussed at the UGI MDT to determine the most appropriate course of 
treatment (20, 78).  Adherence to this recommendation was generally good in this study, with 86.0% 
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cases discussed at an MDT.  However 44.3% of patients who had not been discussed at the MDT 
went on to receive active treatment as well.  It is also concerning to note that there were frequently 
significant delays between diagnosis and discussion at the MDT, with a fifth of patients waiting more 
than three months.  This may reflect ‘surveillance by proxy’ and puts the patient at risk of disease 
progression.   
In terms of patient management a key finding of this study was that a third of cases of HGD were 
managed by surveillance alone, this is contrary to current recommended practice (20).  The 
proportion of patients managed by surveillance alone increased as the age of the patient increased, 
but limitations of the dataset prevented us from investigating whether this was due to increased 
prevalence of comorbidities making them unfit for treatment or patient/clinician choice.  This area 
needs further exploration and changes to the HGD dataset should make this possible in future.  
Finally patients who were managed in high volume centres were significantly more likely to receive 
active treatment, after adjusting patient’s age and sex.  While this could in part reflect the fact that 
patients referred on to these high volume centres were already identified as requiring endoscopic 
treatment, it is also possible that clinicians at non-specialist hospitals are not fully informed about 
the possible treatment options.  As a result patients may be making choices about treatment 
without adequate information about endoscopic treatment options. 
 Strengths and limitations 3.5.1
Until now there have been no national databases available which collect data on all patients newly 
diagnosed with HGD of the oesophagus.  This study is therefore unique in providing an insight into 
the management of HGD on a national level using patient level data, previous national surveys have 
relied on clinician reported management instead.  In the long term it is hoped that by linking this 
dataset with Hospital Episode Statistics it will be possible to monitor further treatment and long-
term outcomes for patients with HGD in England.   
The most significant limitation of this dataset was the lack of certainty regarding the case 
ascertainment achieved by the audit.  For patients diagnosed with oesophago-gastric (OG) cancer 
who have data submitted to the audit, the 2nd audit is consistently achieving around 80% case 
ascertainment (2, 77, 145).  In contrast for HGD there is no unique International Classification of 
Diseases (ICD-10) code or Systematized Nomenclature of Medicine (SNOWMED) code which can be 
recorded in national data sources to identify patients with HGD.  As a result it is not possible to 
calculate the actual case ascertainment of the NOGCA for HGD patients.  Overall 67% of NHS trusts 
submitted data for patients with HGD to the NOGCA, while this suggests cases of HGD were missed 
in the NOGCA given the low incidence of HGD one would not expect all of the smaller trusts to have 
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diagnosed a case of HGD in a year.  Furthermore, it is important to realise that data collection for 
patients with HGD is managed by the same procedures at a trust level as collection of data for 
patients with OG cancer, so there is no reason to believe that the case-ascertainment for HGD is not 
as high as it is for OG cancer.   
Uncertainty about the study’s case ascertainment does not impact on the major findings of this 
study, namely the high proportion of patients managed by surveillance alone and the considerable 
variation in its management across NHS trusts.  While the magnitude of any selection bias cannot be 
quantified, it is possible to confidently infer the direction of any bias.  Cases of HGD which were 
discussed at the UGI MDT were more likely to be considered for active treatment and have their 
data submitted to the audit.  As a result our study is likely to have underestimated the proportion of 
patients managed by surveillance alone.   
The final limitation of the NOGCA HGD dataset was the limited information available about the 
endoscopic findings and the lack of information about why a particular treatment modality was 
chosen.  Several variables relating to endoscopic findings were not mandatory or had the option of 
unknown; as a result conclusions relating to the endoscopic findings are limited.  In addition the 
dataset did not collect information on the reason why endoscopic surveillance was chosen.  In order 
to address these limitations substantial changes have since been made to the HGD dataset 
(Appendix D).   
Publication related to this work: Chadwick et al, Gastrointestinal Endoscopy 2016; 
83(4): 736-42 
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4. Systematic Review comparing radiofrequency ablation and 
complete endoscopic resection in treating dysplastic Barrett’s 
oesophagus 
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4.1 Introduction 
Barrett’s oesophagus has long been known to be a significant risk factor for the development of oesophageal 
cancer (23, 24, 30), with the risk of cancer increasing from 0.1% per year for non-dysplastic Barrett’s 
oesophagus (25, 33) to 5.6% per year where there is evidence of high grade dysplasia (HGD) (36).  As a result 
UK guidelines recommend that patients with HGD of the oesophagus should be considered for treatment to 
reduce the risk of progression to cancer in future, with the most recent guidelines favouring endoscopic 
therapy over surgery or surveillance alone (20).   
In considering the endoscopic treatment of dysplastic Barrett’s oesophagus, it is important to ensure that 
the entire Barrett’s segment is treated because localised resection of only the dysplastic lesion of concern at 
endoscopy can be associated with significant problems.  Firstly, dysplasia is often an incidental finding on 
random biopsies with no visible lesion.  Secondly, early studies demonstrated that localised endoscopic 
resection was associated with a significant risk of a metachronous lesion developing in the remaining 
Barrett’s segment in future (86, 87).  As such current best practice is to remove or ablate the entire Barrett’s 
segment when treating an area of dysplasia.  As briefly discussed in Chapter 1 two distinct endoscopic 
approaches can be used to achieve this endoscopically, complete endoscopic resection and ablation. 
Complete endoscopic mucosal resection (CEMR)  
Complete endoscopic mucosal resection of the entire Barrett’s segment was first reported in humans by 
Seewald et al (146), with a report by Satodate et al going on to demonstrate the subsequent process of 
squamous reepithelialisation of the Barrett’s segment (147).  Since then several studies have been done to 
show that complete endoscopic resection can achieve complete eradication of Barrett’s mucosa (71, 73, 148-
155).   
CEMR has the advantage of providing a large histological specimen, and may also result in the removal of the 
genetic alterations associated with neoplasia, which in turn may reduce the risk of progression to neoplasia 
in future (156).  It is also hoped that by resecting the mucosa as deep as the submucosa, one may also be 
able to reduce the risk of ‘buried Barrett’s’.  Buried Barrett’s describes the presence of ‘glandular epithelium 
beneath intact layer of squamous epithelium without communication to the surface’ (157).  These areas of 
Barrett’s oesophagus are not visible endoscopically, so there is concern about the risk of malignant 
transformation without detection (158). 
However complete endoscopic resection is associated with significant disadvantages, firstly concerns have 
been raised about the high risk of complications associated with this technique (131), there is also 
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uncertainty about whether this technique is appropriate when treating long segments of Barrett’s 
oesophagus (146, 156).   
Endoscopic Ablation 
An alternative to CEMR is using endoscopic ablation to ablate the entire segment of Barrett’s mucosa; this 
allows regrowth of normal squamous mucosa in its place.  Ablation can be achieved using a variety of 
techniques including photodynamic therapy (PDT), argon plasma coagulation (APC), and more recently, 
radiofrequency ablation (RFA).  As discussed in Chapter 1 studies using PDT and APC have reported relatively 
poor outcomes, with a high risk of future recurrence (101-104, 159).  However, over the last decade 
radiofrequency ablation (RFA) has been developed, this approach uses high-frequency alternating current to 
destroy the neoplastic mucosa.  A recent review has demonstrated superior efficacy and lower complication 
rates associated with RFA compared to previous ablative techniques (105), as a result RFA is now considered 
the ablative treatment of choice in Europe.   
Ablation of the neoplastic mucosa rather than resection is also associated with several disadvantages.  
Firstly, this approach does not provide a histological specimen.  It is therefore important to ensure that any 
visible nodules are resected prior to the application of RFA.  Secondly there is concern that ablative therapy 
may allow the persistence of genetic alterations associated with Barrett’s oesophagus in the mucosa, thus 
increasing the risk of future neoplasia (160).   
4.2 Aims of this chapter 
Despite numerous studies being done in the past to investigate the safety and efficacy of both complete 
endoscopic resection and radiofrequency ablation individually, only one randomised controlled trial (RCT) 
has attempted to directly compare the two techniques (131).   
So the aim of this chapter is to provide a systematic review of the available of literature, and compare the 
efficacy and safety of these two techniques.  This is important because RFA is substantially more expensive 
than complete endoscopic resection and may require multiple procedures over 6 months or more.  
Therefore, in order to justify the use of RFA in the future it must be convincingly proven to be superior to 
complete endoscopic resection, in terms of both efficacy and risk of complications. 
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4.3 Methods 
The reporting of this systematic review follows the recommendations of the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) (161).   
 Study selection criteria 4.3.1
For the purposes of this review the inclusion and exclusion criteria were defined as follows: 
Inclusion criteria 
- Original research papers published in the last 10 years, no language restrictions were in place 
- Study population: Adults over 18, with evidence of HGD or intramucosal cancer (IMC) within a 
segment of Barrett’s oesophagus at the point of inclusion 
- Aim of treatment: Complete eradication of all dysplasia and intestinal metaplasia in the oesophagus 
- Intervention: Complete endoscopic resection or RFA used to treat the neoplastic lesion and the 
remaining Barrett’s mucosa.   
 
Exclusion criteria 
- Studies where participants had had previous endoscopic treatment for Barrett’s oesophagus (e.g.  
use of APC or PDT), or previous reflux surgery 
- Studies where the patient cohorts overlapped with other studies, these studies were excluded to 
avoid dual reporting of the same patient cohort.  In this situation the paper with the longest follow 
up and most detailed results was included.   
 Search Process and Study Selection 4.3.2
In January 2013 a systematic literature search was performed to identify any published studies that met our 
inclusion and exclusion criteria.   
An initial database search of PubMed (MEDLINE), EMBASE and the Cochrane Library was performed.  The 
search strategy is outlined in Table 4-1.  After removing duplicate records, a total of 251 references were 
identified. 
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Table 4-1 MEDLINE and EMBASE search strategy 
# Searches Results 
1 (barret* and (oesophagus or oesophagus)).mp.[mp=ti, ab, ot, nm, hw, kf, 
ps, rs, ui, an, sh, tn, dm, mf, dv, kw] 
16,967 
2 (endoscop* or EMR or RFA or HALO or radiofrequ*).mp.[mp=ti, ab, ot, 
nm, hw, kf, ps, rs, ui, an, sh, tn, dm, mf, dv, kw] 
392,674 
3 Complet*.mp.[mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, sh, tn, dm, mf, dv, 
kw] 
1,726,898 
4 1 and 2 and 3 1,213 
5 Limit 4 to human 1,023 
6 Limit 5 to yr=”2002-Current” 817 
7 Limit 6 to ‘review articles’ [Limit not valid in Embase; records were 
retained] 
566 
8 6 not 7 251 
 
Bibliographies of included articles and the abstracts from the last 3 years of Digestive Disease Week were 
also reviewed to identify additional studies that should be considered for inclusion.  Results from abstracts 
were only considered if there was sufficient information included in the abstract to demonstrate that the 
study met the review’s inclusion criteria, and was of an acceptable methodological standard. 
Two independent observers (myself (GC) and Sheraz Markar (SM)) then screened all the abstracts to 
determine eligibility for inclusion in the study.  Finally full text of potentially relevant publications was 
reviewed to determine final inclusion in this review.   
 Summary Measures 4.3.3
The principal outcome measures assessed were complete eradication of dysplasia (CE-D) and intestinal 
metaplasia (CE-IM) at the end of planned treatment.  This was defined as the absence of any dysplasia or 
intestinal metaplasia, respectively, on oesophageal biopsies taken within 12 months of completing 
treatment.   
‘Escape treatment’ was allowed during the initial treatment stage.  This was defined as any treatment 
deviation away from the pre-planned treatment regime prior to the completion of the initial treatment 
regimen.  For instance, use of RFA to ablate small areas of residual Barrett’s oesophagus after complete 
endoscopic resection.  The frequency with which ‘escape’ treatment was needed was noted and recorded in 
Table 4-3. 
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Secondary outcomes assessed included: 
- CE-D/CE-IM at follow-up endoscopy, more than 12 months after completion of treatment.  During 
follow up, additional ‘touch up’ treatment to treat small areas of recurrence was allowed, but it’s use 
was again clearly documented and reported (Table 4-5, Table 4-6).   
- Short term complications, related to the initial endoscopic treatment e.g.  bleeding or perforation. 
- Long term complications of treatment e.g.  oesophageal stenosis, ‘buried Barrett’s’.   
- Long term risk of cancer recurrence. 
 Data Extraction 4.3.4
Data was independently extracted from relevant publications by myself and SM, using a standardised 
extraction template (Table 4-2). 
Table 4-2 Data extraction template 
Study Details 
Where was study performed? Country, type of hospital, single or multicentre. 
Study years  
Specific inclusion and exclusion criteria  
Assessment of study quality Guided by the Newcastle-Ottowa assessment scale. 
Patient Characteristics 
Number of patients  
Age of patients Including median or mean age, and range of ages. 
Length of Barrett’s treated Including median or mean length, and range. 
Presence of nodular lesion   
Intervention 
Planned Intervention CEMR or RFA. 
Number of treatment sessions  
Use of ‘escape treatment’ Number requiring this and type of treatment used e.g.  APC. 
Use of acid suppressive medication Use of proton pump inhibitors, hydrogen receptor antagonists 
and sucrulfate. 
Outcome Assessment 
Pathology review Number of pathologists who reviewed the sample, and access 
to specialist pathologists 
Biopsy protocol Details of where biopsies were taken from, including those 
taken from the neo-squamous columnar junction and just distal 
to it. 
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Table 4-2 Data extraction template (continued) 
Results 
CE-D and CE-IM at completion of 
treatment 
 
Follow up duration Time in months patient was followed up for, starting from once 
patient finishes planned treatment (time=0). 
Where follow up duration was only reported from the start of 
treatment this was also recorded.   
CE-D and CE-IM at end of follow up  
Incidence of short term complications  Including details of management strategy 
Incidence of long term complications Including details of management strategy 
Prevalence of Buried Barrett’s Were biopsies taken specifically looking for Buried Barrett’s and 
if so what was the incidence? 
Incidence of cancer recurrence or 
progression of HGD to cancer 
 
 
 Presentation of Results 4.3.5
Results of the studies reviewed are presented on an intention to treat (ITT) basis.  Patients were excluded 
from analysis if the initial endoscopy revealed the lesion was not amenable to endoscopic treatment (e.g.  
due to submucosal invasion) and the patient was subsequently referred for alternative treatment e.g.  
surgery.   
Where patients were lost to follow up or did not complete treatment, they had success of treatment 
determined by most the recent histology results.  Where this was unknown, they were considered to be 
treatment failures.   
It is important to note that some of the retrospective studies did not report results on an ITT basis, and only 
reported results for patients who successfully completed treatment and follow up, these studies are 
highlighted in the results (Table 4-5, Table 4-6). 
 Statistical Methods  4.3.6
Summary estimates for effectiveness outcomes were generated by pooling results from the prospective 
studies to calculate an overall mean and 95% confidence intervals (95% CI).  Retrospective studies were 
excluded from this analysis because a significant proportion of these did not report results on an ITT basis. 
Overall means for all the studies were also calculated for the risks of short and long-term complications.   
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 Assessment of study quality 4.3.7
The majority of studies were observational cohort studies (162), so the Newcastle-Ottawa Scale for cohort 
studies was chosen to assess the quality of included studies.  Details of this assessment scale are provided in 
Appendix E. 
4.4 Results 
 Search Results 4.4.1
The initial search identified 1,213 potentially relevant papers (Table 4-1).  In line with the study’s exclusion 
criteria, 190 studies not conducted on humans and 206 papers published before 2002 were excluded from 
this review.  A further 566 papers were review articles, and these were also excluded.   
This left us with 251 papers to be considered for inclusion, each paper was reviewed independently by GC 
and SM to determine whether the study met this reviews inclusion and exclusion criteria.  On the basis of 
the title and abstract 221 studies were excluded, and after full text review a further 9 papers were excluded 
(Figure 4-1) (72, 163-170).  Repeating the search in October 2013 yielded one additional paper that met the 
study inclusion criteria (171).  None of the abstracts identified included sufficient detail for inclusion in this 
review.  There was no disagreement between the two reviewers with regard to which studies that should be 
included in this review. 
Figure 4-1 PRISMA flow diagram of study selection process 
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of title and abstract 
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- 2 Excluded as patients reported in other trials (72, 168)
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This left 22 studies for inclusion in this review, including 18 cohort studies (10 evaluating complete 
endoscopic resection alone (71, 73, 146, 149-155), and 8 evaluating RFA alone (172-179)), and 2 RCTs (1 RFA 
vs Sham (180), and 1 RFA vs complete endoscopic resection (131)).  The final two studies were follow up 
papers, providing longer term results from previous trials (171, 181).  The design of individual studies is 
summarised in Table 4-3.   
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Table 4-3 Summary of study design and participant characteristics for all included studies 
  
Study Enrolled Patients Planned Intervention  
1
st
 Author  Country Study Years Study Design No of 
centres in 
study 
N Median Age 
(Range or IQR) 
or mean* (±
SD) 
Median Length of 
Barrett’s in cm 
(Range or IQR) or 
mean* (±SD) 
Planned 
treatment 
Overall 
Median no.  
treatment 
sessions 
(Range/IQR) 
or mean*  
Reported use of 
‘escape’ treatment  
Use of acid 
suppressive 
medication 
after 
treatment 
N (%) Type of 
treatment 
Van Vilsteren 
(131) 
Netherlands 
and 
Germany 
2006 - 2008 Randomised 
Control Trial 
Two 22 69 (55-73) C2M4 (IQR C1-3, 
M2-5) 
RFA arm 3 (IQR 3-4) 4 
(18%) 
2 hot 
biopsy, 1 
ER, 1 ER + 
APC 
Triple 
therapy 
25 68 (45-88) C2M4 (IQR C1-3, 
M2-5) 
CEMR arm 2 (IQR 1-3) 8 
(32%) 
5 RFA, 3 
APC 
Triple 
therapy 
Shaheen 
(181) 
US NR Multicentre 61 66* (±8.8) 5.2* (±2.1) RFA follow up 
trial 
NR NR NR PPI 
Shaheen 
(180) 
US NR Multicentre 42 66* (±9.1) 5.3* (±1.9) RFA vs Sham NR NR NR PPI 
Phoa (171) Netherlands NR Prospective 
Cohort study 
 
Multicentre 55 65* (±9.6) C4M5 (IQR C1-5, 
M4-8) 
RFA follow up 
trial 
NR NR NR Triple 
therapy 
Chung  (73) Australia 2003 - 2010 Multicentre 77 65 (IQR 58-70) C0M2 (IQR C0-1, 
M1-3) 
CEMR 2 (IQR 1-3) NR NR PPI 
Pouw (172) Europe NR Multicentre 24 65* (±9.8) C6M8 (C2-9, M4-
10) 
RFA 3 (IQR 3-4) 2 (8%) 2 ER Triple 
therapy 
Sharma  (173)  US 2006 - 2007 Single 24 73 (51-81) 6 (1-12) RFA 2(IQR 3-4) 2 (8%) 2 ER PPI 
 
Gondrie (174) Netherlands 2005 Single 11 60 (57-67) 5 (4-7) RFA 5 1 (9%) 1 ER Triple 
therapy 
Gondrie (175) Netherlands 2005 - 2006 Single 12 70 (IQR 53-76) 7 (IQR 6.5-8) RFA 4 1 (8%) 1 ER Triple 
therapy 
Peters (149) Netherlands 2003 - 2004 Single 39 65* (±7.9) 4 (3-5) CEMR 3 (2-3) 34 
(87%) 
34 APC Triple 
therapy 
Giovannini  
(150) 
France  1999 - 2002 Single 21 63* (42-75) 3.5*(2-5) CEMR 2 2 
(10%) 
2 CRT PPI 
Seewald 
(146) 
Germany 2000 - 2002 Single 12 64 (43-88) 5(1-10) CEMR 2-3 NR NR PPI 
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Table 4-3 Summary of study design and participant characteristics for all included studies (continued) 
IQR – Interquartile range, SD – Standard deviation of mean, NR – Not reported, NA – Not Applicable 
US – United States, CxMx – Length of Barrett’s according to Prague Criteria 
ER – Endoscopic resection, APC- Argon Plasma Coagulation, CRT - Chemoradiotherapy 
PPI – Proton Pump Inhibitor, Triple therapy – PPI and hydrogen receptor antagonist and sucrulfate 
Study Enrolled Patients Planned Intervention 
1st Author  Country Study 
Years 
Study Design No of 
centres in 
study 
N Median Age 
(Range or IQR) 
or mean* (±
SD) 
Median Length of 
Barrett’s in cm 
(Range or IQR) or 
mean* (±SD) 
Planned 
treatment 
Overall 
Median no.  
treatment 
sessions 
(Range/IQR) 
or mean*  
Reported use of 
‘escape’ treatment  
Use of acid 
suppressive 
medication 
after 
treatment 
N, % Type of 
treatment 
Kim (176) US 2006 -2011 Retrospective 
Cohort  
 
Single   65 69 * (±10) 4.4 * (±3.1) EMR/RFA 3.5 * NR NR PPI 
104 64 * (±11) 4.8 * (±3.4) RFA only 2.8 * NR NR PPI 
Gerke (151) US 2006 - 2010 Multicentre   41 70 (49-85) 3 (1-10) CEMR 2 (1-6) 3 
(7%) 
3 APC PPI 
Pouw (152) Europe 2000 - 2006 Multicentre 169 64 (57-71) 3 (2-5) CEMR 2 (2-3) 103 
(61%) 
103 APC PPI 
Lyday (177) US 2004 - 2008 Multicentre   31 NR NR RFA NR NR NR NR 
Vassilou  (178) NR 2005 - 2009 Single   12 NR NR RFA NR NR NR PPI 
Chennat  (71) US 2003 - 2008 Single   49 67 * (49-86) 2 (1-12) CEMR 1-4 23 
(47%) 
19 APC, 4 
RFA 
PPI 
Pouw  (153) Belgium 2001 - 2006 Single   34 67 * (±10) C1M4 (C0-2, M2-5) CEMR 2 (IQR 1-2) 27 
(79%) 
27 APC PPI 
Ganz (179) US 2004 - 2007 Multicentre   92 68 (IQR 59-75) 6 (IQR 5-8) RFA NR NR NR PPI 
Larghi  (154) US 2001 - 2004 Two   24 64 * (±12) 2.5 (1-8) CEMR 2 (1-5) 13 
(54%) 
13 APC PPI 
Lopes  (155)  France 1999 - 2005 Single   41 66 * (±11) 4.9 * (±3.4) CEMR 1.5 * 7 
(17%) 
6 APC, 1 
CRT, 1 CRT 
+ APC 
PPI 
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Overall the studies included 1,087 patients (532 treated with CEMR and 555 with RFA).  Some patients 
included in these studies had not completed treatment, so these patients were only considered in analysis 
looking at the safety of the two techniques and not analysis looking at treatment efficacy.  Individual studies 
were small, ranging from 11 to 77 patients for prospective studies and 12 to 169 patients for retrospective 
studies.  The three largest studies were all retrospective (152, 176, 179).   
Patient characteristics were similar across studies (Table 4-3), except for median length of Barrett’s which 
varied between 2cm (73) and 10cm (178).   
All studies using RFA as the primary treatment modality included some patients with nodular disease. In the 
study by Shaheen et al some patients had had an endoscopic resection performed just prior to inclusion in 
the study (180).  Where RFA was the treatment modality of choice, the initial endoscopic resection did not 
extend beyond the nodule of concern and in nearly all cases a single specimen was removed and the 
resection was completed at a single session (Table 4-6).  Only one study directly compared outcomes for 
patients with and without resections prior to RFA (176). 
 Methodological Quality 4.4.2
Methodological quality of included studies was formally assessed using the Newcastle-Ottawa scale for 
cohort studies (Table 4-4).   
All studies included patients with confirmed HGD or IMC, and had a representative patient population.  The 
papers all described the application of the two techniques clearly and in a reproducible manner.   
The majority of included studies were observational in design, looking at patient outcomes after treatment.  
Only three studies had a control group (131, 180, 181), and only one of these studies directly compared the 
two techniques (131).  These three studies scored highly on comparability, because patients were randomly 
allocated across the groups.   
All studies assessed outcomes based on independent assessment of histological findings.  There was most 
difference between the studies in relation to their follow period and how they accounted for patients lost to 
follow up.  Follow up periods were generally short and inconsistently reported, with some studies reporting 
follow up duration from the start of treatment instead of completion, meaning that actual follow up period 
may have been considerably shorter  (173, 177-179, 181).  Several studies reported follow up periods of less 
than 1 year after completion of treatment (146, 149, 174, 176, 180), while four studies did not report results 
on an intention to treat basis (177-179, 181). 
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Table 4-4 Newcastle-Ottawa assessment of study quality 
 Selection Comparability Outcome 
Representiveness 
of the exposed 
cohort 
Selection of 
the non-
exposed 
cohort 
Ascertainment 
of exposure 
Demonstration 
outcome of 
interest not 
present at start 
Comparability of 
cohorts on the 
basis of the 
design or analysis 
Assessment 
of outcome 
Was the follow 
up long enough 
for outcomes to 
occur 
Adequacy of 
follow up 
cohorts 
Van Vilsteren 
(131) 
1 1 1 1 2 1 1 1 
Shaheen (181) 1 1 1 1 2 1 1 0 (Follow up 
not reported 
on ITT basis) 
Shaheen (180) 1 1 1 1 2 1 0 1 
Phoa (171) 1 No control  1 1 No control 1 1 1 
Chung (73) 1 1 1 1 1 1 
Pouw (172) 1 1 1 1 1 1 
Sharma (173) 1 1 1 1 1 1 
Gondrie (174) 1 1 1 1 1 1 
Gondrie (175) 1 1 1 1 0 1 
Peters (149) 1 1 1 1 0 1 
Giovannini 
(150) 
1 1 1 1 1 1 
Seewald (146) 1 1 1 1 0 1 
Kim (176) 1 1 1 1 0 1 
Gerke (151) 1 1 1 1 1 1 
Pouw (152) 1 1 1 1 1 1 
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Table 4-4 Newcastle-Ottawa assessment of study quality (continued) 
 
 
 Selection Comparability Outcome 
Representiveness 
of the exposed 
cohort 
Selection of 
the non-
exposed 
cohort 
Ascertainment 
of exposure 
Demonstration 
outcome of 
interest not 
present at start 
Comparability of 
cohorts on the 
basis of the 
design or analysis 
Assessment 
of outcome 
Was the follow 
up long enough 
for outcomes to 
occur 
Adequacy of 
follow up 
cohorts 
Lyday (177)  0 (Unknown for 
HGD subset) 
No control 1 1 No control 1 1 0 (Follow up 
not reported 
on ITT basis) 
Vassilou (178) 0 (Unknown for 
HGD subset) 
1 1 1 1 0 (Follow up 
not reported 
on ITT basis) 
Chennat (71) 1 1 1 1 1 1 
Pouw (168) 1 1 1 1 1 1 
Ganz (179) 1 1 1 1 Unknown 0 (Follow up 
not reported 
on ITT basis) 
Larghi (154) 1 1 1 1 1 1 
Lopes (155)  1 1 1 1 1 1 
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 Treatment Outcomes  4.4.3
Treatment technique was evenly split between the studies, with 11 using complete endoscopic resection and 
12 using RFA.   
Where complete endoscopic resection was used, the median number of resection sessions required was two.  
However in 9 studies additional ‘escape’ treatment was required during the treatment stage, most commonly 
APC to treat small areas of residual Barrett’s (Table 4-3).   
Where RFA was the primary modality, both circumferential and focal ablation was available in all except one 
study by Ganz et al where focal RFA was not available (179).  Standard energy settings and procedure 
protocols were used in all except two studies, one study by Lyday et al used lower energy settings for 
circumferential ablation (177), the other by Gondrie et al who only used the ‘double-double’ technique for 
focal ablation in the later part of their study (174).  Patients received a median of 2 RFA sessions, one 
circumferential and one focal.  ‘Escape’ treatment was only required in 5 studies, this commonly included 
resection of a residual nodule (131, 172-175) and APC (131). 
The short term efficacy of treatment was assessed at the end of endoscopic therapy.  Where complete 
endoscopic resection was used, complete eradication of dysplasia was achieved in 83-100% of patients, and 
complete eradication of intestinal metaplasia was achieved in 80-96% patients at the end of treatment (Table 
4-5).  Respective figures after RFA were 81-100% CE-D, and 55-100% CE-IM (Table 4-6).   
Several of the retrospective studies did not present results on an intention to treat basis, so in order to 
calculate the overall mean results for treatment efficacy the results from only the prospective studies were 
pooled.  On this basis, complete eradication of dysplasia was achieved in 95% (95% CI 87-99%) after complete 
endoscopic resection, and 92% (95% CI 85-96%) after RFA.  The corresponding figures for complete eradication 
of intestinal metaplasia were 89% (95% CI 79-95%) and 88% (95% CI 81-93%).   
Good long term treatment durability was seen with both complete endoscopic resection and RFA.  Overall 85-
100% of patients who received complete endoscopic resection had no evidence of dysplasia at follow up, 
compared to 79-100% of patients treated with RFA.  Respective figures for eradication of intestinal metaplasia 
were more variable, 75-100% after complete endoscopic resection and 54-100% after RFA.   
Reported follow up periods were relatively short, with a median follow up of 21 months (range 15-61) after 
RFA and 23 months (range 17-32) after complete endoscopic resection.  Furthermore the range of follow up 
periods reported within studies varied hugely, for instance Lopes et al reported a median follow up of 32 
months, but this ranged between 0-83 months for individual patients in this study (155).  Nonetheless it 
reassuring to note that a recent study by Phoa et al reported good treatment durability after 5 years follow up, 
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with successful maintenance of CE-IM in 54/55 (98.2%) patients (with only 3 patients requiring additional 
‘touch up’ treatment during follow up to achieve this level of response).   
Use of ‘touch up’ treatment to maintain durability of successful eradication was more frequent among 
patients who had been treated with complete endoscopic resection than those treated with RFA (Table 4-5, 
Table 4-6).  After complete endoscopic resection 27 patients required a repeat resection for a dysplastic lesion, 
while RFA and APC were also used in several studies to treat small areas of recurrence.  In contrast use of 
‘touch up’ treatment after RFA was limited to three studies, one used RFA to treat small areas of recurrence 
(although it was not reported how many patients required this) (180), while two studies used repeat 
endoscopic resection to treat IMC (171, 173), and one of these studies also treated a patient with recurrent 
low grade dysplasia using APC (171).   
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Table 4-5 Histological outcomes after complete endoscopic resection 
Study End of Treatment  Follow up Buried Barrett’s (%) 
1st Author  No. 
patients 
Intention to Treat 
(only oesophageal biopsies), n (%) 
Median time 
from treatment 
end in (months)  
Additional ‘touch up’ 
treatment during FU for 
recurrence 
Intention to Treat (only oesophageal 
biopsies), n (%) 
CE-D  CE-IM CE-D  CE-IM 
Van Vilsteren (131)  
(CEMR arm)  
25 25 (100%) 24 (96%) 20  1  
IMC at NSCJ treated with ER  
25 (100%) 24 (96%) 2 (8%) 
Chung (73) 77 100% ‘technical success’, 
endoscopic absence of visible 
Barrett’s but no biopsies taken 
17  - 70/73 (96%) 68/73 (93%) 0 (0%) 
Peters (149) 39 36 (92%) 33 (85%) - - - - 4 (11%) 
Giovannini (150) 20 - - 18  2 
HGD treated ER  
17 (85%) 15 (75%) - 
Seewald (146) 12 100% ‘technical success’, 
endoscopic absence of visible 
Barrett’s but no biopsies taken 
- - - - - 
*Gerke (151) 41 34 (83%) 33 (80%) 24  2  
1 LGD treated ER/RFA 
1 IM treated ER 
28/28(100%) 28/28 (100%) - 
**Pouw (152) 169 165 (98%) 146 (86%) 27  9 
3 HGD/IMC at NSCJ treated ER, 
6 IM treated ER/APC/biopsy 
156/160 (98%) 146/160 (91%) 5 (3%) 
Chennat (71) 32 - - 17  - 32 (100%) 31 (97%) 1 (3%) 
Pouw (153) 34 34 (100%) 31 (91%) 23  3  
2 HGD treated ER 
1 LGD treated APC  
31 (91%) 26 (76%) - 
Larghi (154) 24 - - 28  1  
IMC at NSCJ treated ER  
24 (100%) 22 (92%) 2 (8%) 
Lopes (155) 41 - - 32 10  
Treated repeat ER, with APC  in 
2 & CRT in 1 
- 37 (90%) - 
 
IMC – Intramucosal cancer, LGD – Low grade dysplasia 
APC – argon plasma coagulation, CRT – chemoradiotherapy, ER – endoscopic resection, NSCJ – Neosquamous columnar junction 
* Reported results at follow up for 32 patients where complete remission of IM initially, 4 of these dropped as only had LGD at initial endoscopy. 
** Reported results at follow up for 160 patients who achieved CE-D at end of treatment and continued follow up.    
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Table 4-6 Histological outcomes after RFA 
 
Study  Use of ER prior to RFA  End of Treatment Follow up Buried Barrett’s 
(%) 
1
st
 Author  No. 
patients 
Number 
(%) 
Median 
number of 
resection 
sessions 
Median 
number of 
resections per 
session 
Intention to Treat 
(only oesophageal biopsies) 
Median time 
from treatment 
end (months) 
Additional ‘touch up’ 
treatment during FU 
for recurrence 
Intention to Treat 
(only oesophageal biopsies) 
CE-D  CE-IM CE-D  CE-IM 
Van Vilsteren 
(131)  
(RFA arm)  
22 18 (82%) NR NR 21 (95%) 21 (95%) 15  - 21 (95%) 21 (95%) 0  
*Shaheen 
(181) 
 0 - - - - 24 ** Some patients had 
touch up RFA  
50/54 (93%) 48/54 (89%) - 
 0 - - 36 ** Some patients had 
touch up RFA 
23/24 (96%) - - 
Shaheen 
(180) 
 
42 0 - - 34 (81%) 31 (74%) - - - - - 
Phoa (171) 55 40 (73%) NR NR Not reported as patients 
followed up from other 
reported studies 
61 3 
1 LGD treated APC 
2 IMC treated ER 
54 (98%) 54 (98%) 0 
Pouw (172)   24 23 (96%) 1 NR 24 (100%) 23 (96%) 22  - 24 (100%) 22 (92%) 0  
Sharma (173) 24 2 (8%) 1 1 - - 23 **  2  
IMC found at 3 
months treated with 
ER 
19 (79%) 16 (67%) 0  
Gondrie 
(174) 
11 6 (55%) 1 1 11 (100%) 11 (100%) 14  - 11 (100%) 11 (100%) 0 
Gondrie 
(175) 
12 7 (58%) 1 2 12 (100%) 12 (100%) - - - - 0 
 
IMC – Intramucosal cancer, LGD – Low grade dysplasia 
APC – argon plasma coagulation, ER – Endoscopic resection, NR – Not reported 
* Studies where results are not reported on ITT basis, as information regarding rest of cohort was not available.   
** Studies in which follow up duration was recorded from the first endoscopic treatment, not the end of initial planned treatment.   
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Table 4-6 Histological outcomes after RFA (continued) 
 
IMC – Intramucosal cancer, LGD – Low grade dysplasia 
APC – argon plasma coagulation, ER – Endoscopic resection, NR – Not reported 
* Studies where results are not reported on ITT basis, as information regarding rest of cohort was not available.   
** Studies in which follow up duration was recorded from the first endoscopic treatment, not the end of initial planned treatment.   
Study  Use of ER prior to RFA  End of Treatment Follow up Buried Barrett’s 
(%) 1
st
 Author  No. 
patients 
Number 
(%) 
Median 
number of 
resection 
sessions 
Median 
number of 
resections per 
session 
Intention to Treat 
(only oesophageal biopsies) 
Median time 
from treatment 
end (months) 
Additional treatment 
during FU 
Intention to Treat 
(only oesophageal biopsies) 
CE-D  CE-IM CE-D  CE-IM 
Kim (176) 
(ER/RFA 
arm)  
50 65 (100%) 1 1 47 (94%) 44 (88%) - - - - - 
Kim (176) 
(RFA only 
arm)  
98 0 - - 81 (83%) 76 (78%) - - - - - 
*Lyday 
(177) 
31 7 (23%) NR NR 26 (84%) 17 (55%) 20 ** - 10/10 (100%) 8/10 (80%) 0 
*Vassilou 
(178) 
12 NR NR NR - - 20 ** - 10 (83%) 8 (67%) 0 
*Ganz (179) 92 24 (26%) NR NR - - 12** - 74 (80%) 50 (54%) - 
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 Short term complications  4.4.4
In order to calculate the short term complication rates associated with both techniques results from both 
the prospective and retrospective studies were pooled for each treatment modality.  The most frequent 
complication reported after complete endoscopic resection was bleeding, reported in 57 patients (10.7%), 
while oesophageal perforation was only reported in 12 (2.3%) patients (with all except one of these cases 
were managed conservatively (152)) (Table 4-7).  However reported complication rates did vary significantly 
across studies, with two studies reporting bleeding in a third of patients (146, 151), and several other studies 
not reporting any cases (71, 149, 152).   
In contrast very few patients treated with RFA suffered an immediate complication of treatment (Table 4-8), 
with bleeding only reported in 6 (1.5%) patients and no reported perforations attributable to RFA.   
 Long term complications  4.4.5
The most common long term complication after complete endoscopic resection was stricture formation, 
affecting 38% (201/529) of patients.  While most strictures were successfully treated with simple dilatation, 
some strictures were relatively resistant to treatment with 9 patients requiring a stent insertion and 6 
patients requiring incision of a stricture.  In contrast strictures were a relatively rare occurrence after RFA, 
affecting only 4% (16/403) of patients and most of these patients had had a previous endoscopic resection.  
Finally buried Barrett’s was infrequently reported across all studies, with only 14 cases reported after 
complete endoscopic resection (3.8%) and no reported cases after RFA (Table 4-7, Table 4-8).   
Nonetheless if endoscopic treatment is to replace surgery in the management of dysplastic Barrett’s 
oesophagus, then it is very important to establish the risk of progression to cancer in future.  Given the 
limited and varied follow up periods reported in studies to date, it was not possible to calculate the 
incidence of recurrence per year.  Despite these limitations reported rates of recurrence did appear to be 
low affecting only 9 (1.7%) patients treated with complete endoscopic resection and 11 (2.0%) patients 
treated with RFA.  6 of the cases detected after RFA may have been prevalent cancers, as they were 
detected within 3 months of starting treatment.  If you consider this to be the case, the risk of cancer 
developing during follow-up after RFA was 0.9% (5/539).   
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Table 4-7 Complications after complete endoscopic resection 
Study Adverse Events  Rates of progression to 
cancer Short Term Long Term 
1
st
 Author 
and Year 
Number 
Patients 
Acute bleeds 
endoscopically 
treated (%) 
Perforation (%) Overall short 
term adverse 
event rate (%) 
Stenosis requiring 
treatment (%) 
Van Vilsteren 
(131)  
(CEMR arm)  
25 5 (20%) 1 (4%) 
 
7 (28%) 22 (88%) 
Treated median 4 
dilatations, 1 required 
incision 
1/25 
IMC at NSCJ treated ER 
Chung (73) 77 7 (9%) 0 8 (10%) 24/74 (32%) 
Treated median 3 
dilatations  
0/77 
Peters (149) 39 0 1 (3%) 
 
3 (8%) 10 (26%) 
Treated median 5 
dilatations 
0/39 
Giovannini 
(150) 
 
21 4 (19%) 0 4 (19%) 0 0/21 
Seewald 
(146) 
12 4 (33%) 0 4 (33%) 2 (17%) 
Treated with 
dilatation 
0/12 
Gerke (151) 41 13 (32%) 2 (5%) 
 
15 (37%) 18 (44%) 
Treated with median 
3 dilatations, 1 
required incision and 
2 stents 
0/41 
Pouw (152) 169 0 4 (2%) 
(1 required 
surgery) 
8 (5%) 84 (50%) 
Treated median 3 
dilatations, 4 required 
incision and 2 stents  
1/169 
Persistent HGD 
progressed to cancer 
treated surgically  
Chennat (71) 49 0 0 2 (4%) 18 (37%) 
Treated median 1.5 
dilatations, 2 also 
required steroid 
injection and 1 stent. 
0/49 
Pouw (174) 34 14/55 (25%) 
sessions 
2 (6%) 
 
- 19 (56%) 
Treated median 2 
dilatations, 4 required 
stents 
1/34 
Recurrent cancer 
treated  surgically  
Larghi (154) 24 2 (8%) 0 2 (8%) 3 (13%) 
Treated median 1 
dilatation  
1/24 
HGD progressed to IMC 
treated ER 
Lopes (155) 41 8 (20%) 
(1 with 
perforation) 
2 (5%) 
 
9 (22%) 1 (2%) 
Treated with 
dilatation  
5/41 
1 died of cancer 
24mths after EMR, 1 
treated surgically and 3 
treated with repeat ER 
OVERALL    62/498  
(12.5%) 
201/529  
(38.0%) 
9/532  
(1.7%) 
 
IMC – Intramucosal cancer, ER – Endoscopic resection, NSCJ – Neosquamous columnar junction 
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Table 4-8 Complications after RFA 
Study Adverse Events Rates of progression to 
cancer (%) Short Term Long Term 
1
st
 Author  Number 
Patients 
Acute bleeds 
endoscopically 
treated (%) 
Perforation (%) Overall short 
term adverse 
events rate (%) 
Stenosis requiring 
treatment (%) 
Van Vilsteren 
(131) (RFA 
arm)  
22 2 (9%) 
Occurred after 
ER  
0 3 (14%) 3/21 (14%) 
Treated median 3 
dilatations.  All had 
had large ER prior to 
RFA. 
0/22 
Pouw (172) 24 0 1 (4%) 
After initial ER  
2 (8%) 1 (4%) 
Treated with 5 
dilatations, had had 
widespread ER prior 
to RFA 
0/24 
Sharma (173) 24 0 0 0 (0%) 0 2/24  
Diagnosed at 3 months, 
likely prevalent cancer 
treated successfully 
with ER 
Gondrie (174) 11 0 0 1 (9%) 0 0/11 
Gondrie (175) 12 0 0 0 1 (8%) 
Treated with 1 
dilatation, had had 
prior ER 
0/12 
*Kim (176) 
(ER/RFA arm)  
65 2 (3%) 
Occurred after 
ER 
0 2 (3%) 3 (5%) 
Treated with median 
1 dilatation 
0/65 
Kim (176) 
(RFA only 
arm)  
104 2 (2%) 0 2 (2%) 8 (8%) 
Treated with median 
1 dilatation 
2/104 
*Ganz (179) 142 0 0 0 0 2/142  
Diagnosed at 3 months, 
likely prevalent cancer 
Shaheen 
(181) 
63 Long term follow up trial  No additional cases 
Shaheen 
(180) 
42 Unknown heterogeneous group reported including HGD and LGD within Barrett’s. 1/42  
Diagnosed at 3 months, 
likely prevalent cancer 
treated successfully 
with ER 
Phoa (171) 54 Long term follow up trial 2/54  
Treated successfully 
with ER 
*Lyday (177) 39 Unknown, heterogeneous group reported including HGD, LGD and non-dysplastic 
Barrett’s.   
2/39  
1 Diagnosed at 2 
months, likely prevalent 
cancer.  1 diagnosed at 
4 months treated with 
CRT 
Vassilou (178) 25 Unknown, heterogeneous group reported including HGD, LGD and non-dysplastic 
Barrett’s. 
0 
OVERALL   10/404 (2.5%) 16/403  
(4.0%) 
11/539  
(2.0%) 
* Results from the safety cohort selected for inclusion in this review  
LGD – Low grade dysplasia, ER – Endoscopic resection, CRT – Chemo radiotherapy 
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4.5 Discussion 
With the publication of the most recent BSG guidelines for the management of Barrett’s 
oesophagus, there has been a shift in the approach taken to manage the disease.  Until recently 
oesophagectomy has been considered the treatment of choice for dysplastic Barrett’s oesophagus, 
due to the risk of disease recurrence with localised endoscopic therapies (78).  However significant 
advances in endoscopic techniques now allow the endoscopic treatment of dysplastic Barrett’s and 
the remaining Barrett’s segment, as a result endoscopic treatment is now replacing surgery as the 
treatment of choice for HGD (20).   
This review aimed to determine whether there was a significant difference in the efficacy and safety 
of two commonly used endoscopic techniques, complete endoscopic resection and RFA, in the 
management of dysplastic Barrett’s.  Only one RCT which compared the two approaches directly was 
identified (131), with the rest of the evidence presented in this review coming from observational 
cohort studies and one RCT comparing RFA to sham treatment (180).   
 Success of Treatment 4.5.1
In reviewing the efficacy of both treatments it is important to consider both the initial treatment 
success, and the long term durability of treatment.  Results from this review suggest that both 
complete endoscopic resection and RFA produce high rates of complete eradication of dysplasia and 
intestinal metaplasia at the end of treatment.  However in order to achieve these results additional 
‘escape’ treatment was required in 50% of patients treated with complete endoscopic resection, 
compared to only 11% of patients treated with RFA.  This is important because it impacts on the 
overall number of treatment sessions required.  Nonetheless it is encouraging to note that ‘escape’ 
treatment, with either resection or radiofrequency ablation, appears to be safe and effective.  In this 
respect RFA is superior to other ablative approaches, which can cause deeper scarring preventing 
future endoscopic resection. 
It has previously been suggested that resection of a nodule prior to RFA may impact on the efficacy 
of RFA, with Okoro et al reporting that this reduced the rate of CE-IM from 74% to 43% (164).  
However this study included patients with non-dysplastic Barrett’s oesophagus, which may have 
resulted in selection bias causing baseline differences between the groups because it is likely that 
only more advanced cases required resection of a nodule prior to ablation.  Only one study was 
identified in this review which compared outcomes for patients with dysplastic Barrett’s with and 
without resection of nodule prior to RFA (176).  This study reported no significant differences in 
treatment efficacy and complication rates between the two groups.  This is important because the 
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proportion of patients who required resection of a nodule prior to RFA varied significantly between 
studies (between 8% (173) and 96% (152)), so it is reassuring to note that this is unlikely to have 
impacted on outcomes. 
For patients treated with RFA there was significant variability in the success of treatment.  This 
variability in part reflects different equipment available for the studies.  If one considers the two 
studies with the lowest long term durability of CE-IM, in one study focal RFA was not available (179) 
and in the other focal RFA was only available in the later study years (180).  This may have resulted 
in small areas of residual Barrett’s oesophagus being left untreated, because further circumferential 
RFA was not justified.  Lower rates of CE-IM were also seen where the regimen for washing the 
probe was less intensive (179), since then more intensive standardised washing regimens have been 
introduced. 
In the past attempts have been made identify patient factors which predict the efficacy of RFA using 
sub-group analysis, but results have been variable.  Shaheen et al showed that although patients 
who were younger, with shorter segments of Barrett’s and shorter history of dysplasia were more 
likely to respond to RFA, none of these factors were significant on logistic regression analysis (181).  
A more recent study by Van Vilsteren et al found that poor response to RFA after 3 months of 
treatment may predict failure to successfully eradicate intestinal metaplasia (182).  Active reflux 
oesophagitis has also been reported to be associated with lower success rates, this may account for 
the high rates of successful eradication in studies using triple acid suppression (131, 149, 152, 174, 
175). 
Finally it is important realise that studies followed variable biopsy regimens when assessing the 
success of treatment.  Current UK guidelines recommend that quadratic biopsies are taken every 
2cm from the entire Barrett’s segment (20), but debates continue regarding the relevance of 
histology findings at and just distal to the neosquamous columnar junction (NSCJ) (183).  Morales et 
al reported that 25% of the healthy population had evidence of intestinal metaplasia in the cardia, 
suggesting this finding is clinically irrelevant (184).  However, other studies have suggested that the 
risk of recurrence of dysplasia was highest in this area (185, 186).  For this review outcomes for 
treatment efficacy were reported based on the absence of intestinal metaplasia and dysplasia on 
oesophageal biopsies only.  If one took the alternative approach and considered results of biopsies 
taken at and just distal to the NSCJ junction as well, this had minimal impact on rates of eradication 
of dysplasia but did reduce rates of eradication of intestinal metaplasia.  However, it was interesting 
to note that several studies reported recurrence of cancers around the NSCJ (131, 154, 172).  These 
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results suggest that while it is important to biopsy this area and treat dysplasia if found, the 
relevance of finding intestinal metaplasia is still questionable.   
The study went on to evaluate the durability of treatment, this analysis was associated with several 
problems.  Firstly follow up periods reported were short, and secondly there was lack of 
standardisation across studies in how follow up periods were reported.  The durability of RFA in 
treating non-dysplastic Barrett’s is well established, with Fleischer et al reporting that 92% of 
patients maintained CE-IM 5 years after treatment (187), however evidence with regard to the 
longer term durability of RFA  in treating dysplastic Barrett’s is more sparse.  A recent study by Phoa 
reported good durability of RFA after 5 years follow up (171).  The rest of the studies included in this 
review relied on outcomes after less than two years follow up, except a study by Shaheen et al who 
reported outcomes at three years but only for a select subgroup of patients who had achieved 
complete eradication of intestinal metaplasia at two years.  In contrast durability of complete 
endoscopic resection efficacy in treating dysplastic Barrett’s oesophagus has been reported more 
widely, with 4 studies (all retrospective) providing outcomes on an intention to treat basis after 
more than two years follow up (151, 152, 154, 155).   
While acknowledging these limitations the review demonstrates that overall follow up outcomes 
were comparable for the two techniques, but clearly demonstrates that additional ‘touch up’ 
treatment for recurrent disease was required more frequently after complete endoscopic resection 
than after RFA.  Allowing the use of ‘touch up’ treatment during follow up made the results more 
applicable to everyday clinical practice, but does affect comparability of results.   
 Complications  4.5.2
RFA appears to have significantly lower rates of both short and long term complications, compared 
to complete endoscopic resection.  The most frequent long term complication associated with both 
complete endoscopic resection and RFA was stricture formation, but the rate was significantly higher 
for patients treated with complete endoscopic resection compared to RFA (38% vs 4%).  This is 
concerning because strictures could be relatively resistant to treatment, in one recent study 5/22 
patients treated with complete endoscopic resection required five or more dilatations (131).  As a 
result some patients needed several therapeutic endoscopies to treat complications, this in turn 
increased their risk of further complications (e.g.  perforation).  While studies have suggested that 
pre-emptive dilation may reduce the incidence and duration of strictures, this is very resource 
intensive requiring frequent endoscopies (188).   
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Reasons for stenosis are multifactorial but may include both patient factors, such as pre- treatment 
luminal diameter and length of Barrett’s, and technical factors such as diathermy settings and 
resection technique (the last two factors are particularly important because they are potentially 
modifiable).  The relative importance of each factor is still debated and has been extensively 
explored, with several studies suggesting that increased overall length of Barrett’s was associated 
with higher stricture rates (73, 149, 151, 177), while others have suggested that it is the 
circumferential length of Barrett’s (154) or number of resection sessions required (71) which is 
important.   
Buried Barrett’s refers to the persistence of glandular epithelium beneath the new squamous 
epithelium, these buried glands are not visible endoscopically so there a risk of dysplastic 
progression without detection.  Overall the risk of buried Barrett’s reported in this review were very 
low, affecting 3-11% of patients treated with complete endoscopic resection, while there were no 
reported cases after RFA (although this has been reported elsewhere)(189).  Where buried Barrett’s 
was seen it was frequently associated with use of APC as an ‘escape’ treatment (71, 149, 154), 
suggesting use of APC should be avoided where possible.   
If endoscopic therapy is to replace surgery as the treatment of choice for HGD, it is very important to 
monitor the rates of progression to cancer during follow up.  A previous meta-analysis has reported 
that 5.6% of patients with untreated HGD progress to cancer each year (36).  Given the relatively 
short and variable follow up periods reported here it was difficult to assess the impact of endoscopic 
treatment on this risk, despite this our results do tentatively suggest that both treatments reduce 
this risk.  After a median follow up of just under 2 years the risk of progression to cancer was 1.7% 
after complete endoscopic resection and 0.9% after RFA.  These results should be interpreted 
cautiously, given the relatively small study populations and short follow up periods reported. 
 Other treatment considerations 4.5.3
Decisions regarding the most appropriate choice of endoscopic treatment must also take into 
account the individual merits of each technique.  Firstly complete endoscopic resection has the 
advantage of providing a large histological specimen, which can result in changes to the histological 
staging in up to 30% of cases (190).  This in turn can impact on planned treatment, it is therefore 
important that any suspicious nodules are removed prior to RFA.   
One also needs to consider the most appropriate treatment for a specific patient.  None of the 
studies included in this review used complete endoscopic resection to treat segments of Barrett’s 
with a median length >5cm, in contrast Vassiliou et al demonstrated the efficacy of RFA in Barrett’s 
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up to 10cm long (178).  It may therefore be sensible to restrict use of complete endoscopic resection 
to short segments of Barrett’s, given that studies have shown that length of Barrett’s is a significant 
factor in predicting the success of complete endoscopic resection (170), furthermore the risk of 
oesophageal strictures with complete endoscopic resection appears to increase when longer 
segments of Barrett’s are treated (73, 149, 151, 172, 177).   
Finally choice of treatment should be guided by endoscopist’s expertise and experience.  Studies 
have shown that there is a significant learning curve associated with learning complete endoscopic 
resection, and this is associated with a higher risk of complications when performing early 
procedures (129).  As a result it may be sensible to restrict the use of CEMR to high volume centres.  
In contrast the learning associated with learning RFA is subject to debate, an early study by Zemlyak 
et al reported minimal learning curve associated with learning RFA (169), while a more recent study 
found that the number of RFA treatment sessions required to achieve CE-IM was significantly lower 
if the endoscopist/centre had performed 30 RFA procedures (130).   
Publication related to this work: Chadwick et al, GI Endoscopy 2014; 79(5): 718-31 
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5. Cohort study of oesophageal cancer missed at endoscopy 
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5.1 Introduction 
Oesophageal cancer is frequently diagnosed at a late stage, as a result only 30-40% of patients are 
considered suitable for treatment with curative intent at diagnosis (2) and only 1 in 7 patients survive more 
than 5 years (1).  If one is going to make a significant impact on the overall survival from the disease, it is key 
to try and increase the proportion of oesophageal cancers diagnosed at an early stage.  To this end the UK 
Department of Health has adopted various initiatives to try and promote symptom recognition and early 
diagnosis of the disease, including the launch of the ‘Be Clear on Cancer’ campaign for oesophago-gastric 
cancer in January 2015 (191). 
In the meantime it is important to recognise the fact that a significant proportion of oesophageal cancers are 
potentially missed at initial endoscopy (53-59).  This is concerning because many clinicians consider that if a 
patient has had a recent normal endoscopy the diagnosis of cancer has been ruled out, leading to further 
delays in investigation.  It is therefore important to assess the impact a missed diagnosis may have on 
disease stage at diagnosis and patient outcomes.   
5.2 Aims of this chapter 
As discussed in Chapter 1 previous studies investigating the proportion of oesophageal cancers missed at 
endoscopy have been subject to significant limitations.  This study aims to address some of these limitations 
by investigating at a national level the proportion of oesophageal cancers missed at endoscopy within three 
years of diagnosis.  This analysis is made possible by linking data from three national databases.  The study 
goes on to investigate clinical findings at previous endoscopy and patient factors associated with higher miss 
rates, before going on to investigate the impact of a missed diagnosis on planned treatment intent and 1-
year survival.   
5.3 Methods 
This retrospective population-based cohort study used linked data from three national data sources: the 
second National Oesophago-Gastric Cancer Audit (NOGCA), mortality data from the Office for National 
Statistics (ONS), and data from the Hospital Episode Statistics (HES) database.   
Patients were considered for inclusion in this study if they were diagnosed with oesophageal or gastro-
oesophageal junction (GOJ) cancer between 1st April 2011 and 31st March 2012, and had a record 
submitted to the NOGCA which was successfully linked to HES.  The extract of HES data used in this study 
covered admissions between January 2008 and March 2012.  NOGCA records were linked to their HES and 
ONS records using the patient’s National Health Service (NHS) number (a unique identifier for each UK 
resident).  This resulted in 93% of NOGCA records being successfully linked to their corresponding HES 
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records.  Over the period covered by this study, the audit achieved 83% case-ascertainment when compared 
to HES (77). 
Having linked the three data sources it was important to verify consistency of key information across the 
datasets, in particular the accuracy with which ‘date of diagnosis’ was recorded in the audit.  It was 
important to verify this date because ‘date of diagnosis’ was used as a reference date when calculating the 
timing of previous endoscopies.  In order to do this all HES records in which a diagnosis of oesophageal or 
GOJ cancer was recorded were identified, by searching for the following International Classification of 
Diseases 10th edition (ICD-10) codes: C15 (malignant neoplasm of the oesophagus), C160 (malignant 
neoplasm of stomach cardia including gastro-oesophageal junction), and D001 (carcinoma in situ of the 
oesophagus) (136).  Then, the first date a diagnosis of oesophageal or GOJ cancer was recorded in HES was 
identified (as HES does not record the date of cancer diagnosis) and this date was compared to the ‘date of 
diagnosis’ recorded in the NOGCA dataset.  Patients were excluded from analysis if there was no record of 
oesophageal/GOJ cancer in HES, or if the diagnosis of oesophageal/GOJ recorded in HES was more than a 
month before the date of diagnosis in the NOGCA dataset.   
Data required for this study was extracted from each of the three separate datasets.  The NOGCA dataset 
provided information on patient demographics, route of referral, date of diagnosis, tumour site and stage, 
and treatment plan (Table 5-1).   
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Table 5-1 Summary of data extracted from the NOGCA dataset 
Patient Demographics 
Age at diagnosis  
Sex  
History of Barrett’s oesophagus  
Initial referral and diagnosis data 
Date of referral  
Source of referral GP referral (non-emergency, to outpatient clinics).  Further split 
into: 
- Urgent for suspected cancer 
- Non-urgent 
Referral after an emergency admission (via Accident & 
Emergency, Medical Admissions Unit, etc.)  
‘Other hospital referral’ (patients referred by a hospital 
consultant from a non-emergency setting).   
Defined according to NOGCA data manual (192). 
Date of diagnosis  
Diagnosis and Staging 
Type of cancer Adenocarcinoma, squamous cell cancer, other 
Tumour site Upper oesophagus, mid oesophagus, lower oesophagus, gastro-
oesophageal junction 
Stage at diagnosis Stage of cancer was defined using the Union for International 
Cancer Control (UICC) TNM 6 Classification (68). 
Treatment Plan 
Treatment Intent Curative, non-curative 
 
While HES was used to identify previous endoscopic examinations (oesophago-gastric duodenoscopy 
(OGDs)), by searching for the following operation procedure codes in HES: G16 (diagnostic fibreoptic 
examination of the oesophagus) and G45 (diagnostic fibreoptic examination of the upper gastrointestinal 
tract)(136).  In order to test the reliability of our coding algorithms and data linkage, we aimed to confirm 
that all patients included in analysis had had an endoscopy coded for in HES within one month of ‘date of 
diagnosis’ of cancer.  This analysis demonstrated that 92.5% of patients had had one recorded.   
Diagnostic codes recorded in HES relating to previous endoscopies were also analysed for common 
indications for endoscopy and common endoscopic findings (Table 5-2).   
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Table 5-2 ICD-10 diagnosis codes used to identify common indications for endoscopy and endoscopic findings.   
ICD-10 Code Indication for endoscopy  
Alarm symptoms 
D500   Iron deficiency anaemia secondary to blood loss (chronic) 
D508   Other iron deficiency anaemia 
D509   Iron deficiency anaemia, unspecified 
D649   Anaemia, unspecified 
R11   Nausea and vomiting 
R13   Dysphagia 
R190   Intra-abdominal and pelvic swelling, mass and lump 
R630   Anorexia 
R634   Abnormal weight loss 
Other gastro-intestinal symptoms 
K30   Dyspepsia 
R07   Pain in throat and chest 
R10   Abdominal and pelvic pain 
R12   Heartburn 
Gastrointestinal bleed 
K920   Haematemesis 
K921   Melaena 
K922   Gastrointestinal haemorrhage unspecified 
 Findings at endoscopy 
K20   Oesophagitis 
K21   Gastro-oesophageal reflux disease 
K221   Ulcer of oesophagus 
K222   Oesophageal obstruction 
K226   Gastro-oesophageal laceration haemorrhage syndrome 
K228   Other specified diseases of oesophagus – Haemorrhage of oesophagus NOS 
 
The principal outcome measures used to describe patterns of past endoscopy were: 
- Patients who had had an endoscopy within 3 and 12 months of cancer diagnosis 
- Patients who had had an endoscopy within 1 and 3 years before cancer diagnosis, but not in the year 
preceding diagnosis.   
Endoscopies performed within 3 months of cancer diagnosis were excluded, because they may have formed 
part of the diagnostic work (e.g.  where initial histology suspicious but non-diagnostic) or may have 
represented planned repeat endoscopies (e.g.  follow up of an oesophageal ulcer).  Endoscopies performed 
more than 3 years before the diagnosis of cancer were also excluded due to uncertainty regarding the 
natural history of the disease.   
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 Data Analysis 5.3.1
Initial analysis calculated the proportion of patients from the complete cohort, who had had an endoscopy 
within 3-12 months of diagnosis or within 1-3 years.  Rates of past endoscopy were then calculated and 
analysed by patient characteristics including age at diagnosis, sex, site and type of cancer, history of Barrett’s 
oesophagus, stage at diagnosis, and route to diagnosis.  The chi-square test was used to test the significance 
of differences across patient groups, and p-values less than 0.05 were considered statistically significant.  
Among patients who had had a previous endoscopy, the total number of endoscopies performed in the 3 
years prior to diagnosis and the frequency with which particular conditions were recorded was also noted.   
Finally, using multiple logistic regression models the relationship between a previous endoscopy, planned 
treatment intent (curative vs palliative) and 1-year survival was examined.  This model was used to estimate 
the relative risk of having planned curative treatment and surviving 1-year, respectively, for patients who 
had an endoscopy in the previous 3-12 months, and previous 1-3 years compared to patients who had not 
had a recent endoscopy.  Relative risks were adjusted for patient age, sex, and performance status, as well 
as type of cancer, tumour site and TNM stage at diagnosis.  Missing values for these covariates were 
imputed using multiple imputation by chained equations (138).  The imputation model included age at 
diagnosis, sex, type of cancer, tumour site, performance status and referral source.  Ten imputation datasets 
were created.   
5.4 Results 
 Selection of analysis cohort 5.4.1
The linked HES-NOGCA dataset identified 7,497 patients diagnosed with oesophageal or GOJ cancer between 
1st April 2011 and 31st March 2012 in England.  After excluding 331 (4.4%) patients who did not have a 
diagnosis of oesophageal/GOJ cancer recorded in HES (these patients frequently had a diagnosis of gastric 
cancer recorded instead) and 223 (3.0%) patients whose ‘date of diagnosis’ in the NOGCA dataset was not 
consistent with HES, 6,943 (92.6%) patients were left in the analysis cohort (Figure 5-1).   
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Figure 5-1 Flow diagram describing the inclusion of patients from the NOGCA dataset after linkage with data from HES 
dataset.   
Full NOGCA dataset. 
Patients diagnosed with cancer of the 
oesophagus or GOJ between April 
2011 and March 2012
N=8,062
Patients in NOGCA dataset linked to 
records from HES
N=7,497
Excluded
Patients in NOGCA dataset 
with no records in HES
N=565
Final linked NOGCA-HES dataset 
N=6,943
Excluded
Inconsistency of tumour site
N=331
Date of diagnosis uncertain
N=223
 
 
 Summary of Patient Characteristics 5.4.2
The characteristics of the analysed cohort are summarised in Table 5-3 (first column).  The mean (SD) age at 
diagnosis was 70.6 (±11.5) years and 70.8% of patients were men.  74.6% of cancers were located in the 
lower oesophagus or GOJ.  The majority (72.5%) of referrals came from General Practitioners (GPs), and 
three quarters of these referrals were urgent for suspected cancer.  Of the remaining cases, 10.4% of 
referrals resulted from an emergency admission and 17.2% of patients had been referred by another 
hospital consultant.  TNM stage at diagnosis was known for 4,787 patients (68.9%), and where this was 
known 72.1% of patients were diagnosed with stage 3 or 4 cancer and only 4.7% of cancers were diagnosed 
at stage 0 or 1.    
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Table 5-3 Characteristics of patients in the study cohort, and the proportion of patients who had undergone a previous 
endoscopy in the 3 years prior to diagnosis of oesophageal cancer 
 Entire 
Cohort, n 
(%*) 
Patients with 
no previous 
endoscopy, n 
(%*) 
Patients endoscoped within 
3-12 months of diagnosis, n 
(%**) 
Patients endoscoped within 
12-36 months of diagnosis, n 
(%**) 
Number Overall p-value Number Overall p-value 
Patients 6,943 6,406 214 (3.1)  323 (4.7)  
Age Group, year 
  <55    623 (   9.0)     574 (  9.0)  16 (2.6)  0.791   33 (5.3) 0.598 
  55-64 1,457 (21.0) 1,347 (21.0) 43 (3.0)   67 (4.6) 
  65-74 2,110 (30.4) 1,936 (30.2) 72 (3.5) 101 (4.8) 
  75-84 1,971 (28.4) 1,820 (28.4) 57 (2.9)   94 (4.8) 
  ≥85    782 (11.3)    729 (11.4) 25 (3.2)   28 (3.6) 
Sex, n (%) 
  Male 4,915 (70.8) 4,538 (70.8) 149 (3.0) 0.671 228 (4.6) 0.935 
  Female 2,028 (29.2) 1,868 (29.2)   65 (3.2)   95 (4.7) 
Type of cancer 
  Adenocarcinoma 4,827 (69.5) 4,458 (69.6) 152 (3.2) 0.814 217 (4.5) 0.514 
  Squamous cell 1,651 (23.8) 1,524 (23.8)   47 (2.9)   80 (4.9) 
  Other    465 (  6.7)    424 (  6.6)   15 (3.2)   26 (5.6) 
Site of Cancer1 
  Upper Oesophagus    351 (  5.1)     315 (  4.9) 19 (5.4)  0.040   17 (4.8) 0.099 
  Mid Oesophagus 1,411 (20.3) 1,303 (20.3) 37 (2.6)   71 (5.0) 
  Lower Oesophagus 2,891 (41.6) 2,648 (41.3) 94 (3.3) 149 (5.2) 
  GOJ 2,290 (33.0) 2,140 (33.4) 64 (2.8)   86 (3.8) 
History of Barrett’s Oesophagus 
  No 6,742 (97.1) 6,262 (97.8)  199 (3.0)  <0.001 281 (  4.2)  <0.001 
  Yes    201 (  2.9)    144 (  2.3)   15 (7.5)   42 (20.9) 
T-Stage at Diagnosis 
  Stage 0/1    302 (  5.9)    203 (  4.3) 47 (15.6) <0.001   52 (17.2) <0.001 
  Stage 2    848 (16.6)    753 (16.0) 36 (4.3)   59 (  7.0) 
  Stage 3 3,268 (63.9) 3,106 (65.9) 54 (1.7) 105 (  3.2) 
  Stage 4    694 (13.6)    654 (13.9) 16 (2.3)   24 (  3.5) 
  Missing values 1,831 1,690 58 (3.2)   83 (  4.5) 
TNM Stage at Diagnosis 
  Stage 0/1    227 (  4.7)    150 (  3.4) 36 (15.9) <0.001   41 (18.1) <0.001 
  Stage 2 1,106 (23.1)    995 (22.4) 44 (4.0)   67 (  6.1) 
  Stage 3 1,600 (33.4) 1,524 (34.3) 26 (1.6)   50 (  3.1) 
  Stage 4 1,854 (38.7) 1,775 (39.9) 26 (1.4)   53 (  2.9) 
  Missing values 2,156 1,962 82 (3.8) 112 (  5.2) 
Route to diagnosis 
  GP Routine 1,085 (17.5)    978 (17.0) 43 (4.0) <0.001   64 (5.9) <0.001 
  GP Urgent 3,418 (55.0) 3,307 (57.4) 32 (0.9)   79 (2.3) 
  Emergency 
admission 
   645 (10.4)    594 (10.3) 22 (3.4)   29 (4.5) 
  Other Hospital   
  Referral 
1,069 (17.2)    886 (15.4) 80 (7.5) 103 (9.6) 
  Missing values    726    641 37 (5.1)   48 (6.6) 
 
1 Definitions of oesophageal cancer site: Upper <24cm from incisors, mid 24-32cm from incisors and lower >32cm from incisors.  GOJ tumours 
included Siewert I/II and III cancers.   
*Column percentage**Row percentage 
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 Previous endoscopic examinations 5.4.3
Of the 6,943 patients considered for analysis, 537 (7.8%, 95% CI 7.1-8.4%) had had at least one 
endoscopy within three years of their cancer diagnosis.  214 patients (3.1%, 95% CI 2.7-3.5) had had 
an endoscopy within 3 and 12 months of diagnosis, and a further 323 (4.7%, 95% CI 4.2-5.2) had had 
one between 1 and 3 years before diagnosis.   
Table 5-3 looks at the proportion of patients who had had a previous endoscopy according to various 
patient characteristics.  This demonstrates that the rates of previous endoscopy were not associated 
with patient age, sex or cancer histology.  However, the rate of previous endoscopy was significantly 
associated with TNM stage at diagnosis, such that the proportion of patients with early stage disease 
who had had a previous endoscopy was significantly higher than for those diagnosed with more 
advanced disease (p<0.001).  Among patients with TNM stage 0/1 disease at diagnosis, 15.9% had 
had an endoscopy within 3-12 months and a further 18.1% had had one in the preceding 1-3 years.  
This compares to 4.0% and 6.1% respectively for stage 2 cancers, and 1.5% and 3.0% respectively for 
stage 3/4 cancers.  This pattern was most closely linked to the size of the tumour (T-stage) at 
diagnosis.  A significant association between tumour site and the rate of previous endoscopy was 
also demonstrated (p<0.001).  So while only 3% of patients with lower oesophageal and GOJ cancers 
had had an endoscopy within 3-12 months, 5.4% of patients diagnosed with upper oesophageal 
cancers had had one (p=0.040).   
Patients with a history or Barrett’s oesophagus were also more likely to have had a previous 
endoscopy (p<0.001).  Where stage at diagnosis was known for these patients the disease tended to 
be early stage, with 72.7% of patients who were diagnosed within 3-12 months of endoscopy and 
33.3% of patients who were diagnosed within 1-3 years of endoscopy having stage 0/1 disease at 
diagnosis.   
Patients referred by another hospital consultant were also roughly twice as likely to have had a 
previous endoscopy compared with those referred by a GP, for both of the primary outcome 
measures.  Stage at of disease at diagnosis varied significantly depending on the route to diagnosis 
for patients who had had an endoscopy in the previous 1-3 years (p<0.001).  While 34.7% of patients 
referred by another consultant had stage 0/1 disease at diagnosis, only 12.2% of patients referred by 
GP and 0% of patients referred as a result of an emergency admission were stage 0/1 at diagnosis.  
These findings would be consistent with a proportion of referrals from other consultants 
representing planned surveillance endoscopies.   
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Overall 75.9% of patients diagnosed with cancer who had been referred by their GP were referred 
urgently, but this proportion fell significantly to 42.7% (p<0.001) for patients who had had a previous 
non-diagnostic endoscopy in the last year.  Furthermore, those patients who were referred by their 
GP and had had a prior endoscopy waited significantly longer between referral and diagnosis than 
those who had not had one before, irrespective of the urgency of referral.  So while, 0.4% of urgent 
GP referrals with no history of a recent endoscopy waited more than 12 weeks from referral to 
diagnosis,  25.0% of those who had had an endoscopy in the preceding year waited more than 12 
weeks (p<0.001).   
 Association between previous endoscopy, treatment intent and 1-year survival  5.4.4
As Table 5-3 demonstrates that there was marked variation in patient characteristics across the 
groups who had and had not had a previous endoscopy, such that patients who had not had a 
previous endoscopy were more likely to have advanced disease at diagnosis, and were less likely to 
have a history of Barrett’s oesophagus and to have been referred by another hospital consultant.  As 
a result, these patients had lower unadjusted rates of planned curative treatment (Table 5-4).  
However, this difference was not statistically significant after adjusting for patient characteristics 
such as age at diagnosis, sex, performance status, as well as type of cancer, tumour site and TNM 
stage at diagnosis.  Similarly, the lower unadjusted 1-year survival rates among patients without a 
history of previous endoscopy improved after adjusting for confounding patient characteristics.   
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Table 5-4 Relationship between endoscopic examination, treatment plan, and 1-year survival among patients 
diagnosed with oesophago-gastric cancer in English National Health Service (NHS) trusts 
Patient group Total 
patients, n 
Patients with 
outcome, n (%) 
Unadjusted OR 
[95% CI] 
Adjusted OR† 
[95% CI] 
Patients with curative 
treatment intent 
5,939* 2200 (37.0)   
  Patients without previous 
  endoscopy 
5,493 1973 (35.9) 1 1 
  Patients endoscoped within  
  3–12 months of diagnosis 
   174     98 (56.3) 2.30 [1.68–3.14] 1.08 [0.66–1.75] 
  Patients endoscoped within    
  1–3 years of diagnosis 
   272   129 (47.4) 1.61 [1.24–2.08] 1.02 [0.68–1.54] 
Patients who survived 1 year  6,943 3246 (46.8)   
  Patients without previous  
  endoscopy 
6,406 2936 (45.8) 1 1 
  Patients endoscoped within  
  3–12 months of diagnosis 
   214   136 (63.6) 2.06 [1.56–2.72] 1.42 [1.02–1.99] 
  Patients endoscoped within  
  1–3 years of diagnosis 
   323   174 (53.9) 1.38 [1.10–1.72] 1.03 [0.80–1.33] 
  
OR – Odds ratio 
 Findings reported at previous endoscopy  5.4.5
Table 5-5 describes the frequency with which specific diagnostic codes were recorded in HES at 
previous endoscopy.  The most common diagnosis reported at previous endoscopy was that of an 
oesophageal ulcer (48%).  Of the 22 patients diagnosed as result of an emergency admission within a 
year of previous endoscopy, 6 patients (27.3%) had had an oesophageal ulcer and 6 patients (27.3%) 
had had alarm symptoms recorded at their previous endoscopy.   
Table 5-5 Common gastro-intestinal diagnoses recorded at previous endoscopic examinations that occurred prior 
to the cancer diagnosis 
Diagnostic codes assigned to 
previous endoscopies 
Patients endoscoped within 3-
12 months of diagnosis (n=214) 
Patients endoscoped within 12-
36 months of diagnosis (n=323) 
Oesophageal ulcer 109 (50.9%) 150 (46.4%) 
Alarm symptoms   39 (18.2%)   81 (25.1%) 
Oesophagitis   24 (11.2%)   33 (10.2%) 
Gastrointestinal bleed   24 (11.2%)   30 (  9.3%) 
Oesophageal obstruction   16 (  7.5%)     6 (  1.9%) 
Other gastrointestinal 
 symptoms 
  18 (  8.4%)   28 (  8.7%) 
115 
 
Among the 537 patients who had had an endoscopy in the 3 years prior to diagnosis, 386 (71.9%) 
had only had one endoscopy, 101 (18.8%) had had two, and 50 had had three or more endoscopies 
(9.3%) (Table 5-4).  41 (82%) patients who had had 3 or more previous endoscopies had previously 
been diagnosed with an oesophageal ulcer.   
Table 5-6 Number of endoscopies performed in the 3 years prior to cancer diagnosis 
Number of 
Endoscopies 
Patients endoscoped within 3-12 
months of diagnosis (n=214) 
Patients endoscoped within 12-36 
months of diagnosis (n=323) 
1 125 58.4% 261 80.8% 
2   57 26.6%   44 13.6% 
≥3    32 15.0%   18   5.6% 
 
Furthermore there was a strong association between disease stage at diagnosis and the number of 
previous endoscopic examinations that the patient had had in the last 3 years (p=0.014) (Table 5-7).  
So while 49.4% of patients with stage 0/1 disease had had more than one endoscopy in the previous 
three years, only 19.0% of stage 4 cancers had.  Furthermore 22.1% of stage 0/1 cancers were 
diagnosed after 3 or more endoscopies in the previous three years.   
Table 5-7 Number of endoscopies performed in the 3 years prior to diagnosis of cancer, stratified by pre-
treatment stage at diagnosis 
Total number of 
endoscopies in 3-36 months 
before diagnosis 
Stage at Diagnosis 
0/1 (n=77) 2 (n=111) 3 (n=76) 4 (n=79) 
n % n % n % n % 
1 39  50.6 85 76.6 58 76.3 64 81.0 
2 21  27.3 19 17.1   9 11.8 11 13.9 
3   6    7.8   3   2.7   6   7.9   3   3.8 
≥4 11 14.3   4   3.6   3   3.9   1   1.3 
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5.5 Discussion 
Among this cohort of English NHS patients diagnosed with oesophageal cancer, 3.1% (95% CI, 2.7-
3.5) of patients had had an endoscopy within 3-12 months of diagnosis, and a further 4.7% (95% CI, 
4.2-5.2%) of patients had had one between 1-3 years before diagnosis.  This suggests that 7.8% (95% 
CI, 7.1-8.4%) of cancers may have been missed at initial endoscopy within 3 years of diagnosis.  This 
figure lies at the lower end of the range of rates reported in previous studies (5.0-14.3%) (53-56).  By 
reporting results on a national basis this study is able to provide a more precise estimate of the likely 
miss rate in England, and reflects what is happening in everyday clinical practice.  The study goes on 
to demonstrate that patients who had had a prior endoscopy were more likely to be diagnosed with 
early stage disease, and have an upper oesophageal cancer.   
These results therefore suggest that a significant proportion of oesophageal cancers are being 
missed at endoscopy in England, unless these cancers progressed rapidly enough that they went 
from an early endoscopically invisible lesion to an advanced cancer over a short time frame.  If one 
considers the later scenario to be the case, then a more conservative estimate of the miss rate may 
be 2.0% or 5.6%, representing stage 2-4 cancers diagnosed within 1 year or 3 years of endoscopy 
respectively.  However, the initial overall figure may be more accurate because studies looking at the 
natural history of untreated early oesophageal cancer have suggested that progression of the 
disease is slow with some patients surviving more than 5 years after diagnosis (60, 61).   
Nonetheless one reason to go with the more conservative estimate of miss rate and focus on only 
stage 2-4 cancers, was the inability to identify patients undergoing surveillance endoscopies in this 
study.  Our results showed that patients with a history of Barrett’s oesophagus or referred by 
another hospital consultant were more likely to have had a previous endoscopy, and it is likely that 
some of these previous endoscopies represent surveillance endoscopies.  Unfortunately there was 
no record in the audit of surveillance endoscopies at that time (although the dataset has since been 
amended to address this (Appendix C)), and there is currently no national registry for Barrett’s 
oesophagus which identifies all patients undergoing surveillance endoscopies.   
Previous studies have come up with various different reasons for failing to diagnose a cancer at 
initial endoscopy (53-55).  These include failure of the endoscopist to identify a potential lesion, or 
where a lesion is seen failing to recognise its significance resulting in the clinician deciding not to 
biopsy it or taking an insufficient number of biopsies.  Raftopoulos et al found that where a cancer 
was potentially missed at endoscopy nearly three-quarters of patients had had abnormal findings 
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identified at the site where a cancer was subsequently reported (53).  This suggests that the initial 
endoscopist may not have recognised the malignant potential of their finding.  Raftopoulos et al 
went on to demonstrate that that if a patient had had an entirely normal endoscopy in the last year 
the risk of a missed cancer was 1.1%, but this risk rose to 3.5% if you considered all endoscopies 
done in the last year.  It is therefore very important to ensure that all suspicious lesions are 
adequately biopsied, as this dramatically increases the diagnostic yield (52).  This study found that 
early stage lesions were significantly more likely to be missed, this probably reflects the fact that 
they can present with very subtle changes in mucosal colour or contour (193).  It is therefore 
important to consider using high-resolution endoscopy and enhanced endoscopic imaging 
techniques (e.g.  narrow band imaging) to increase detection of these early lesions, although their 
use in preference to white light endoscopy is not recommended.  An additional area to consider is 
the impact of proton pump inhibitors (PPIs) on endoscopy findings.  PPIs promote mucosal healing, 
and in doing so may increase the chance that a lesion is missed at endoscopy in patients taking them 
(194).  It is therefore important to ensure that PPIs are not be started where a diagnosis of cancer is 
suspected and the patient is being referred for urgent endoscopy, and to consider stopping PPIs 
prior to endoscopy where a patient is already on one.   
Finally, previous studies have suggested that the mid and upper oesophagus may be less well 
inspected at endoscopy reducing the chance that subtle lesions are identified, this may be because 
the endoscope is often rapidly withdrawn during the final stages of the procedure (54).  Our results 
were in line with this finding, as this study reported higher rates of previous endoscopy for patients 
diagnosed with upper oesophageal cancer than lower oesophageal and GOJ cancers (53, 54, 56).  
This highlights the need for careful inspection of this area.   
Analysis of the diagnostic codes recorded in HES at the time of previous endoscopy, showed that the 
most common code recorded in HES was that for oesophageal ulcers, which was recorded at half of 
previous endoscopies.  This compares to an incidence of oesophageal ulcers of 1.16% in unselected 
patients undergoing an endoscopy (195).  Of the 259 patients previously diagnosed with an 
oesophageal ulcer, 20 (7.6%) patients required three or more endoscopies before a diagnosis of 
cancer was made.  This finding could be interpreted in two ways, firstly it may reflect the fact that 
the endoscopists had a clinical suspicion of malignancy and patients were brought back for regular 
surveillance endoscopies.  In which case our estimated miss rate would be a slight overestimate.  An 
alternative explanation is that the original biopsies were insufficient for a diagnosis of cancer, and 
therefore a chance to diagnose the cancer at an earlier stage was missed.  It is important to reflect 
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on the fact that although the risk of oesophageal cancer in patients previously diagnosed with 
oesophageal ulcers in Barrett’s oesophagus is well recognised (66), there are currently no national 
guidelines for the surveillance of oesophageal ulcers.  In contrast there are clear national guidelines 
for the management and follow up of gastric ulcers (49). 
In summary it is important to ensure that clinicians are made aware of the risk of missing cancers at 
endoscopy, as results from this study showed that where a patient had had a recent endoscopy GPs 
were significantly less likely to re-refer the patient urgently (p<0.001).  GPs should be encouraged to 
re-refer patients urgently for out-patient review and further investigation, where they feel a patient 
is still at high risk of malignancy.   
Finally, while it is difficult to evaluate the consequences of a missed diagnosis, this study found no 
evidence that a history of previous endoscopy affected planned treatment intent.  However this 
finding needs to be interpreted with caution, and does not imply that a missed diagnosis does not 
adversely affect patient outcomes.  In order to formally evaluate the effect of the delay, one needs 
either information about the stage of the disease at the time of previous endoscopy or information 
on the speed of progression of the disease.  Considering the first approach, future studies may be 
able to go back and re-examine previous histology results to look for errors in pathological 
interpretation, but this would not help in cases where insufficient biopsies were taken.  Alternatively 
with information about the delay in diagnosis and speed of progression of oesophageal cancer, one 
could look at the impact of a missed diagnosis.  This approach has been used to model the 
consequences of missed diagnoses for breast and cervical cancers (196), but further research is still 
needed on the natural history of oesophageal cancer. 
 Limitations 5.5.1
Specific limitations of this paper are discussed in detail here, while more general limitations 
associated with using national datasets for healthcare research are discussed in Chapter 7.  There 
are three key limitations of this study which need to be considered.   
Firstly neither the NOGCA nor the HES dataset recorded the indication for the initial endoscopy.  
Without this information it is not possible to be certain whether repeat endoscopies were planned 
follow up endoscopies investigating previous suspicious findings.  In order to limit the impact these 
repeat endoscopies may have had on the miss rate, endoscopies performed within 3-months of 
diagnosis were excluded.  It was also not possible to identify patients undergoing planned 
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surveillance endoscopies for Barrett’s oesophagus, and this may have led to the overall miss rate 
being slightly overestimated. 
Secondly, our calculation of missed cancer rates depended on complete coding of all endoscopies in 
HES.  However a small proportion of patients will have had their initial endoscopy done either 
privately, or outside of England.  In these cases the initial endoscopy will not have been recorded in 
HES, and this may mean that our calculated miss rate is a slight under-estimate. 
Finally, there may have been residual confounding in the analysis looking at the association between 
previous endoscopy, treatment intent and 1-year outcomes.  Within the dataset some of the data 
was missing for two variables, and multiple imputation models for these variables relied on the 
assumption that the data were ‘missing at random’. 
Publication related to this work: Chadwick et al, Endoscopy 2014; 46(7): 553-60 
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6. Management and survival of early oesophageal 
adenocarcinomas 
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6.1 Introduction 
Oesophagectomy is the standard treatment for the majority of cases of oesophageal cancer, but is 
associated with significant morbidity and long-term impact on quality of life (83).  However studies 
have shown that the risk of lymphatic spread is very low (0-2%) (88, 89) for oesophageal tumours 
limited to the mucosa, as a result focus has shifted towards using less invasive endoscopic treatment 
options (e.g. endoscopic mucosal resection (EMR) and radiofrequency ablation (RFA)) for the 
management of these early cancers (20, 132, 133).  Once there is evidence of submucosal invasion 
the risk of lymphatic spread can be as high as 20% (70, 89), consequently surgery remains the 
treatment of choice in the majority of these cases. Although endoscopic therapy may still be 
considered if tumour invasion is limited to the most superficial layer of the submucosa, the tumour 
is well differentiated and there is no evidence of lymphovascular invasion (20).   
As discussed in Chapter 1 there is limited up to date research into the long term outcomes for early 
cancers treated endoscopically and surgically, with no large scale population studies performed 
outside of the US.  Furthermore the studies that have been done have pooled data collected over 
many years, over a period when there were significant advances in endoscopic treatment options. 
This limits the applicability of their results to current practice.  In addition no studies have been done 
to date to investigate the uptake of endoscopic therapy in England.   
6.2 Aims of this chapter 
This study aimed to investigate the treatment modalities used to treat early oesophageal cancer in 
England and associated 5 year survival outcomes, using data collected for the 1st National 
Oesophago-Gastric Cancer Audit (NOGCA) between 2007 and 2009.   
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6.3 Methods 
This retrospective cohort study combined information from three national databases: the 1st 
NOGCA, Hospital Episode Statistics (HES), and the Office for National Statistics (ONS) death register.  
NOGCA records were linked to HES and ONS records using the patient’s NHS number (a unique 
identifier for each UK resident), date of birth, sex and postcode.  The extract of HES used for this 
study covered all hospital admissions between September 2007 and November 2009.  While the 
ONS extract used covered deaths up to January 2015.   
Patients were considered for inclusion in this study if they were diagnosed with oesophageal or 
gastro-oesophageal junction (GOJ) cancer between 1st October 2007 and 30th June 2009, and had a 
record submitted to the NOGCA.  Over this time frame the NOGCA achieved 71% case ascertainment 
for English patients diagnosed with oesophago-gastric cancer and 82% for patients managed with a 
surgical resection (85).  The cohort was then limited to those patients with a histological diagnosis of 
adenocarcinoma, to avoid histological heterogeneity.   
The NOGCA dataset provided information on patient demographics, source of referral, date of 
diagnosis, tumour site and stage, treatment plan and finally surgical approach and outcomes (Table 
6-1).  Patients were defined as having early stage oesophageal cancer if their pre-treatment stage at 
diagnosis was T0/1 with no evidence of nodal or metastatic spread.  Patients were excluded from all 
analysis where pre-treatment stage was unknown.   
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Table 6-1 Summary of data extracted from NOGCA dataset 
Patient Demographics 
Age at diagnosis  
Sex  
Performance status ECOG score for performance status in cancer patients (Appendix A). 
Comorbidities  
Initial referral and diagnosis data 
Source of referral GP referral (non-emergency, to outpatient clinics).  Further split in: 
- Urgent for suspected cancer 
- Non-urgent 
Referral after an emergency admission (via Accident & Emergency, Medical 
Admissions Unit, etc.)  
‘Other hospital referral’ (patients referred by a hospital consultant from a 
non-emergency setting).   
Defined according to NOGCA data manual (192). 
Date of diagnosis  
Diagnosis and Staging 
Type of cancer Adenocarcinoma, squamous cell cancer, other 
Tumour site Upper/mid oesophagus, lower oesophagus and GOJ 
Stage at diagnosis Stage of cancer, defined using the Union for International Cancer Control 
(UICC) TNM 6 Classification (68). 
Treatment Plan 
Treatment Intent Curative or palliative 
Treatment modality Curative 
Surgery  oncology, definitive radiotherapy or chemoradiotherapy, 
endoscopic mucosal resection 
Palliative 
Surgery, oncology, endoscopic palliation, best supportive care 
Surgery 
Surgical approach  
Complications Defined according to the NOGCA data manual (134) 
Pathological TNM 
 stage 
Stage of cancer  
 
By linking the NOGCA dataset to HES, information was extracted on all endoscopic, surgical and 
oncological interventions the patient underwent after diagnosis by searching for specific operative 
procedure codes in HES using the Office of Population Censuses and Surveys Classification version 4 
(OPCS) codes, as outlined in Table 6-2.   
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Table 6-2 OPCS codes used to identify primary treatment modality and therapeutic interventions after initial 
therapy 
 Procedure Specific OPCS codes for 
procedures under endoscopic 
control  
Non-specific OPCS codes for 
procedure, only considered if they 
occurred in the same episode as a 
definite endoscopic procedure 
Curative 
Surgery 
Oesophagectomy G01 
G02 
G03 
 
Endoscopic 
procedure 
Diagnostic OGD G16 
G19.1/8/9 
G21.4 
G45 
 
Ablation G14.2/3/5/7 
G17.2/3 
G42.2 
G43.2/3/4/5/7 
Y08 
Y11.4 
Y13.1/4/6 
Resection G14.1/6 
G17.1 
G42.1 
G43.1 
 
Other therapeutic 
OGD 
G14.8/9 
G15.8/9 
G17.8/9 
G18.8/9 
G42.8/9 
G43.8/9 
G44.8/9 
G46.8/9 
 
Dilatation G15.2/3/5 
G18.2/3/5 
G44.3/6 
Y40 
Stent insertion G15.4/6/7 
G18.4 
G21.5 
G44.1 
G11.2/8/9 
Y02.1/2/8/9 
Y14.1/2/3/4/8/9 
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Table 6-2 OPCS codes used to identify primary treatment modality and therapeutic interventions after initial 
therapy (continued) 
 Procedure Specific OPCS codes for 
procedures under endoscopic 
control  
Non-specific OPCS codes for 
procedure, only considered if they 
occurred in the same episode as a 
definite endoscopic procedure 
Oncological 
Treatment 
Chemotherapy X70 
X71 
X72 
X73 
X352 
 
Radiotherapy X65 
X67 
Y91 
Y902 
Y92 
Y352 
 
 
At this stage, a HES-based definition of primary treatment modality was derived for each patient 
based on the OPCS intervention codes recorded after the date of diagnosis.  Patients were grouped 
according to their most invasive treatment modality because using HES it is not possible to 
determine with certainty whether EMRs performed prior to surgery were performed with diagnostic 
or therapeutic intent.   The derived HES-based treatment modality was then compared with the 
planned treatment modality recorded in the NOGCA dataset, to confirm consistency of information 
across the data sources.  Patients were excluded from analysis where data was inconsistent or 
primary treatment modality was not recorded in HES.   
Following any endoscopic procedure, the International Classification of Diseases (ICD-10) diagnostic 
codes related to that episode and any subsequent episode were searched to identify major 
endoscopic complications.  While surgical complications and outcomes were derived from the 
NOGCA dataset. 
The principal outcome measures assessed were:  
- Choice of primary treatment modality for early oesophageal cancer, derived from HES. 
- 5-year survival calculated based on date of diagnosis and then stratified by primary 
treatment modality.   
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 Data Analysis 6.3.1
Initial analysis calculated the proportion of patients with a diagnosis of early oesophageal 
adenocarcinoma, this was calculated from all patients with known disease stage at diagnosis.  
Patient characteristics were then compared across the groups diagnosed with early and late stage 
disease to look for significant differences, using the t-test and chi-square test to test for statistical 
significance as appropriate.  P-values less than 0.05 were considered statistically significant. Patients 
were later grouped according to their primary treatment modality, and patient characteristics were 
again compared across these groups.  
Using data provided by the ONS death register, 5 year survival was estimated for patients according 
to their primary treatment modality and results were presented using Kaplan-Meier graphs.  The log 
rank test was used to test for significant difference between survival curves. 
6.4 Results 
The linked dataset identified 10,792 patients diagnosed with oesophageal or GOJ cancer in England 
between 1st October 2007 and 30th June 2009.  Of these, 7,611 patients had a histological diagnosis 
of adenocarcinoma and were considered for inclusion in this study.  2,371 patients were excluded 
from analysis due to incomplete staging details.  This left 5,240 (68.8%) patients for analysis (Figure 
6-1). However it should be noted that patients missing T stage at diagnosis were significantly more 
likely to be managed with palliative intent and had worse long term outcomes than those considered 
for analysis.   
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Figure 6-1 Flow diagram describing the selection of patients from the NOGCA-HES linked database for analysis 
Full NOGCA-HES linked dataset  
Oesophageal or GOJ cancers diagnosed 
1st Oct 2007-30th June 2009
n=10,792
Patients with oesophageal 
adenocarcinomas
n=7,611
Excluded patients who did not
 have a histological diagnosis of 
adenocarcinoma
n=3,181
Final dataset for initial analysis 
n=5,240
Excluded patients who did not have 
T-stage at diagnosis recorded
n=2,371
 
The characteristics of the analysed cohort are summarised in Table 6-3 (first column).  The mean (±
SD) age of these patients at diagnosis was 69.8 (±11.6) years and 80.0% were men.  89.4% of cancers 
were located in the lower oesophagus or GOJ.  Overall 1- and 5-year survival for the entire cohort 
was 53.6% (n=2,810) and 17.8% (n=934), respectively.   
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Table 6-3 Characteristics of patients in the overall study cohort and by the extent of disease (early or advanced 
cancer).   
 
 Entire cohort 
n (%*) 
Early cancer Late stage cancer p-value 
n (%*) n (%*) 
Patients 5,240 354  4,886   
Age, years, mean (±SD) 69.8±11.6 69.1±11.2 68.4±11.0 1.0 
Male 4,190 (80.0) 280 (79.1) 3,910 (80.0) 0.673 
Tumour location  
0.001   Upper / Middle oesophagus    555 (10.6)   39 (11.0)    516 (10.6) 
  Lower oesophagus 3,442 (65.7) 260 (73.5) 3,182 (65.1) 
  GOJ 1,245 (23.7)   55 (15.5) 1,188 (24.3) 
Performance status  
0.018   0/1 2,919 (74.2) 206 (80.5) 2,713 (73.8) 
  2/3/4 1,014 (25.8)   50 (19.5)    964 (26.2) 
  Missing 1,307   98 1,209 
Any co-morbidity except Barrett’s oesophagus  
0.252   No 3,009 (57.4) 193 (54.5) 2,816 (57.6) 
  Yes 2,231 (42.6) 161 (45.5) 2,070 (42.4) 
History of Barrett’s oesophagus  
<0.001   No  4,981 (95.1) 295 (83.3) 4,686 (95.9) 
  Yes    259 (  4.9)   59 (16.7)    200 (  4.1) 
Source of referral  
<0.001   Emergency    478 (10.0)   30 (  9.7)    448 (10.1) 
  GP 3,508 (73.7) 168 (54.2) 3,340 (75.0) 
  Other Hospital Referral    775 (16.3) 112 (36.1)    663 (14.9) 
  Missing    479   44     435 
Planned treatment intent  
<0.001   Curative 2,440 (48.0) 260 (75.4) 2,180 (46.0) 
  Palliative 2,643 (52.0)   85 (24.6) 2,558 (54.0) 
  Missing    157     9    148 
 
* Column percentages 
 
Where stage at diagnosis was known, 354 (6.8%) patients had early stage disease at diagnosis.  
Patient characteristics such as age at diagnosis and sex were not significantly different according to 
disease stage at diagnosis.  However, patients diagnosed with early stage disease were more likely to 
have a history of Barrett’s oesophagus (16.7% vs 4.1%, p<0.001), and they also tended to have a 
better performance status score (performance status 0/1 80.5% vs 2/3/4 73.8%, p=0.018).  Finally, 
patients who were referred by another hospital consultant were more likely to have early stage 
disease at diagnosis (36.1% vs 14.9%, p<0.001).   
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As expected patients who were diagnosed with early stage disease were significantly more likely to 
be managed with curative intent compared to those diagnosed with more advanced disease (75.4% 
vs 46.0%, p<0.001).  Further analysis of the subset of patients with early cancers who were managed 
with palliative intent revealed they were on average older (mean age at diagnosis 76.8 years vs 66.4 
years, p<0.001) and/or had a worse performance status (performance status of 2 or more 51.0% vs 
11.9%, p<0.001) than those treated with curative intent.  All 59 patients diagnosed with early cancer 
who had a history of Barrett’s oesophagus were managed with curative intent, compared to only 
207 out of the 295 (70.2%) patients with no history of Barrett’s oesophagus. 
 Primary treatment modality for early cancers managed curatively 6.4.1
Using HES, primary treatment modality was determined for 244 (93.8%) of the 260 patients 
diagnosed with early cancer who were managed with curative intent.  Where this was known, 191 
(78.3%) had a curative surgical resection, 42 (17.2%) were treated endoscopically, and 11 (4.5%) 
received definitive oncological treatment (Figure 6-2).  Primary treatment modality could not be 
determined from HES for the remaining 16 patients, due to missing or non-specific data in HES (e.g.  
only diagnostic endoscopy recorded in HES where the planned treatment modality was endoscopic).   
Figure 6-2 Primary treatment modality derived from HES, for patients with early oesophageal adenocarcinoma 
Patients diagnosed at early stage 
n=354
Patients with early stage oesophageal 
adenocarcinomas managed curatively
n=260
Excluded patients managed with palliative 
intent 
n=94
Surgical treatment 
(n=191)
Endoscopic 
treatment 
(n=42) 
Definitive oncology 
(n=11) 
Excluded patients whose primary treatment 
modality could not be determined from HES 
n=16
 
10 patients who had a curative surgical resection had had an EMR performed at or soon after 
diagnosis and went on to have surgery within 3 months of diagnosis, it is likely that these 
represented diagnostic staging EMRs.  For a further 4 patients who had an EMR before surgery the 
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intention of initial EMR was less certain, these patients had an EMR shortly after diagnosis and 
proceeded to have a subsequent diagnostic endoscopy before proceeding to surgery more than 3 
months after diagnosis.  These EMRs could therefore represent diagnostic EMRs with delayed 
surgery, or EMRs performed with curative intention where the resection failed and the patient 
proceeded to surgery.  If one accepts the later interpretation, then 8.7% (4/46) of patients failed to 
have their disease controlled endoscopically where this was the initial treatment intent.   
Table 6-4 examines the patient characteristics for patients who received the two main treatment 
modalities.  Patients managed surgically were substantially younger (mean age at diagnosis 64.3 
years vs 72.6 years, p<0.001) and were less likely to have a previous diagnosis of Barrett’s 
oesophagus (21.5% vs 35.7%, p=0.05) than those managed endoscopically.   
Table 6-4 Characteristics of patients with early oesophageal cancer who underwent curative treatment by 
treatment modality  
 Surgery Endoscopic 
treatment 
p-value 
 
Number of patients, n 191 42  
Age group, years, mean (±SD) 64.3±9.4 72.6±8.6 <0.001 
Male, n (%*) 153 (80.1) 35 (83.3) 0.631 
Tumour location, n (%*)  
0.444   Upper / Middle oesophagus   14 (  7.3)   5 (11.9) 
  Lower oesophagus 154 (80.6) 34 (81.0) 
  GOJ    23 (12.1)   3 (  7.1) 
Performance status, n (%*)  
0.158   0/1 138 (92.0) 26 (83.9) 
  2/3/4   12 (  8.0)   5 (16.1) 
  Missing   41 11 
Any co-morbidity except Barrett’s oesophagus, n (%*)  
0.713   None  106 (55.5) 22 (52.4) 
  One or more   85 (45.5) 20 (47.6) 
Barrett’s oesophagus, n (%*)  
0.050   No 150 (78.5) 27 (64.3) 
  Yes   41 (21.5) 15 (35.7) 
 
* Column percentage 
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Treatment and outcomes of patients who had surgery as their treatment modality 
Table 6-5 summarises the staging, treatment and outcomes for patients managed surgically.   
Table 6-5 Details of surgery and associated outcomes 
 Surgery (n=191) 
Pre-operative EUS, n (%) 143 (74.9) 
Use of pre-operative chemotherapy, n (%)   18 (  9.4) 
Times from diagnosis to surgery, days (IQR)  
  No neo-adjuvant treatment   62 (46-91) 
  Neo-adjuvant treatment first 134 (100-161) 
Length of stay from, days (IQR)   16 (12-26) 
Surgical approach, n (%*)  
  Left Thoracic   23 (13.8) 
  2-Phase (Ivor-Lewis) 109 (65.3) 
  3-Phase (McKeown)   22 (13.2) 
  Trans-hiatal   13 (  7.8) 
  Missing   24 
Planned MI/Hybrid surgery, n (%)   56 (32.2) 
Any post-operative complication, n (%)   64 (33.5) 
Return to theatre, n (%)   20 (12.0) 
Post-operative endoscopic treatment e.g.  dilatation or stent, n (%)   45 (23.6) 
Pathology stage (available for n=171), n (%*) 
  T0/T1, N0, M0 119 (69.6) 
  T1, N1, M0   11 (  6.4) 
  T1, N1, M1     1 (  0.6) 
  T2, N0, M0   10 (  5.8) 
  T2, N1/2, M0   15 (  8.8) 
  T3, N0, M0     4 (  2.3) 
  T3, N1/2, M0   11 (  6.4) 
 
* Column percentage 
EUS – Endoscopic ultrasound, MI – Minimally invasive 
 
Analysis of NOGCA dataset revealed that 64 (33.5%) patients suffered at least one post-operative 
complication, with 20 (12%) patients requiring a further unplanned operation.  Other frequent 
complications included respiratory complications affecting 36 (18.8%) patients and cardiac 
complications affecting 9 (4.7%) patients.  Further analysis of the HES episodes after surgery 
revealed that 45 (23.6%) patients needed a further endoscopic intervention, including 11 stents and 
39 dilatations (with 5 patients requiring both).  12 patients required ≥3 dilatations.   
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Where the patient had had a surgical resection, a separate pathology report was recorded for 171 
patients (89.5%).  In 52 cases (30.4%) the disease was upstaged post-operatively, with 25 tumours 
subsequently found to be T2 and 15 found to be T3, a few patients were also found to have evidence 
of lymphatic and metastatic spread (Table 6-5).  Given that almost a third of patients had their 
disease upstaged post-operatively it was important to assess the adequacy of pre-operative staging 
investigations, our analysis demonstrated that a pre-operative EUS significantly reduced the 
proportion of patients found to have more advanced disease post-operatively, from 47.6% to 24.8% 
(p=0.005).   
Overall survival rates were calculated for all patients managed surgically, 90.1% (95% CI 84.9 to 93.9) 
survived 1 year post diagnosis and 66.0% (95% CI 58.8 to 72.7) survived 5 years (Figure 6-3).  
However, only 84.0% of patients with an ASA (American Society of Anesthesiologists) grade of 3 or 
more survived 1 year.  As may be expected patients who were found to have more advanced disease 
on their post-operative specimen were significantly less likely to survive (Log-rank test, p<0.001) 
(Figure 6-3).   
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Figure 6-3 Kaplan-Meier survival curves for patients who had curative surgery for early oesophageal 
adenocarcinoma, overall (A) and stratified according to post-operative pathology results (B) 
(A) 
 
(B) 
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Treatment and outcomes of patients who had endoscopic therapy as their treatment modality 
42 patients received endoscopic therapy for their early cancers, their treatment modality and 
outcomes are summarised in Table 6-6.  The vast majority of endoscopic procedures were performed 
as a day case (78.6%), with only 6 (14.3%) patients requiring overnight admission and 3 (7.1%) 
patients requiring admission for 2 nights.  Analysis of HES codes associated with these episodes did 
not reveal any complications that would account for these overnight stays.   
Table 6-6 Characteristics and outcomes of patients managed endoscopically 
 Endoscopic treatment  
(n=42) 
Pre-treatment EUS, n (%) 15 (35.7) 
Time from diagnosis to EMR, days (IQR) 56 (0-81) 
Endoscopic treatment, n (%*) 
  EMR alone 28 (66.7) 
  EMR and Ablation  13 (31.9) 
  Ablation alone   1 (  2.4) 
Repeat endoscopic treatment required, n (%) 23 (54.8) 
Stricture post treatment requiring further treatment, n (%)   2 (  8.7) 
 
* Column percentage 
 
The risk of complications appeared to be low after endoscopic therapy with no reported 
perforations, and only 2 patients (4.8%) required a stent or dilatation at a later date.  However 23 
(54.8%) patients required further endoscopic treatment, including 8 patients (19.1%) who required ≥
3 treatment sessions.   
Overall survival for patients managed endoscopically was 100% (95% CI 91.6 to 100* (one-sided 
test)) at 1 year and 66.7% (95% 50.5 to 80.4) at 5 years (Figure 6-4).   
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Figure 6-4 Kaplan-Meier survival curves for patients who had endoscopic therapy for early oesophageal 
adenocarcinoma 
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6.5 Discussion 
Using the NOGCA dataset this study identified 354 patients in England who had been diagnosed with 
early stage oesophageal adenocarcinomas between 2007 and 2009.  This equates to 6.8% (95% CI 
6.1-7.5) of all oesophageal adenocarcinomas diagnosed in England over this time frame.  Although 
this figure appears low, it probably reflects the upper estimate of the true incidence of early stage 
disease in England, because a significant number of patients were missing information on stage at 
diagnosis and these patients were more likely to have more advanced disease at diagnosis. 
Early diagnosis of oesophageal cancer was significantly associated with a history of Barrett’s 
oesophagus and referral by another hospital consultant.  This probably reflects the fact that a 
proportion of these cancers were detected as a result of surveillance endoscopies performed for 
Barrett’s oesophagus.  Unfortunately limitations of the dataset prevented further investigation into 
this, but changes to the dataset will allow this to be investigated in future.   
Given the changing treatment options available for the treatment of early oesophageal cancer and 
the shift in guidelines towards recommending endoscopic therapy in preference to surgery (20), it 
was important to investigate current use of endoscopic therapy in England.  This study found that 
only 17.2% of patients with early cancers were managed endoscopically, much lower than the 29% 
reported to have been managed endoscopically over a similar timeframe in a study from the US 
using the Surveillance Epidemiology and End Results (SEER) national database (114).   
However if endoscopic therapy is to replace surgery as the treatment of choice for early cancer then 
it is important to produce more conclusive evidence regarding the long term outcomes associated 
with its use.  The current literature base is sparse and previous studies have been subject to 
significant limitations.  One of the main limitations of previous studies is that they have relied on 
data pooled data over long periods (ranging between 5 and 13 years), and collected as early as 1998 
(111-115).  It is important to realise that in 1998 endoscopic therapy was a relatively novel technique 
and use would have been limited to very few specialist centres.  Since then the treatment options 
and outcomes for oesophageal cancer have changed considerably (20, 48, 78), as a consequence 
results from previous studies may not provide an accurate representation of current practice and 
outcomes.  Finally previous studies have attempted to directly compare outcomes of patients 
managed endoscopically and surgically, but these comparisons were limited for to two main reasons.  
Firstly previous single centre studies have relied on small sample sizes, and consequently may have 
been underpowered to detect significant differences in outcomes (111, 112).  In addition their 
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results reflect the outcomes achieved in tertiary research centres, and therefore may not be 
generalizable to the wider population.  Secondly previous national studies have lacked some of the 
details required to make accurate comparisons across patient groups, for instance information on 
treatment intent, ASA grade and performance status (113-115).  As a result their reported outcomes 
are subject to bias from unmeasured confounders making it difficult to draw valid conclusions about 
the relative effectiveness of each treatment modality.  These differences may account for the 
variability in reported outcomes, with US population-based studies reporting better overall 5 year 
survival for patients managed surgically and no difference in cancer specific mortality (113, 114), 
while previous single centre studies have reported no difference in outcomes (111, 112).  In this 
study outcomes for both groups are reported, however in contrast to previous studies the decision 
was made not to directly compare their outcomes using a multivariable cox regression, because 
baseline characteristics of the two groups differed significantly.  While some of these differences 
could be adjusted for (e.g.  age), limitations of our dataset meant other potential confounders (e.g.  
depth of mucosal/submucosal invasion) could not be adjusted for and as a result it was felt to be 
inappropriate to attempt to make direct comparisons across the two groups.   
This study reported that 66.7% of patients managed endoscopically survived 5 years after diagnosis.  
However, our results also suggest that 8.7% of patients who were initially managed endoscopically 
later went on to require a salvage oesophagectomy.  Previous national studies have been unable to 
estimate this failure rate for endoscopic therapy, because they have relied on the SEER database 
which only records the most invasive treatment modality (113-115).   
Other secondary outcomes reported included the use of pre-operative staging investigations.  This 
study found that a quarter of patients did not undergo a staging EUS, and these patients were 
significantly more likely to have their disease upstaged post-operatively compared to those who had 
had a pre-operative EUS (47.6% vs 24.8%, p=0.005).  This in turn had a direct impact on patient 
outcomes, only 44.2% of patients who had their disease upstaged post-operatively survived five 
years compared to 74.0% of those with confirmed early stage disease on post-operative pathology. 
Finally previous studies have reported higher rates of recurrence after endoscopic therapy 
compared to surgery (6-20% vs 0-2% surgery group) (111, 112, 197), and that a significant 
proportion of patients were lost to follow up 3 years after endoscopic treatment (197).  As a result 
this study investigated the proportion of patients managed endoscopically who required repeated 
therapeutic endoscopies, and demonstrated that 54.8% of patients managed endoscopically 
required further endoscopic treatment.   
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This highlights the important of achieving high levels of patient compliance in endoscopic follow up if 
endoscopic therapy is to be used as the treatment of choice for early cancers.   
Strengths and weakness of the study 
The major strength of this study comes from the fact that is the largest cohort of patients with early 
oesophageal cancer identified in England and all patients were diagnosed over a relatively short time 
frame (21 months).  As a result this study should not be prone to some of the limitations affecting 
previous studies which relied on data collected over many years, over a period of time when there 
were substantial advances in the treatment options available.  Furthermore the study had access to 
data on key prognostic factors (e.g.  ASA grade) which were not available in previous national studies 
and which were shown to impact significantly on treatment outcomes in this study.  Finally for the 
first time this study was also able to examine the use of staging investigations and the impact this 
had on post-operative histology results on a national level.   
The study did have several limitations though.  Firstly HES is designed primarily as an administrative 
dataset which aims to capture details relating to all NHS hospital admissions in England, as a result it 
is subject to coding errors.  Of particular concern is the fact that it is likely that a proportion of 
therapeutic endoscopies were non-specifically coded for in HES and were therefore not picked up 
this study.  This limitation is highlighted by the fact that for the 16 patients where primary treatment 
modality could not be established from HES, 6 (37.5%) had been planned to undergo an endoscopic 
resection.  Consequently, the study may have underestimated both the frequency of repeat 
endoscopic interventions and the proportion of patients undergoing endoscopic resections as 
primary treatment modality.   
This study did not attempt to compare outcomes across patients managed endoscopically and 
surgically for two main reasons.  Firstly the extract of ONS used for this study did not provide cause 
of death, this is important because it is likely that patients managed endoscopically had a higher all 
cause mortality than those managed surgically, as they were older and frailer (114).  Secondly the 
dataset did not distinguish between tumours invading the mucosa and submucosa, this is important 
because surgery remains the mainstay of treatment where there is submucosal invasion.  As a result 
there were baseline characteristics between the two groups that could not be adjusted for.   
Publication related to this work: Chadwick et al, British Journal of Surgery, 2016; 
103(5): 544-52 
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7. Discussion and Conclusions 
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The aims of this thesis were to further investigate the management of early neoplastic changes in 
the oesophagus in England.  Having reviewed the current literature in the Chapter 1, several keys 
gaps in the literature were identified which this thesis aims to address by performing several 
separate studies, including: 
- Investigation into the current management of high grade dysplasia (HGD) of the oesophagus 
in England.   
- Systematic review comparing the safety and efficacy of complete endoscopic resection and 
radiofrequency ablation in the treatment of dysplastic Barrett’s oesophagus.   
- Investigation into the proportion of oesophageal cancers missed at endoscopy in England. 
- Investigation into the management and 5 year survival outcomes associated with the 
treatment of early oesophageal adenocarcinoma in England.   
 
7.1 Implications for clinical practice  
The results of these studies raise several salient findings which may have important implications for 
clinical practice, and which will be discussed in greater detail in the next section.   
Over the last few years, national guidelines have been updated to recommend endoscopic 
treatment instead of surgery as the treatment of choice for oesophageal HGD (20).  It is therefore 
important to establish the best endoscopic treatment, in terms of both treatment efficacy (short and 
long term) and risk of complications.  As discussed in the Introduction (Chapter 1) two broad 
approaches exist for the endoscopic treatment of dysplastic Barrett’s oesophagus, complete 
endoscopic mucosal resection (EMR) and ablation.  With radiofrequency ablation (RFA) now 
considered the ablative approach of choice in Europe, our review sought to compare outcomes after 
RFA and complete EMR.  To date the evidence base comparing the two techniques is limited, with 
only one randomised control trial (RCT) directly comparing their outcomes (131), highlighting the 
need to systematically review the available literature in order to be able to draw any firm 
conclusions, as done in Chapter 4.   
This review demonstrated that while there is extensive evidence regarding the short term efficacy of 
both techniques, the body of literature regarding their longer term efficacy is limited.  Pooling 
results from prospective studies found that complete eradication of dysplasia at the end of 
treatment was achieved in 95% (95%CI 87-99%) of patients treated with complete endoscopic 
resection and 92% (95%CI 85-96%) treated with RFA.  It is equally important, if not more important, 
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to investigate the longer term durability of treatment if endoscopic therapy is to replace surgery as 
the treatment of choice for HGD.  Unfortunately assessment of long term treatment durability was 
difficult for two reasons i) follow up periods were variably reported and ii) overall follow up periods 
were relatively short with a median follow up of under two years.  Overall 85-100% of patients 
treated with complete endoscopic resection and 79-100% of patients who received RFA were 
reported to have maintained complete eradication of dysplasia at follow up endoscopy.  However, it 
was not possible to accurately calculate the risk of progression to cancer due to the limited and 
varied follow up periods reported.  Nonetheless overall rates of progression did appear to be low, 
with only 1.7% of patients treated with complete endoscopic resection and 0.9% of patients treated 
with RFA developing cancer during follow up.  These figures are substantially lower than the 5.6% 
per year reported risk of progression to cancer if HGD is left untreated (36).  Another important 
consideration of treatment is the risk of complications, and this varied substantially by treatment 
modality.  Overall 38% of patients treated with complete endoscopic resection developed an 
oesophageal stricture, compared to only 4% treated with RFA.   
So, the results of our systematic review conclude that while both complete EMR and RFA have 
proven short term efficacy in the treatment of HGD, complication rates were significantly higher 
after complete EMR.  Further studies need to be done to demonstrate the longer term (5-10 year) 
durability of both approaches.  It is also important to appreciate that the results of this review 
demonstrate the ongoing risk of recurrence of dysplasia after endoscopic treatment and therefore 
the need for continuing endoscopic surveillance.   
The remaining studies in this thesis used data collected for the National Oesophago-Gastric Cancer 
Audit (NOGCA), which provided us with a unique opportunity to explore the management of early 
neoplastic changes in the oesophagus in England using patient level data.   
Until now studies looking at the management of HGD in England have had significant limitations.  
Firstly previous studies have relied on the results from surveys of clinicians looking at the reported 
management of patients with HGD (120-123), without access to patient level data.  These studies 
reported considerable variability in the management of HGD in England and lack of adherence to 
national guidelines.  Secondly these studies were conducted many years ago (between 1997-2005), 
at a time when treatment options for HGD were much more limited and endoscopic therapy was a 
relatively novel approach, with use limited to a few specialist centres.  Since then there has been a 
dramatic shift in the management of HGD, with the most recent BSG guidelines recommending that 
all patients with HGD of the oesophagus are considered for endoscopic therapy in preferences to 
either surgery or surveillance alone (20).  It is therefore important to investigate current 
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management of HGD in England and adherence to national guidelines, in order to ensure any gaps in 
care are identified and improve care of patients in the future.   
In April 2012 the NOGCA started collecting information on all patients newly diagnosed with HGD of 
the oesophagus in England, providing us with a unique opportunity to investigate their management 
further.  This is the first national database in the world collecting data on this subgroup of patients.  
The detailed results of our study are presented in Chapter 3 which highlights several key findings.  
Firstly, there is significant variation in the management of oesophageal HGD across England, with a 
third of patients managed by surveillance alone.  Factors associated with this management plan 
were investigated, and our study found that patients who had not had the diagnosis of HGD 
confirmed (either on repeat biopsy or by a second pathologist) and had not had their case discussed 
at the UGI MDT were more likely to be managed by surveillance alone.  Further our analysis 
demonstrated that there is a significant association between the volume of patients treated for HGD 
at a particular NHS trust and the proportion of patients managed by surveillance alone, such that 
patients managed in low volume trusts were five times more likely to be managed by surveillance 
alone than patients managed in high volume trusts.  Currently the majority of trusts in England treat 
less than 5 cases of HGD each year.  These two findings highlight the lack of centralisation of HGD 
services in England currently.  It is therefore important to consider whether the management of 
patients with HGD should be centralised in future, to ensure that all patients get equal access to 
these newer endoscopic therapies.  The most recent NOGCA report (198) makes the following 
recommendation based on this finding:  
‘A significant proportion of cases of HGD are still managed by surveillance alone, despite the 
BSG recommending that all patients should be considered for active treatment.  It is 
important that NHS Trusts and Health Boards consider referral of patients with HGD to a 
specialist centre which has experience of treating HGD’ 
It will therefore be interesting to see whether care of patients with HGD does undergo a process of 
centralisation over the coming years.  
The thesis then turned to look at the management of oesophageal cancer in England.  The overall 
prognosis for patients diagnosed with oesophageal cancer is dismal with only 15% of patients 
surviving 5 years (1).  This is down to the fact that a substantial proportion of patients have their 
cancers diagnosed at a late stage, and as a result only a third of patients are considered for curative 
therapy (2).  It is therefore important to try to increase the proportion of patients diagnosed with 
early stage disease and optimise their management.   
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Endoscopy and biopsy is widely regarded as the investigation of choice for the diagnosis of 
oesophageal cancer (48), Nonetheless previous studies have reported that a significant proportion of 
oesophageal cancers may have been missed at initial endoscopy (53-59), however these studies 
have been subject to significant limitations.  Firstly, all previous studies have been single centre 
(except one (57)), and as a result they have relied on data collected over many years (up to 14 years 
(53)) in order to achieve reasonable patient numbers.  Despite the long study inclusion periods 
examined, these single centre studies still had relatively small patient numbers, between 110 (54) 
and 1075 (59), making it difficult to investigate associations between patient characteristics and miss 
rates.  Secondly previous studies have lacked access to key information such as stage at diagnosis, 
and treatment plan following diagnosis.  These factors are important to investigate in order to 
establish the potential impact of a missed diagnosis.   
In order to address some of these limitations Chapter 5 used data collected for the NOGCA, linked to 
Hospital Episode Statistics (HES) and Office for National Statistics (ONS) mortality data, to investigate 
the proportion of oesophageal cancers that were potentially missed at endoscopy and the impact a 
missed diagnosis may have had on patient outcomes.  This study identified 6,943 cases of 
oesophageal/or junctional cancer diagnosed over one year in England.  537 (7.8%, 95% CI 7.1-8.4) 
patients had had an endoscopy in the previous 3 years including 214 (3.1%, 95% CI 2.7-3.5) patients 
who had had one in the previous 3-12 months.  Further analysis went on to demonstrate that early 
cancers (p<0.001) and cancers located in the upper oesophagus (0.004) were significantly more likely 
to have been missed at endoscopy in the preceding 12 months.  The study went on to examine 
diagnostic codes associated with previous endoscopies and revealed that 50.9% of patients who had 
had an endoscopy in the previous three years had previously been diagnosed with an oesophageal 
ulcer.  Finally the study investigated the potential impact of a missed diagnosis on treatment plan 
and 1 year survival.  While this study established no clear impact on outcomes, it is important to 
realise that this was difficult to evaluate given the poor evidence base regarding the natural 
progression of untreated oesophageal cancer and the inability to review initial endoscopy and 
pathology findings.  Furthermore important differences in outcomes may not have been detected 
within the 1 year follow up time frame.   
This is the first time that the problem of missed oesophageal cancers at endoscopy has been 
investigated on a national level and our results raise key areas that could be targeted in order to 
improve practice in future.  Firstly, it highlights the importance of careful visualisation of the upper 
oesophagus on both intubation and extubation in order to reduce the risk of missing lesions in this 
region.  Secondly, where an oesophageal ulcer is identified it is important to ensure adequate 
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biopsies are taken and the patient is considered for a repeat endoscopy at 6-8 weeks to confirm 
ulcer healing (as is common practice for gastric ulcers).  This is a key finding, because there are 
currently no national guidelines focusing on the management and follow up of oesophageal ulcers, 
and suggests that development of such guidelines should be considered with incorporation of 
oesophageal ulcer follow up into the auditable outcomes assessed by Joint Advisory Group (JAG).  
Finally, it is crucial that clinicians are made more aware of the risk of cancer in patients who have 
had a previous non-diagnostic endoscopy, and are encouraged to re-refer patients urgently for 
review and investigation where they feel the risk of malignancy is still high. 
The final study presented in this thesis investigated the management and long term outcomes of 
patients diagnosed with early oesophageal cancer in England.  As previously stated, survival for 
oesophageal cancer is closely linked to the disease stage at diagnosis and once diagnosed careful 
consideration needs to go into the most appropriate treatment option.  Until recently 
oesophagectomy has been considered the treatment of choice for such lesions, but this is major 
surgery and associated with significant mortality and complication rates (2).  Given the low risk of 
lymphatic spread where the cancer is localised to the mucosa or most superficial layer of the 
submucosa (88, 89), localised endoscopic therapy is now considered the treatment of choice for 
these early lesions (20).  It is therefore important to monitor the long term outcomes associated 
with this approach, to ensure these are comparable to those achieved through a surgical resection.   
Current evidence regarding the long term outcomes associated with the endoscopic and surgical 
management of early oesophageal cancers is limited. Previous studies have been subject to 
significant limitations, including small sample sizes, use of data pooled over many years and the 
potential impact of on unmeasured confounders on outcomes when comparing the two techniques.  
These limitations may account for some of the variability in results reported.   
Chapter 6 aims to overcome some of these limitations by investigating the patterns of management 
of early oesophageal cancer in England, using linked data from three national databases collected 
over 21 months between 2007-2009.  This study identified 10,792 patients diagnosed with 
oesophageal cancers, 5,240 of these were selected for analysis as they had been diagnosed with 
oesophageal adenocarcinomas and had complete staging information submitted to the NOGCA.  354 
(6.8%) of these patients were diagnosed with early stage oesophageal adenocarcinoma.  Three 
quarters were managed with curative intent, with the majority of these patients having a curative 
resection and only 1 in 5 patients were treated endoscopically.  In contrast to previous studies this 
study did not attempt to directly compare outcomes for patients managed endoscopically and 
surgically, due the observational nature of the study and clear differences in the baseline 
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characteristics of the two groups.  However, 5-survival rates associated with both therapies were 
reported, 66.7% (95% CI 50.5 to 80.4) after endoscopic treatment and 66.0% (95% CI 58.8 to 72.7) 
after surgery.  It is important to appreciate that endoscopic treatment options were in their infancy 
in 2007, and as a result it is likely that practice and outcomes will have changed since then. 
Nonetheless it is still crucially important to monitor the longer term (5 year) outcomes associated 
with treatment as this study does.  
One key area that this study addressed that has not been investigated in previous studies was the 
use of staging investigations in the diagnosis of early oesophageal cancer.  This study found a quarter 
of patients managed surgically had not had a pre-operative staging endoscopic ultrasound (EUS).  
Our analysis demonstrated that these patients were significantly more likely to have their disease 
upstaged post-operatively (47.6% vs 24.8%, p=0.005) and as expected patients who were upstaged 
post-operatively had significantly worse outcomes (only 44.2% survived 5 years compared to 74.0% 
of those who had confirmed early stage disease on post-operative pathology).   
In conclusion this study highlights several areas where care of patients with oesophageal cancer can 
be improved in England.  Firstly, only 6.8% of oesophageal adenocarcinomas are diagnosed at an 
early stage and a quarter of these patients are managed with palliative intent.  The UK government 
is taking steps to try and increase the proportion of cancers diagnosed early by increasing the 
public’s awareness of sinister symptoms, with the launch of the ‘Be Clear on Cancer’ campaign for 
oesophago-gastric cancer in January 2015 (191).  Secondly, the high proportion of patients with early 
cancer managed with palliative intent may reflect the relatively low uptake of endoscopic therapy in 
England 5 years ago.  Future studies need to investigate whether the proportion of patients with 
early cancer managed endoscopically has increased in light of the changes to the BSG guidelines (20) 
and the impact this has had on the proportion of patients with early cancer managed with palliative 
intent.  Finally our results suggest that staging investigations are currently being underutilised, and 
as a result a significant proportion of patients are upstaged post-operatively.  NHS trusts therefore 
need to review their practice and improve staging of cancers in future.   
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7.2 Methodological considerations 
A degree of caution always needs to be employed when interpreting the results of any study and this 
section aims to highlight the more general methodological considerations which may impact on the 
validity of the results presented in each chapter.  Given the nature of a systematic review, the 
limitations of this type of work differed from those of the other chapters which present original 
research, and these two types of research are therefore considered separately.   
 Systematic review 7.2.1
7.2.1.1 External validity 
In considering the external validity of the results of this review, the inclusion criteria for the review 
were broad including all studies published in any language in the last ten years, and only excluding 
studies where patients had had previous endoscopic treatment for their HGD or previous reflux 
surgery.  Furthermore patients included in each study were broadly representative of patients with 
Barrett’s oesophagus including all patients over the age of 18 with any length of Barrett’s 
oesophagus.   
The studies identified in this review came from a number of different countries.  However, it is 
important to note that all of the prospective RFA studies came from two research groups in Europe, 
and this may limit the validity of their results if applied to less specialised centres.  In contrast the 
retrospective studies came from a far greater spectrum of centres, including a community centre in 
the US (177), making their results more generally applicable.  Nonetheless given that dysplastic 
Barrett’s is a relatively rare condition it may be preferable to limit its management to high volume 
specialist centres.   
7.2.1.2 Limitations  
Narrative reviews are associated with specific limitations, such as relying on a limited search of the 
literature and making recommendations strongly based on opinions.  In contrast a systematic 
review, as performed in Chapter 4, aims to summarise all the available evidence and provide an 
unbiased presentation of the literature with some kind of precise estimate of the magnitude of any 
treatment effect.   
However this reliance on previously published literature is the major limitation of any systematic 
review.  Publication bias can substantially affect the results of any review, because it is likely that 
only studies with more favourable results will have been published.  As a result it is likely that the 
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benefits of any treatment effect are over-estimated, and this factor needs to be considered when 
interpreting the outcomes of our review.   
In considering the quality of studies included in this review it important to ensure this is formally 
assessed, as was done in Chapter 4 using the Ottawa-Newcastle assessment scale.  This assessment 
highlighted some of the limitations of available literature.  Firstly the majority of previous studies 
were observational in design and therefore lacked a control arm.  Secondly studies were generally 
small and provided limited longer term follow up data, with several studies providing less than 1 
year follow up data (146, 149, 175, 176) and others only reporting follow up outcomes on subsets of 
their study group (181).  Given the limited data available on follow up outcomes from prospective 
studies, the decision was made at the start to include retrospective studies in this review as well.  
Inclusion of these studies had the advantage of providing more data on long term follow up results, 
but was associated with limitations.  Most importantly, several of the retrospective studies did not 
present results on an intention to treat basis, which may mean that the results presented are over 
optimistic due to preferential drop out of treatment failures.  In order to overcome this limitation, 
pooled results from only the prospective studies were present separately as well.  Despite this our 
conclusions about the longer term durability of both treatments remain tentative.   
 Original research papers 7.2.2
All three of the original research papers presented in this thesis (Chapters 3, 5 and 6), used data 
collected on a national basis, including both routinely collected administrative data and data 
collected specifically for the NOGCA.  The main advantage of using national datasets is that the 
results are more representative than those from single-centre studies, and provide more precise 
estimates of the outcomes considered.   
However use of national datasets to address specific research questions is associated with significant 
limitations.  Firstly, individual studies in this thesis may have benefited from more detailed 
information in specific areas, for instance the study into missed oesophageal cancer would have 
benefited from access to the indication for initial endoscopy and results from the initial endoscopy 
report.  However, this would have required access to patient records which was not feasible in the 
context of a National Clinical Audit.  Secondly, with any research using national databases, one must 
accept that the accuracy of the results of these studies rely on the quality of data submitted.  As a 
result steps were taken throughout our analysis to limit our patient cohorts to those patients whose 
data was consistent across the different databases.  This limited the impact any coding errors may 
have had on overall results.   
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Overall it was felt that the benefits of using these national datasets to address our specific research 
questions outweighed these limitations.  The next section goes on to review in greater detail the 
specific advantages and disadvantages of each national dataset. 
7.2.2.1 National-Oesophago Gastric Cancer Audit 
The primary dataset used in this thesis was the NOGCA dataset.  This data is comprehensively 
collected and submitted by all NHS trusts.  The NOGCA aims to collect data on all patients with a 
new diagnosis of invasive epithelial oesophago-gastric cancer in England and Wales, and more 
recently HGD of the oesophagus in England.   
Participation in the NOGCA is mandatory for NHS trusts in England, with inclusion of participation 
levels in trusts Quality Accounts which are externally audited and submitted to the Secretary of 
State.  As a result the quality and robustness of data collected from this source should be very high.  
The case ascertainment for the second NOGCA was 83% for patients diagnosed with oesophago-
gastric cancer in England, and over 90% for patients undergoing a curative resection (77).  The 
results of our studies should therefore be truly representative of current management of 
oesophageal cancer and HGD in England.  Although it is important to appreciate that within 
individual studies there was the possibility of selection bias,  as data entry was not mandatory in all 
fields.  For instance in Chapter 6 patients who had incomplete staging information submitted to the 
audit were found to more likely to be managed with palliative intent and have worse outcomes, it is 
therefore likely that our study overestimated the proportion of cancers diagnosed at an early stage. 
Nonetheless significant benefits are gained from having such a large cohorts of patients to study, 
including having the statistical power to perform additional subgroup analysis which has been 
limited in previous single centre studies addressing similar research questions.   
Use of the NOGCA dataset did have its own limitations.  Firstly, as discussed in Chapter 3 there is no 
unique International Classification of Diseases (ICD-10) code or Systematized Nomenclature of 
Medicine (SNOWMED) code used to record the diagnosis of HGD in the national administrative 
datasets.  As a result it is not possible to establish the case ascertainment for HGD cases submitted 
to the audit.  Although there is no reason to believe this will have affected the major findings of the 
study, it may mean that the study underestimated the proportion of patients managed by 
surveillance alone.   
Secondly, the NOGCA dataset did not collect data on some variables which would have provided 
additional weight to our study’s results.  For instance in the paper looking at missed oesophageal 
cancers at endoscopy, it was not possible to identify patients who had undergone planned 
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surveillance endoscopies.  As a result our estimate of the miss rate may be a slight overestimate.  
While the paper on the management of early cancer would have benefited from additional 
information on the depth of tumour invasion, in order to better risk stratify patients.  In addition 
several data items were not mandatory for the NOGCA dataset, particularly in the HGD dataset.  This 
reduced the quality of the data available in certain fields e.g.  length of Barrett’s was missing for a 
high proportion of patients.  This may have introduced the risk selection bias, as patients with this 
data entered in these fields in the NOGCA may have differed systematically from the rest of the 
cohort, although there is no reason to believe this to be the case.  In order to reduce the effect of 
this problem in the future, the HGD dataset has been substantially modified to make more variables 
mandatory for the next data collection year (Appendix D).   
7.2.2.2 Hospital Episode Statistics  
HES was designed as an administrative database, but is increasingly being used in health care 
research.  As a result previous studies have raised questions about the reliability with which data 
was recorded in HES.  The accuracy of data being submitted to HES has since been well validated, 
with recent studies showing that the quality of coding has improved substantially over time (199).   
Linking the NOGCA data to HES allowed more in depth research questions to be addressed, which 
would not have been possible using the NOGCA dataset alone.  For instance it provided information 
about previous endoscopic and surgical procedures that the patients had underdone.  This allowed 
investigation into both the proportion of oesophageal cancers potentially missed at endoscopy, and 
the management of early oesophageal cancers on a national basis.   
Linkage of the two datasets also allowed for substantial data validation to occur, thus reducing the 
risk of coding errors impacting on results.  For instance in Chapter 5, the accuracy of ‘date of 
diagnosis’ submitted to the audit was validated using HES data, and patients were dropped from 
analysis where this data was inconsistent because this date was crucial for determining the timing of 
previous investigations.  Furthermore using NOGCA data the quality of coding of endoscopic 
procedures in HES was confirmed.  For instance in Chapter 5 it was very important to ensure all 
endoscopies were accurately recorded in HES, this was demonstrated by the fact that 92.5% of 
patients with a new diagnosis of oesophageal cancer had had an endoscopy recorded in HES within 
one month of diagnosis. 
It is important to realise that use of HES does still have limitations attached.  Firstly HES only collects 
data on hospital admissions in NHS hospitals in England.  As a result any procedures performed in 
private hospitals or in Scotland/Wales will not have been picked up.  However, these figures are 
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expected to be low and the impact of this limitation is expected to be extremely small when 
considering data on such a large scale.  Furthermore the coding of some endoscopic procedures was 
non-specific and ambiguous, this may have caused under-reporting of endoscopic resections in 
Chapter 6.  As a result this study may have underestimated both the proportion of patients treated 
endoscopically, and the frequency of repeat endoscopic interventions.   
7.2.2.3 Office for National Statistics 
Finally the NOGCA dataset was linked to ONS mortality data.  This data linkage allowed us to define 
outcomes such as survival after diagnosis without increasing the burden of data collection for 
participating units, and also ensured complete follow up of patients.  This had the advantage that 
one could look at 5 year survival outcomes for patients diagnosed with early oesophageal cancer on 
a national level.   
While ONS data can also provide access to cause of death, the extract of ONS used in our studies did 
not provide this information.  This limited the analysis that could be performed looking at outcomes 
for patients managed endoscopically versus surgically for early cancers, because it was likely that 
patients managed endoscopically had a higher all cause mortality than those managed surgically, as 
they were older and frailer.  In order to combat this limitation, future extracts of ONS received in this 
unit will include details on cause of death as well.   
 
  
154 
 
7.3 Conclusions 
Use of linked national datasets in the studies performed in this thesis provided a unique insight into 
the current management of HGD and oesophageal cancer in England.  In doing so it highlighted 
several key areas where care can be improved in future.   
Firstly, there is currently huge variation in the management of HGD in England with a significant 
proportion of patients managed by surveillance alone.  Further analysis showed that this proportion 
was higher for patients managed in low volume centres.  It is therefore important that careful 
consideration goes into the centralisation of HGD treatment services in England, in order to optimise 
the management of these patients.   
Secondly in order to improve the outcomes for oesophageal cancer in future it is important to try 
and improve the proportion of patients diagnosed at an early stage.  Our analysis showed that 
currently only 6.8% of oesophageal cancers are diagnosed at an early stage, and that a substantial 
proportion of cancers were potentially missed at prior endoscopy.  This highlights an area where 
care of patients could potentially be improved, in order to achieve this it is important that any 
suspicious lesions are adequately biopsied and appropriately followed up. 
Finally in treating Barrett’s oesophagus with HGD it is important to consider treatment using RFA in 
preference to complete endoscopic resection, given that our review demonstrated that while the 
efficacy of both treatment approaches was similar the risk associated with complete endoscopic 
resection were much higher.   
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7.4 Future work 
The development of the NOGCA dataset and linkage with other administrative databases provides a 
number of unique opportunities for research in the future.  Areas that may warrant further 
investigation include:  
 Analysis of the impact of the ‘Be Clear on Cancer’ campaign 7.4.1
Currently only 15% of patients diagnosed with oesophago-gastric (OG) cancer survive 5 years post 
diagnosis (1), but this is related to the high proportion of cancers diagnosed at a relatively late stage.  
As a result only 30-40% of OG cancers are suitable for curative treatment at diagnosis (2).  The 
government has therefore been taking steps to try and increase the proportion of these cancers 
diagnosed at early stage. This resulted in the launch of the ‘Be Clear on Cancer campaign’ for OG 
cancer, which aimed to improve early diagnosis of these cancers by raising public awareness of their 
signs/symptoms, and to encourage patients to see their GP without delay if they had concerns (191).  
This national campaign was run based on evidence collected from seven local campaigns which ran 
between April and July 2012 and were extended into regional pilots which ran from February to 
March 2014.  Cancer Research UK evaluated the success of these local and regional pilots by 
analyzing the effect the campaign had on symptom awareness, referrals rates from GP to secondary 
care, cancer detection rates and endoscopy to cancer diagnosis conversion rates (200). They 
reported the following, an increase in spontaneous awareness of the symptom ‘difficulty swallowing’ 
in those aged 55 and over (7% to 14%, statistically significant). This resulted in a 17% increase 
(statistically significant) in the number of GP visits for dysphagia in patients over 55 during the 
campaign. A significant increase in the number of urgent referrals for suspected upper GI cancer in 
pilot areas compared with control areas, from 26% to 16%, which they estimated would equate to 
approximately 16 extra endoscopies referrals each week for an average size trust.  Finally they 
showed that although there was a 20% increase in the number of oesophageal cancers diagnosed 
following a 2 week-wait referral for suspected upper GI cancer following the campaign, this 
difference was not statistically significant and there was also no significant change in the conversion 
rate. 
The ‘Be clear on cancer’ OG campaign ran from 26 January to 22 February 2015 (in England).  The 
campaign was aimed at men and women aged 50 years and over and focused on two key messages:  
- ‘Having heartburn, most days, for 3 weeks or more could be a sign of cancer – tell your 
doctor.’ Figure 7-1 shows an example of some of the campaign material. 
- ‘Food sticking when you swallow could be a sign of cancer – tell your doctor.’ 
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Figure 7-1 Media image from the ‘Be clear on cancer’ campaign 
http://www.cancerresearchuk.org/health-professional/early-diagnosis-activities/be-clear-on-cancer/oesophago-gastric-cancers-
campaign/resources-and-tools 
 
It is therefore important to determine the success of the campaign on a national level, which can be 
done by investigating the following, (i) the number of cancers diagnosed at an early stage and 
therefore suitable for treatment with curative intent, (ii) the number of patients referred for 
endoscopy during campaign period and the conversion rate to OG cancer. These questions can be 
addressed by linking data from the NOGCA to HES and ONS, to compare endoscopy activity and 
oesophageal cancer outcomes between 26th Jan to 22nd March 2015 ‘campaign’ period with the 
same 8 week period in 2014 ‘control’ period. 
Several key outcomes need to be assessed to do this. Firstly HES can be used to compare the 
number of cancers diagnosed in the ‘campaign’ vs the ‘control’ period. Then NOGCA data can be 
used to investigate changes in the patterns of referrals in greater detail, looking specifically for 
changes in the proportion of patients diagnosed after a GP referral and after an emergency hospital 
admission. It is then important to look at the impact the campaign had on cancer diagnosis and 
outcomes using NOGCA and ONS data, this analysis could look at changes in the proportion of 
cancers diagnosed at an early stage, and changes in the proportion of patients managed with 
curative intent and the proportion of patients who survive 1 year.  Finally using HES data one could 
assess the impact of the campaign on hospital resources, in particular the total number of 
endoscopies done over the relevant time frame and the overall endoscopy to cancer diagnosis 
conversion rate.  
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 Variation in OGD referral rates in English GP practices and effect on outcomes 7.4.2
 
GPs have had direct access OGDs since the 1980s, with introduction of 2 week-wait referrals in 2000.  
In 2013 Shawihdi et al used HES to demonstrate that there was significant variation in GP referral 
practices across England, including within PCTs (201).  They went on to demonstrate that patients 
belonging to GP practices with lower referral rates had worse outcomes, with a lower proportion of 
patients undergoing a major resection, a higher proportion of patients being diagnosed as a result of 
an emergency admission and a lower proportion of patients surviving one year after diagnosis.  
However, this paper had several limitations. Firstly it was unable to reliably distinguish between 
oesophageal and gastric cancer using HES. This is important because gastric cancers typically present 
with vaguer symptoms, and are therefore less likely to be referred for early investigation. Secondly 
they did not access to date of diagnosis or route to referral, these details had to be inferred from 
HES. As a result they could only determine which referrals were as a result of an emergency 
admission, and they were unable to look at use of routine and urgent GP referrals. This is important 
in order to look at whether GP with low referral rates refer a greater proportion of patients as two 
week wait referrals, suggesting the GPs had a higher threshold for referrals. Finally this paper was 
unable to establish important tumour characteristics (e.g type of cancer, site of cancer, stage at 
diagnosis) and initial treatment plan using HES data. Stage at diagnosis is important to determine 
whether patients belonging to GP practices with low referral rates were more likely to have their 
disease diagnosed at a later stage. While the lack of information on treatment plan including both 
treatment intent and treatment modality meant they could not identify surgical resections 
performed with non-curative intent or patients treated with alternative curative treatment options 
such as definitive oncology or a localised endoscopic resection for early cancer  
Linking NOGCA data with HES allows some of these limitations to be addressed. In order to do this 
analysis the NOGCA dataset will need to be linked to the overall HES dataset managed by the Royal 
College of Surgeons in order to detect all OGDs done within a specified time frame.  
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 Investigation into the long term outcomes of patients diagnosed with HGD of the 7.4.3
oesophagus 
Current follow up data looking at the long term outcomes for patients with HGD is limited, with 
studies coming primarily from specialist research centres. It is important to realise that outcomes 
achieved in these specialist centres may not be representative of those achieved in lower volume 
non-research centres.   
The national cohort of patients with newly diagnosed HGD established by the NOGCA is unique 
worldwide.  This provides us with an exciting opportunity to explore both the natural progression of 
the disease on a large scale, and the outcomes achieved with different treatment option. By linking 
this dataset to HES for patients with HGD it will be possible to investigate this is greater detail.  
In particular this study aims to investigate the proportion of patients requiring further endoscopic 
therapy, the proportion of patients who go on to require a surgical resection at a later date and the 
risk of progression to cancer in future.  It will also be possible to investigate whether the outcomes 
of patients with HGD managed in high volume treatment centres differ from those managed in lower 
volume centres.  This will be the first time this type of study has been performed at a national level 
for this group of patients.  
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Appendix 
(A) ECOG Performance Status 
Developed by the Eastern Cooperative Oncology Group (202). 
Grade ECOG Performance Status 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature, e.g., light house work, office work 
2 
Ambulatory and capable of all self-care but unable to carry out any work activities; 
up and about more than 50% of waking hours 
3 
Capable of only limited self-care; confined to bed or chair more than 50% of waking 
hours 
4 Completely disabled; cannot carry on any self-care; totally confined to bed or chair 
5 Dead 
 
(B) ASA Grade 
The ASA physical status classification system is a system for assessing the fitness of cases before 
surgery.   
 ASA Grade 
1 Healthy person. 
2 Mild systemic disease. 
3 Severe systemic disease. 
4 Severe systemic disease that is a constant threat to life. 
5 A moribund person who is not expected to survive without the operation. 
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(C) Dataset for the 2nd NOGCA 
 
Patient Details 
Surname: _______________ 
NHS number: _______________ 
Sex: Male      Female      Not specified  
Forename: _________________ 
Postcode:      _________________ 
Date of birth:  _________________ 
 
Initial Referral to Local Oesophago-gastric Team and Diagnostic Process 
Source of referral 
   From surveillance service:   Symptomatic referral    Not known  
Date of endoscopic biopsy in which HGD was first diagnosed:  _______________________ 
Hospital where the endoscopic biopsy was taken:     _______________________ 
Was a second biopsy performed?     Yes   No  
Did the second biopsy show HGD?     Yes   No  
 
Endoscopic Report 
HGD appearance 
   Flat mucosa    Nodular lesion  Depressed lesion         Not known   
Barrett’s Segment 
        Present                 Absent              Not known   
Length of Barrett’s Segment, if present 
   Length of Circumferential Columnar Lining (nearest 0.5 cm):     C ____.___cm 
   Maximum length including tongues/islands of Columnar Lining (nearest 0.5 cm): M ____.___cm 
HGD Lesion (based on pathology report) 
        Unifocal               Multi-focal               Not known   
Was diagnosis confirmed by second pathologist?       Yes                    No        Not known  
 
[PTO] 
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Planned Treatment 
Hospital at which treatment plan made ______________________________ 
Date treatment plan agreed  _____________ 
Was the treatment plan agreed at an MDT meeting?  Yes       No    
Will the patient be referred to a specialist hospital for treatment?  Yes       No       Not applicable   
 
Planned treatment modality 
Surveillance          Radiofrequency ablation  
Oesophagectomy         Argon plasma coagulation  
Photo dynamic therapy        Multipolar electrocautery  
Endoscopic Mucosal Resection  (EMR)      Laser therapy   
Endoscopic Submucosal Dissection (ESD)      Cryotherapy    
 
Use of Endoscopic Mucosal Resection (EMR) / Endoscopic Submucosal Dissection (ESD)  
EMR/ESD was not performed:     Performed for diagnostic purpose:   
Performed for therapeutic purpose:      Performed for both diagnostic and therapeutic purpose:  
 
Date of EMR/ESD: __________________ 
 
Results of EMR/ESD:  
   Complete excision:        Incomplete, follow up Oesophagectomy  
   Incomplete, follow up surveillance    Incomplete, follow up EMR/ESD   
 
Post-treatment Histology (pathology results based on EMR/ESD) 
No high-grade dysplasia or carcinoma    
High-grade dysplasia confirmed      
Intramucosal carcinoma identified     
Submucosal carcinoma or worse     
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National Oesophago-Gastric Cancer Audit 
New Patient Registration datasheet (Oesophageal Gastric Cancer Patients) 
 
Patient Details 
Surname: _______________ 
NHS number: _______________ 
Sex: Male      Female      Not specified  
Forename: _________________ 
Postcode:      _________________ 
Date of birth:  _________________ 
Initial Referral and Diagnosis Data 
Source of referral: Direct from GP      Barrett’s Surveillance      Emergency admission   
              Open access endoscopy           From other consultant                          Not known   
Priority of referral:           Urgent       2-week wait     Routine referral  
  (GP referral only)  
Date of first referral to local oesophago-gastric team for investigation:  __________________________ 
Date of diagnosis:          __________________________ 
Local cancer unit where cancer was diagnosed:     __________________________ 
 
Diagnosis - Site 
Oesophagus: Upper 
1
/3  Middle 
1
/3   Lower 
1
/3  NB: cervical oesophageal tumours 
are NOT included in this audit 
Gastro-Oesophageal Junction (adenocarcinomas only) Siewert classification: 
            1        2            3   
Stomach:  Fundus          Body   Antrum    Pylorus    
Diagnosis - Histology 
Invasive adenocarcinoma         Squamous cell carcinoma   
Adenosquamous carcinoma        Small-cell carcinoma  
Undifferentiated carcinoma        Other epithelial carcinoma  
Unspecified malignant neoplasm (histology not done)   
NB: Non-epithelial tumours (GIST, sarcomas or melanomas) are NOT included in this audit 
 
Staging investigations (please tick all that apply) 
None                           
CT scan       PET / PET – CT scan     
Endoscopic ultrasound (EUS)    EUS Fine needle aspiration    
Staging laparoscopy       Other investigation                                    
Pre – Treatment Stage 
Which TNM version do you use:  TNM v6  TNM v7   
T: 0       Tis       1       1a       1b       2       2a       2b       3       4       4a       4b     x
 
N:   0                     1               2                             3     3a       3b          x
 
M:  0               1                                                                                      x  
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ECOG (WHO) Performance Status 
   0  Carries out all normal activity without  
 restriction 
 3  Limited self-care, confined to bed or      
 chair for >50% waking hours 
   1  Restricted but walks/does light work  4  Fully disabled, confined to bed/chair      
   2 Walks, full self-care but no work.  Up  
 and about >50% of the time   
  
 
Comorbidities (please tick all that apply) 
None     
Cardiovascular disease         Liver failure or cirrhosis           Diabetes    
Chronic renal impairment   Barrett’s oesophagus          Mental illness    
Cerebro/periph vascular         Chronic respiratory disease (including COPD/asthma)    
Other significant condition   
 
Treatment Plan 
Date final care plan agreed:  _____________ 
Treatment intent:   
   Curative:          
   Non-curative (palliative)   (i.e.  surgery, chemotherapy, radiotherapy, endoscopy) 
   No active treatment (supportive care)   (i.e.  non -specific symptomatic treatments) 
 
Details of planned treatment 
  Curative modality        Palliative modality 
  Surgery only     Palliative surgery      
  Chemotherapy and surgery (any combination)      Palliative oncology (unspecified)  
  Chemo-radiotherapy and surgery (any combination)      Endoscopic palliation therapy    
  (Definitive) Radiotherapy only     No active treatment (supportive care)   
  Definitive chemo - radiotherapy  
  Endoscopic mucosal resection   
 
Treatment part of a clinical trial:  
Patient eligible, consented and entered trial     Patient eligible, declined trial  
Reasons for palliative treatment (please tick all that apply)  
  Patient declined treatment      
  Unfit, because of advanced stage cancer  
  Unfit, because significant co-morbidity   
  Unfit, because poor performance status  
  Not known      
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National Oesophago-Gastric Cancer Audit 
Postoperative Datasheet (Oesophageal Gastric Cancer and HGD Patients) 
 
Patient details (for patient identification only)  
Surname _______________  Forename _______________ 
NHS number      _______________  Date of birth   _______________  
Admission and Surgical Details (Main procedure only)  
Hospital name: ___________________ 
Date of admission: ________________  Date of operation:  _________________ 
 
Pre-operative intent of surgery:   Palliative       Curative       
Fitness for Surgery (ASA grade): 1           2       3        4       5  
 
Height (in cm)   ________ (to calculate body mass index) 
Weight (in kg) ________ (to calculate body mass index) 
Smoking:         current smoker   ex-smoker      non-smoker (history unknown)   
never smoked    not known   
 
Procedure  
Surgical Access (thoracic) – the approach used for the thoracic phase of the operation (if applicable) 
Open operation   Thoracoscopic          
converted to open 
Thoracoscopic    
completed 
Not applicable  
 
Surgical Access (abdominal) - the approach used for the thoracic phase of the operation  
Open operation     Laparoscopic            
converted to open    
Laparoscopic         
completed 
 
 
Oesophageal      Gastric 
- Oesophagectomy:    - Gastrectomy:  
      Left thoraco-abdominal approach        Total    Extended total  
      2 – Phase (Ivor-Lewis)          Proximal   Distal    
      3 – Phase (McKeown)           Completion   Merendino  
     Transhiatal                     Wedge/localised gastric resection     
        Bypass procedure / Jejunostomy only   
 Thoracotomy (Open & Shut)   Laparotomy (Open and Shut)     
 
Nodal Dissection 
 Oesophagectomy:  None    1 – field   2 – field   3 – field   
 Gastrectomy:  D0 (peri-gut resection)   D1          D2        D3    
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Postoperative complications and course (please tick all that apply)  
None        Respiratory:  
Anastomotic leak        Pneumonia       
Chyle leak          ARDS    
Haemorrhage             Pulmonary embolism   
Cardiac complication       Pleural effusion   
Acute renal failure    Wound infection    
Other     
Unplanned return to theatre? Y    N   Death in hospital?     Y    N   
Date of discharge or death:  ___________________ 
 
Postoperative pathology and staging  
Length of tumour   _____________________ 
Site: 
Oesophagus: Upper 
1
/3      Middle 
1
/3    Lower 
1
/3   
   NB: cervical oesophageal tumours  are NOT included in this audit 
Gastro-Oesophageal Junction (adenocarcinomas only) Siewert classification: 
            1        2            3   
Stomach:  Fundus          Body   Antrum    Pylorus    
Histology: 
   Invasive Adenocarcinoma      Squamous cell carcinoma   
   Adenosquamous carcinoma    Small-cell carcinoma     
   Undifferentiated carcinoma    Other epithelial carcinoma  
   Malignant Neoplasm               
 
Proximal resection margin involved?   Yes   No    
Distal resection margin involved?   Yes   No    
Circumferential resection margin involved? (<1mm) Yes   No   N/A  
 
Number of lymph nodes examined:  ___________ 
Number of lymph nodes positive:     ___________ 
Postoperative stage  
Which TNM version do you use:  TNM v6  TNM v7   
T: 0       Tis       1       1a       1b       2       2a       2b       3       4       4a       4b     x
 
N:   0                     1               2                             3     3a       3b          x
 
M:  0               1                                                                                      x  
 
Patient had neoadjuvant therapy prior to surgery:  Yes     No  
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National Oesophago-Gastric Cancer Audit 
Chemotherapy/Radiotherapy Datasheet (Oesophageal Gastric Cancer Patients) 
Please fill in this datasheet for every course of oncological treatment received by a patient with oesophago-
gastric cancer.   Most patients will only require one datasheet to be completed.   For patients who have both 
neoadjuvant and adjuvant therapy, complete two separate datasheets.   
 
Patient details (for patient identification only)  
Surname _______________  Forename _______________ 
NHS number      _______________  Date of birth   _______________  
 
Hospital of treatment  
Hospital where oncology treatment took place ___________________       
 
Treatment details  
Treatment intent: 
Neoadjuvant      Adjuvant    Curative    Palliative   
Intended treatment modality:   
Chemotherapy   Radiotherapy   Chemo-radiotherapy   
 
Details of therapy 
Chemotherapy details (if applicable)  
 
Date first cycle started:  ___________  
 
Outcome of treatment:   
Treatment completed as prescribed   
 
Reason if incomplete     
Patient died      
Progressive disease during treatment   
Acute chemotherapy toxicity    
Technical or organisational problems   
Patient choice (interrupted or stopped     
                         treatment)    
Not known         
 
Radiotherapy details (if applicable) 
 
Date first fraction started:  __________ 
 
Outcome of treatment:    
Treatment completed as prescribed   
 
Reason if incomplete      
Patient died      
Progressive disease during treatment   
Acute radiotherapy toxicity    
Technical or organisational problems   
Patient choice (interrupted or stopped     
                         treatment)    
Not known         
 
Post oncology fitness (for neoadjuvant therapy only)  
Patient proceeded to planned curative surgery: Yes   No    Not applicable  
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National Oesophago-Gastric Cancer Audit 
Endoscopic / Radiological Palliative Therapy Datasheet  
(Oesophageal Gastric Cancer Patients) 
Please fill in this datasheet for every patient with oesophago-gastric cancer on the occasion of their FIRST 
PALLIATIVE endoscopic / radiological therapeutic intervention. 
Patient details (for patient identification only)  
Surname _______________  Forename _______________ 
NHS number      _______________  Date of birth   _______________  
Treatment details 
Hospital name: ______________________________________ 
Date of endoscopic / radiological procedure: _______________ 
 
Dysphagia Rating Scale 
0     No dysphagia    3     Able to consume liquids only 
1     Able to eat solids    4     Complete dysphagia 
2     Able to eat semi-solids only   9     Not known 
 
Procedure details 
Type of procedure (tick all that apply) 
  Insertion of stent    Laser therapy   Argon plasma coagulation   
  Photodynamic therapy   Gastrostomy   Brachytherapy       
  Dilatation      (Tick dilatation if it was the only procedure or if required to facilitate treatment) 
  Other    
Is this procedure part of a planned course of multiple interventions?    Yes  No  Not known  
Anaesthesia:  Sedation     Local anaesthetic spray     General anaesthesia   
Sedation and local anaesthetic spray combined                       Not known   
Details of stent procedure, if inserted 
Type of stent: 
   Plastic: expandable  Metal: covered       Metal: Anti-reflux               Not known  
   Biodegradable     Metal: uncovered                     Other    
Method of stent placement: 
   Fluoroscopic control        Endoscopic control      Fluoroscopic & Endoscopic     Not known  
Did the stent deploy successfully?     Yes    No   Not known   
 
Immediate complications following stent insertion (tick all that apply) 
   No complication    Postoperative stricture    Perforation  
   Haemorrhage     Other complications  
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(D) Updated HGD Dataset for the 2nd NOGCA 
 
Patient Details 
Surname: _______________ 
NHS number: _______________ 
Sex: Male      Female      Not specified  
Forename: _________________ 
Postcode:      _________________ 
Date of birth:  _________________ 
 
Initial Referral to Local Oesophago-gastric Team and Diagnostic Process 
Source of referral 
   From surveillance service:   Symptomatic referral    Not known  
Date of endoscopic biopsy in which HGD was first diagnosed:  _______________________ 
Hospital where the endoscopic biopsy was taken:     _______________________ 
 
Was the original diagnosis of HGD confirmed by a second pathologist?  Yes      No       Not known  
Was a repeat biopsy taken to confirm the diagnosis of HGD?                  Yes      No       Not known  
Did the repeat biopsy confirm the diagnosis of HGD?                               Yes      No       Not known  
Was the second biopsy diagnosis of HGD confirmed by a second pathologist?Yes  No  Not known  
Comorbidities? None   Cardiovascular disease     COPD / Asthma     Chronic Renal Impairment  
                         Liver Failure / Cirrhosis   Diabetes   Mental Illness  
                         Cerebro / peripheral vascular disease   Significant other  
 
Endoscopic Report 
At the initial endoscopy where a diagnosis of HGD was made: 
- Were quadrantic biopsies taken every 2cm from the entire segment of Barrett’s? 
Yes      No       Not known  
- Were additional biopsies taken of any visible nodule? 
Yes      No       Not known  
HGD appearance 
   Flat mucosa    Nodular lesion  Depressed lesion         Not known   
Barrett’s Segment 
        Present                 Absent              Not known   
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Endoscopic Report (continued) 
Length of Barrett’s Segment  
Is the length of circumferential columnar lining recorded in the endoscopy report?   Yes      No       
Length of Circumferential Columnar Lining (nearest 0.5 cm):                                     C ___.___   cm 
Is the maximum length of columnar lining recorded in the endoscopy report?                  Yes      No        
Maximum length including tongues/islands of Columnar Lining (nearest 0.5 cm):          M ___.___   cm 
 
HGD Lesion (based on pathology report) 
Unifocal    Multi-focal   Not known   
 
Planned Treatment 
Hospital at which treatment plan made ______________________________ 
Date treatment plan agreed  _____________ 
Was the treatment plan agreed at an MDT meeting?  Yes       No    
Hospital where initial treatment was given   _____________________________ 
Date initial treatment was given   ________ 
 
Planned treatment modality 
Surveillance (follow up endoscopy)       Radiofrequency ablation  
Oesophagectomy         Argon plasma coagulation  
Photo dynamic therapy        Multipolar electrocautery  
Endoscopic Mucosal Resection  (EMR)      Laser therapy   
Endoscopic Submucosal Dissection (ESD)      Cryotherapy    
Other                                                                            No active treatment                 
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Use of surveillance or no active treatment as planned treatment  
What was the reason for this treatment plan? 
Patient choice                                                                  
Patient unfit for endoscopic or surgical treatment      
Lack of access to endoscopic treatment or surgery      
Unknown                                                              
 
Use of surveillance  
If plan was surveillance, when was the next surveillance endoscopy planned for? 
≤ 3 months                               
3-6 months       
7-12 months     
>12 months      
Unknown                     
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Use of Endoscopic Mucosal Resection (EMR) / Endoscopic Submucosal Dissection (ESD)  
Date of EMR/ESD: __________________ 
 
Was excision complete?  Yes      No       Not known  
 
If yes, what was the ongoing plan? 
Further endoscopic treatment of the remaining Barrett’s segment      
Surveillance (follow up endoscopy) only                                              
No further surveillance or treatment                                                     
Not Known                                                                                           
 
If no, what was the ongoing plan? 
Further EMR/ESD                                                                                
Further ablative endoscopic treatment e.g.  RFA, APC                       
Refer for oesophagectomy                                                                  
Surveillance (follow up endoscopy) only                                             
No further surveillance or treatment                                                    
Not Known                                                                                           
 
Post-treatment Histology (pathology results based on EMR/ESD) 
No high-grade dysplasia or carcinoma    
High-grade dysplasia confirmed      
Intramucosal carcinoma identified     
Submucosal carcinoma or worse     
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(E) Newcastle-Ottawa Quality Assessment Scale for Cohort studies 
A study can be awarded a maximum of one start for each numbered item within the Selection and 
Outcome categories.  A maximum of two stars for Comparability. 
Selection 
1. Representativeness of the exposed cohort  
   Truly representative of the community * 
   Somewhat representative of community * 
   Selected group of users  
   No description of derivation of cohort  
2. Selection of the non-exposed cohort  
   Drawn from same community as exposed cohort * 
   Drawn from a different source  
   No description of derivation of the non-exposed cohort  
3. Ascertainment of exposure  
   Secure record * 
   Structured interview * 
   Written self-report  
   No description  
4. Demonstration that outcome of interest was not present at the start  
   Yes * 
   No  
Comparability 
1. Comparability of cohorts on the basis of the design or analysis  
   Study controls for _______(select most important factor) * 
   Study controls for any additional factor * 
Outcome 
1. Assessment of outcome  
   Independent blind assessment * 
   Record linkage * 
   Self-report  
   No description  
2. Was the follow up long enough for outcomes to occur  
   Yes * 
   No  
3. Adequacy of follow up of cohorts  
   Complete follow up – all subjects accounted for  * 
   Subjects lost to follow up unlikely to introduce bias - >___% follow up * 
   Follow up rate <___% and no description of those lost  
   No statement  
 
